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Abstract 
The unique spatiotemporal control provided by photochemical transformations allows for 
exquisite power over biochemical processes. Despite this, relatively little research involving 
novel biocompatible photochemical transformations has been described. This is due in part 
to the difficulty in discovering photochemical reactions which fulfil the strict criteria required 
for biocompatibility, and also a lack of available methods for the reliable site-selective 
modification of proteins. Thus, a method for achieving site selective attachment of novel 
photoactive chemical moieties to biomolecules would represent a significant contribution to 
the field. 
Recently published work has highlighted the photochemical reactivity of thiomaleimides, 
which can be easily and site-selectively installed on protein cysteine residues. This thesis 
describes the discovery and investigation of novel thiomaleimide based photochemical 
reactions, with special focus on utilising these reactions as phototriggers for peptide and 
protein manipulation. The initial work expands on a previously reported thiomaleimide [2+2] 
photocycloaddition to develop a method for photochemically rebridging peptides and 
proteins at the site of a disulfide bond. This method was employed for the photochemical 
activation of the therapeutic peptide Octreotide, and as a tool for generating highly thiol 
stable bis-modified antibody fragment conjugates.  
During the course of this study two novel thiomaleimide-mediated photochemical 
decarboxylation reactions were discovered and their utility as photolabile linkers for 
bioconjugation was explored. This led to the development of a cysteine selective 
photolabile linker based around the thiomaleimide scaffold, which was subsequently 
employed to release an analogue of the cytotoxic drug Doxorubicin from an anti-CEA scFv 
antibody fragment. This work highlights the previously unreported ability of thiomaleimides 
to act as electron acceptors in photoinduced electron transfer reactions, greatly expanding 
the reactivity profile of this chemical motif. 
The excellent photochemical reactivity of thiomaleimides, coupled with the relative ease of 
their installation on proteins, suggests that these reagents could play an important part in 
the future of photochemical protein and peptide manipulation. 
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1: Introduction 
1.1: Photochemistry 
1.1.1: Fundamentals of Photochemistry 
Accurately defining the genesis of modern organic photochemistry is a non-trivial task, 
complicated by a historical lack of understanding at a fundamental level. Despite the 
identification of many photochemical processes throughout history, research into their 
mechanisms only began in earnest in the mid to late 20th century. Advancements in 
quantum mechanics, along with more sophisticated spectroscopic techniques, gave 
researchers unprecedented insight into the underlying processes involved in these unique 
transformations.1 Key work by Zimmerman in the early 1960s used this insight to offer a 
mechanistic explanation for the photochemical rearrangement of 4,4-diphenylhexadienone 
1 to 3,3-diphenylpentenone product 2, providing one of the earliest examples of a truly 
mechanistically reasoned photochemical reaction (Scheme 1).2 Subsequent studies within 
the group expanded on this work and explored the mechanisms of a variety of 
photochemical rearrangements.3–6 
 
Scheme 1 
The photochemical rearrangement of 4,4-diphenylhexadienone 1. 
 
Similarly, parallel work by Hammond explored the role of the excited triplet state in organic 
photochemical transformations.7–9 This work provided mechanistic explanations for a 
variety of photochemical processes which are now common place, such as 
photochemically induced cis-trans isomerisations,10,11 [2+2] cycloadditions,12 and 
photoreductions13,14 (Scheme 2).  
14 
 
 
Scheme 2 
Some early photochemical reactions studied by Hammond et al: (A) Photochemical 
cis-trans isomerisation of piperylene 3.10 (B) Photochemical [2+2] cycloaddition of 
butadiene 5.12 (C) Photochemical reduction of benzophenone 7.13,14  
 
The pioneering work by these groups, and many others, highlighted the importance of the 
excited state and laid the foundation of modern mechanistic organic photochemistry. 
Chemists now have a more complete understanding of the structure and bonding of 
molecules in the excited state, and are thus better equipped to harness the power of 
photochemistry.  The culmination of this research is perhaps best represented 
schematically in a Jablonski diagram (Figure 1). Jablonksi diagrams were first introduced 
by their namesake in 1933 to explain the fluorescence observed in organic dyes,15 but have 
since been adopted to describe a multitude of photochemical processes. The diagram 
depicts the fate of a molecule after absorbing a photon to generate an electronically excited 
state. The decay of this excited state can be categorised into two general processes: 
radiative and non-radiative.  Non-radiative processes involve decay without emission of 
light, and are depicted on a Jablonksi diagram as wavy lines. Non-radiative processes can 
be further divided by the change (or lack of) in spin multiplicity during the decay. If no 
change occurs the process is deemed “spin allowed” and is called an internal conversion 
(IC). This process allows higher energy singlet/triplet states to decay to lower energy 
singlet/triplet states. When a change in spin multiplicity accompanies a non-radiative decay 
the process is deemed “spin forbidden” and is called an intersystem crossing (ISC). This 
process allows for either the lowest energy singlet state to convert into the lowest energy 
triplet state or the lowest energy triplet state to decay to the ground state. Conversion 
between singlet and triplet states via ISC is important as it is the primary route through 
which triplet states are accessed.  Chemical transformations can theoretically take place 
from each of these excited states, though it is worth noting that the lifetimes of excited 
states are often short and competition exists from other processes such as radiative decay. 
Radiative decay processes, depicted by straight lines on a Jablonski diagram, involve 
decay of an excited state accompanied by emission of a photon. Decay of a photon from 
15 
 
an excited singlet state (Sx X ≠ 0) to the singlet ground state (spin allowed) is termed 
fluorescent emission, and decay from an excited triplet state (Tx X ≠ 0) to the singlet 
ground state (spin forbidden) is termed phosphorescence.  
 
Figure 1 
A Jablonski diagram depicting the possible fates of an electronically excited 
compound. 
 
The complexity of the Jablonksi diagram in Figure 1 demonstrates the highly competitive 
nature of photochemical processes. For a chemical transformation to occur the reaction of 
the excited state must out-compete the various decay processes. It is worth noting that 
chemical transformation is not always the desirable outcome and radiative decay 
processes can be advantageous, as in the case with fluorescent probes.16  
Despite these complexities photochemical reactions provide routes to previously 
inaccessible chemical transformations. This unique ability has allowed for the rapid 
evolution of photochemistry from a lab based curiosity to a highly developed field of 
research. Today photochemical reactions are routinely employed for laboratory syntheses17 
and have been exploited for commercial purposes, particularly in the printing,18 renewable 
energy,19,20 polymeric materials,21 and biomedical sectors.22–25 
 
1.1.2: [2+2] photocycloadditions 
Of the photochemical reactions initially studied in the early 20th century photocycloadditions 
have remained relatively well utilised. Perhaps the most intensely studied 
photocycloaddition is the enone-olefin [2+2] photocycloaddition, first observed through the 
conversion of carvone 9 to carvone-camphor 10 in 190826 and studied extensively in the 
1950s and 1960s (Scheme 3).27–33 
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Scheme 3 
The photochemical conversion of S-carvone 9 to carvone-camphor 10.  
 
The general mechanism of this reaction is best demonstrated schematically as outlined in 
Scheme 4. Excitation of the enone 11 to the singlet state (S1) 12, made possible by the n-
bonding electrons of the oxygen atom, is followed by intersystem crossing (ISC) to the n – 
π* triplet state (T1,) 13.34 The excited triplet state 13 is subsequently able to form an excited 
state complex (exciplex) 15 with the ground state olefin 14.35–37 In this exciplex the 
molecules align in a way that maximises the new bonding interactions which are made 
possible through excitation. Though an exciplex cannot be observed directly, it can be 
inferred from the regioselectivity of certain intermolecular photocycloadditions and helps to 
explain the increased reactivity of photocycloadditions when compared to non-
photochemical radical additions.36 
 
Scheme 4 
Photoexcitation of an enone 11 followed by formation of the required enone-olefin 
exciplex 15. 
  
The formed exciplex can then collapse to a 1,4-diradical through bond formation at the α or 
β carbons of the enone and subsequently form cyclobutane 16 (Scheme 5). Relaxation 
back to the ground state enone can occur at several points during the process, though the 
overall process is irreversible due to the formation of the cyclobutane ring. A major route for 
this relaxation is via the cis-trans isomerisation of the enone in the excited state,38 though 
this can be minimised through the use of cyclic enones.35,39 
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Scheme 5 
Formation of a cyclobutane ring 16 through collapse of the exciplex 15. 
 
A clearer explanation of this process can be gained by considering the molecular orbitals 
(MOs) of the reacting species. Molecular orbital theory (in the form of frontier molecular 
orbital theory), was first described by Fukui in 1952,40 and predicts reactivity based on the 
symmetry of interacting molecular orbitals. This theory was developed and expanded by 
Woodward and Hoffman and became the Woodward-Hoffman rules for electrocyclic 
processes.41–44 The theory states that the fate of a reaction can be predicted by considering 
the interaction between the highest occupied molecular orbital (HOMO) of one reactant and 
the lowest unoccupied molecular orbital (LUMO) of another. Applying this theory to the 
enone-olefin cycloaddition explains why the reaction does not proceed from the ground 
state, but occurs rapidly upon photo-excitation. By considering the reacting molecular 
orbitals of the enone 11 and the olefin 14 in the ground state it becomes apparent that 
suprafacial (head on) overlap of the orbitals cannot form a bonding interaction (Scheme 6). 
 
Scheme 6 
A HOMO-LUMO interaction  between a ground state enone 11 and olefin 14. 
 
Upon excitation an electron from the HOMO of the enone gets promoted into a higher 
energy molecular orbital, termed the singly occupied molecular orbital (SOMO). The 
symmetry of the excited state SOMO 13 is complementary to that of the LUMO on the 
olefin 14, enabling a symmetry allowed suprafacial bonding interaction.  
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Scheme 7 
The reaction between enone excited state 13 and olefin ground state 14. 
 
The knowledge gained from this early work has helped to establish the [2+2] 
photocycloaddition as a viable method for the laboratory synthesis of cyclobutane rings. 
Although the enone-olefin [2+2] cycloaddition is the most well studied of these reactions it 
is important to note that enone-alkyne,45–48  arene-olefin,49 enone-enone,11,50,51 and even 
olefin-olefin [2+2] photocycloadditions have been reported, and the reaction is implicit in 
named reactions such as the de Mayo52 and Paternò–Büchi53 reactions. More recently the 
development of enatioselective variants has ensured the inclusion of the reaction in the 
field of asymmetric synthesis. Scheme 8 highlights some examples of photochemical [2+2] 
cycloaddition reactions towards the synthesis of natural products.    
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Scheme 8 
An intramolecular [2+2] photocycloaddition employed: (A) during the synthesis of 
grandisol 17, an important natural product and synthetic precursor.54,55 (B) as a 
final step towards biyouyanagin A 18, a potent HIV replication inhibitor.56 (C) in the 
final step towards (-)-littoralisone 19,57 a compound which shows promise in the 
treatment of neurodegenerative disorders. (D) during the synthesis of (-)-
paeoniflorin 20, a compound with antiandrogenic properties.58 
 
1.1.2.1: [2+2] photocycloadditions of maleimides 
In the context of this thesis the [2+2] photocycloaddition reactions of maleimides deserve 
special mention. Unsurprisingly, due to the conjugation of the double bond with two 
carbonyl systems, maleimides are readily able to act as enones in highly efficient enone-
olefin [2+2] photocycloaddition reactions (Scheme 9).59–62 
 
Scheme 9 
Photochemical cycloadditions involving maleimides: (A) The photochemical [2+2] 
cycloaddition between maleimide 21 and various olefins 22. (B) The intra 
photochemical [2+2] cycloaddition of N-alkene maleimide 24. Subsequent 
rearrangement leads to cyclic product 25.  
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1.1.2.2: [2+2] photocycloaddition reactions of thiomaleimides 
More recently, work within the Baker group has expanded on maleimide photochemistry by 
exploring the photochemical reactivity of thiomaleimides. It was discovered that 
thiomaleimides have much larger extinction coefficients than unsubstituted maleimides, 
9500 cm−1·M−1 compared to 720 cm−1·M−1 at λmax, presumably due to the increased 
conjugation provided by the sulfur lone pair. Studies into the photochemical reactions of 
thiomaleimides showed a substantial increase in reactivity when compared to unsubstituted 
maleimide, with [2+2] photocycloadditions reaching completion within five minutes. A 
reaction between various thiomaleimide analogues 26 and styrene 27 was used to test the 
scope of this reaction (Scheme 10).63 
 
Scheme 10 
Photochemical reactions of thiomaleimide(s) 26 with styrene 27.  
 
Though these reactions proceeded in a quantitative yield, a large excess of alkene was 
required to prevent competition from a thiomaleimide-thiomaleimide [2+2] 
photodimerisation to produce succinimide dimer 29 (Scheme 11). In the absence of an 
alkene this dimerisation reaction was found to proceed quantitatively within five minutes of 
irradiation. Maleimide 21 irradiated under the same conditions required one hour of 
irradiation to form the product in a quantitative yield, highlighting the increased 
photochemical reactivity of thiomaleimides. The application of this reaction forms part of the 
research described in this text.  
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Scheme 11 
(A) Photochemical dimerisation reactions of thiomaleimide(s) 26. (B) A 
comparative photochemical dimerisation reaction of maleimide 21.  
 
The efficiency of the thiomaleimide [2+2] photocycloaddition reactions, coupled with the 
remarkable lack of side reactions, demonstrate a significant step forwards in the field. At 
the time of writing these reactions are arguably the most efficient [2+2] photocyclic 
additions reported in the scientific literature.  This impressive photochemical reactivity 
identifies thiomaleimides as a class of reagents deserving further study. 
1.1.3: Photochemical decarboxylation reactions 
A decarboxylation reaction is defined as a reaction which proceeds with concurrent loss of 
carbon dioxide. This process is most commonly initiated by the production of a carboxyl 
radical which is subsequently able to undergo radical fragmentation. The most famous of 
these reactions is the Barton decarboxylation, in which a pre-formed thiohydroxamate 
(Barton) ester (31) is treated with azobisisobutyronitrile (AIBN) and tributyltin hydride to 
initiate carboxylate radical formation. The resulting alkyl radical (32) is subsequently 
trapped with a suitably reactive compound, often a halogen or hydrogen source (Scheme 
12).64–66 
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Scheme 12 
A Barton decarboxylation initiated by AIBN and tributyltin hydride. 
 
Though radical initiators (such as AIBN and tributyltin hydride) are most commonly 
employed to produce the key carboxylate radical, photochemical methods have also been 
explored. As early as the 1960s and 1970s groups were observing room temperature 
decarboxylations of aliphatic carboxylic acids upon UV irradiation, suggesting a 
photochemical pathway to carboxylate radicals.67–69 More recently photochemical variants 
of the aforementioned Barton decarboxylation have been developed which eliminate the 
need for radical initiators (Scheme 13).70–72  
 
Scheme 13 
A photochemical Barton decarboxylation utilised towards the synthesis of cholanic 
acid analogue 34.  
 
In the case of the photochemical Barton decarboxylation the radical is provided through 
homolytic cleavage of the N-O bond in the thiohydroxamate ester, though this need not be 
the case. Many reactions exploit photoinduced single electron transfer (PET), where an 
electron from the carboxylate 35 is transferred to a photochemically excited electron 
acceptor 36*, to form the necessary carboxylate radical. Various electron acceptors have 
been employed for this purpose, including 1-cyanonaphthalene,73 various heterocyclic 
dyes,74 iminium salts,75 and tetracyanobenzene.76  A general scheme for photochemical 
decarboxylation via PET is shown below (Scheme 14).  
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Scheme 14 
A general scheme demonstrating PET from a carboxylate (35) to an electron 
acceptor (36). 
 
1.1.3.1: Photochemical decarboxylation reactions of phthalimides 
Due to structural similarities with maleimides the photochemical decarboxylation reactions 
of phthalimides are of particular relevance to the work presented in this thesis. Reports of 
phthalimides engaging in decarboxylation reactions exist from as early as 1973,77 though 
the reaction was not properly explored until the late 1980s.78 Okada et al. demonstrated the 
photochemical decarboxylation of o-phthaloyl esters (38) by irradiation in the presence of 
the electron donating 1,6-bis(di-methylamino)pyrene (BDMAP) 40. The authors proposed 
donation of an electron from BDMAP 40 to the excited state phthalimide 39 followed by N-
O bond cleavage and decarboxylation (Scheme 15).  
 
Scheme 15 
The mechanism proposed by Okada et al.78 for the photochemical decarboxylation 
of o-phthaloyl esters (38).  
 
In the early 1990’s Griesbeck et al. expanded on this work by demonstrating an intra-
molecular PET process from an N-pendant carboxylic acid to the phthalimide.79,80 In this 
scenario the carboxylate is the electron donor and the phthalimide the electron acceptor. 
This removes the need for the additional electron donor and expands the utility of the 
reaction (Scheme 16).  
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Scheme 16 
The photochemical decarboxylation of N-phthaloyl-serine 45. 
 
Though in this early example the resulting carbon centred radical was not reacted further, 
this work demonstrated the capability of phthalimides to act as electron acceptors in PET 
reactions. Since their initial discovery phthalimide mediated decarboxylation reactions have 
been thoroughly explored and utilised for a variety of purposes. Though the vast majority of 
the work has been done by Griesbeck et al., the reaction has been successfully adopted by 
other groups. At the time of writing the reaction has been employed towards the synthesis 
of phthalimide containing cyclic compounds and cyclic peptides,81,82 and also as a 
photocage for the timed activation of fluorescent probes.83 A small summary of some of the 
reported uses of phthalimide photodecarboxylations is shown below (Scheme 17).  
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Scheme 17 
A small summary of the photochemical decarboxylation reactions of phthalimides. 
(A) Photochemical macrocyclisation. (B) Photochemical peptide cyclisation. (C) A 
photochemical fluorescent probe. 
 
1.1.4: Photocleavable protecting groups 
Although photochemical reactions which form covalent bonds are often given more 
attention, photolytic bond cleaving processes should be treated with equal importance. 
Early research into photolytic bond breaking reactions was restricted to synthetic organic 
chemistry and was utilised in the photochemical deprotection of amines,84,85 esters,86 and 
carboxylic acids.85,87 The early adoption of these reactions for protecting reactive chemical 
functionality led to them being termed “photocleavable” protecting groups. The general 
scheme below uses the o-nitrobenzyl photocleavable protecting group to demonstrate the 
premise (Scheme 18). 
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Scheme 18 
The general premise of photocleavable protecting groups.  
 
Over the last few decades a plethora of photochemical protecting groups based around a 
variety of chemical structures have been discovered and several excellent reviews have 
been written on the subject.88–90 Though the application of photocleavable protecting 
groups to chemical biology and biochemistry is most pertinent to this work, it is worth noting 
that these important reactions have had a huge influence on several areas of research 
including organic synthesis,17,49,91 polymerisation,92,93 peptide synthesis,94 and surface 
modification.95  
1.1.4.1: Photocleavable protecting groups in chemical biology 
The spatio-temporal release of functional compounds has proven particularly useful to the 
study of biological systems. Commonly employed photocleavable protecting groups, and 
their applications, are outlined in Table 1 below. This list is by no means exhaustive and 
more comprehensive summaries of this area can be found in the literature.89,96–98 
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Table 1 
The applications of commonly employed photochemical protecting groups 
 
Photocage Applications 
 
 
Photochemical release of ATP,99,100 DNA activation,101 RNA 
synthesis,102 natural product synthesis,103 drug delivery,104,105 
photochemically labile nanoparticles.106 
 
Drug delivery,107 protein folding,108,109 photochemical release 
of cAMP, glutamate, and GABA.110,111 
 
Enzyme catalysis,98, photochemical release of ATP,112 
GTP,113 and GABA.114,115 
 
Drug delivery,116 photochemically labile nanoparticles.117 
 
The extensive list of applications in which photocleavable protecting groups are implicit 
perfectly highlights the power of photochemistry and the importance of research into this 
area. This will be discussed in more detail later in this chapter.  
1.2: Chemical modification of proteins and peptides 
1.2.1: Background 
Proteins and peptides are implicated in virtually every biological process within the body, 
and discovering ways to accurately study and probe the form and function of these 
macrostructures is essential to our ongoing understanding. Over the last century the 
importance of natural chemical modification, through post-translational modifications, has 
been extensively researched. These post-translational modifications serve to alter the 
chemistry of the protein or peptide and play essential roles in modulating their function 
inside the body.118 Examples of post-translational modifications include acetylation, 
methylation, and ubiquitination. These are demonstrated below (Scheme 19).  
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Scheme 19 
A small selection of lysine post-translational modifications.  
 
Understanding the true potential of chemical protein modification has led to great efforts 
being made to extend beyond the limits of native post-translation modification. Over the last 
50 years great efforts have been made to discover new methods to modify proteins with 
novel chemical functionality both in vitro and in vivo.119,120 This has been a huge area of 
research within the rapidly expanding field of chemical biology and forms part of the work 
presented in this thesis. Since their conception chemically modified proteins have been 
used for a variety of purposes, with a particular focus placed on the development of novel 
protein based therapeutics.121,122 To this end chemical protein modifications have been 
used to improve the pharmacokinetic and pharmacodynamic properties of known peptidic 
drugs123,124 and to deliver therapeutic payloads to biological targets of interest.121,122,125 
Additionally, chemical protein modification has been employed to attach imaging agents,126 
diagnostic tools127 and radionuclides,128 for both research and therapeutic purposes. 
1.2.2: Amino acid modification 
In order to chemically modify a protein it is necessary to target a suitably reactive chemical 
moiety on the protein’s surface. It is desirable to target the protein with a reagent which 
displays fast reaction kinetics, is site-selective, stable under physiological conditions and 
ultimately non-damaging to the protein or organism being studied. Fortunately, the amino 
acid side chains present a wide range of functionalities which can be targeted by an ever 
expanding tool box of chemical reactions that fulfil these criteria. Protocols for the selective 
modification of arginine 54,129 aspartic/glutamic acid 55,130 cysteine 59,131 histidine 57,132 
lysine 58,120,133 and tyrosine 56134 have been discovered and are routinely employed 
(Scheme 20). Of these methods lysine modification has historically dominated the field, 
though cysteine modification (which will be covered in detail in the next section) has 
recently seen increased attention.   
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Scheme 20 
A selection of chemical modifications for specific amino acid side chains: (A) The 
reaction of arginine 54 with substituted glyoxal.129 (B) The EDC coupling reaction of 
carboxylic acid side chains.130 (C) Tyrosine 56  modification through a three 
component Mannich reaction.134 (D) Histidine 57 modification through a 
functionalised epoxide.132 (E) Lysine 58 modification via activated NHS esters133 or 
isothiocyanates.120  
 
1.2.3: Cysteine modification 
Though each of the amino acid targets has particular advantages the bulk of this work will 
focus on selective cysteine modification. Cysteine residues offer two major benefits over 
the more commonly targeted lysine residues: they display a greater nucleophilicty at low pH 
and are present in a lower natural abundance.120,135 These are desirable qualities when 
selectivity is required.119,136 The second point is particularly relevant for clinical applications 
as it is becoming increasingly apparent that the heterogeneous mixtures resulting from 
lysine modification display less than ideal therapeutic qualities.137 Lysine residues are 
abundant on the surface of proteins, decreasing the site-selectivity of any technique which 
targets them.120 Conversely, cysteine residues have a natural abundance of just 2.26%.135 
This leads to a greater degree of selectivity and homogeneity, especially when combined 
with site directed mutagenesis. For these reasons methods that target cysteine residues 
have seen an enormous amount of interest, especially over the last 20 years. Scheme 21 
displays a selection of some of the more prevalent methods.119,120,122,131,136,137   
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Scheme 21 
Cysteine-selective chemical modifications: (A) Modification using 
haloacetamides.138 (B) Modification using maleimide.139 (C) Modification using 
oxidative disulfide exchange.138 (D) Modification using an alkyl halide.140 (E) 
Modification using diselenide exchange.141 (F) DHA formation using o-
mesitylenesulfonylhydroxylamine (MSH) and subsequent modification using a 
thiol-ene reaction.142 (G) Sulfur-selenide exchange followed by desulfurisation.143 
(H) Modification using a bis-modified pyridazinedione.144,145  
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1.2.3.1: Next generation maleimides as tools for cysteine modification 
Work in the Baker and Caddick groups at UCL has focused on the development of next 
generation cysteine-selective reagents based around the maleimide scaffold.145–153 The 
addition of a leaving group to the alkene of the maleimide greatly expands the reactivity of 
these reagents. Next generation maleimides (61) react with cysteine residues (60) via 
addition-elimination and thus retain the maleimide double bond, further expanding the 
reactivity profile of these reagents and allowing for the incorporation of a second chemical 
or peptidic moiety 62.146,154 Early work with the resulting cysteine-maleimide linkers 
discovered that the modification is reversible under high thiol concentration, opening up the 
possibility that these linkers could be used to develop thiol-cleavable protein-drug 
conjugates which release the chemical payload in the thiol rich intracellular 
environment.146,148,151,155 A summary of the reactivity of next generation maleimides is 
shown below (Scheme 22).  
 
Scheme 22 
The reaction between cysteine and a substituted maleimide 61. Cleavage of the 
maleimide is observed under high thiol concentrations or cell mimicking 
conditions.  
 
A further extension of these maleimides are the disubstituted maleimides.147,149,152,153,156 
These reagents contain two suitable leaving groups and are thus able to react with two 
cysteine residues, making them ideal for insertion into a disulfide bond. Cysteine residues 
are often “tied up” in disulfide bonds, making them unavailable for chemical ligation. 
Chemical tagging of these cysteine residues is dependent on reduction of the disulfide 
bond, which can often lead to structural changes to the quaternary structure of the protein 
and give rise to undesirable issues with stability or functionality. Disubstituted maleimides 
can react with both of the liberated cysteines from a disulfide bridge, reforming the covalent 
link and retaining the three-dimensional structure of the protein. An overview of the 
reactivity of disubstituted maleimides is shown below (Scheme 23). 
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Scheme 23 
Inserting disubstituted maleimide reagents (65) into native disulfide bonds. 
 
Though the importance of disulfide bonds is dependent on a wide range of factors, 
including the size of the protein and the position of the bridge within the proteins structure, 
it is clear that maintaining their presence is hugely beneficial. In smaller proteins such as 
insulin and somatostatin, used for the treatment of diabetes and neuroendocrine tumours 
respectively, the disulfide is known to be essential for the function of the peptide.157 Often, 
especially in larger proteins such as immunoglobulins, the accessible disulfide bonds are 
not essential for function but do provide a significant degree of thermal stability.158 
Maintaining this stability is valuable for any therapeutic application.  
1.2.4: Antibody modification 
The power of chemical protein modification is perhaps best exemplified by the rapidly 
expanding field of antibody conjugation. Antibodies have an innate specificity for the 
antigen against which they are expressed, which makes them an attractive vehicle for the 
targeted delivery of small molecules. Over the last three decades a considerable amount of 
research has been dedicated to developing methods for reliably modifying antibodies and 
their associated fragments.125,128,159–163  
1.2.4.1: Antibody structure 
Antibodies are large glycoproteins which are responsible for identifying and eliminating 
foreign bodies. Consequently, their evolution has been directly linked to their ability to 
recognise particular disease markers, which has in turn led to a high degree of target 
specificity. So far five classes of antibodies have been identified in vertebrates; IgA, IgD, 
IgE, IgG and IgM.164–166 IgG antibodies represent the predominant class of human 
immunoglobulins and can be further categorised into four sub-families; IgG1, IgG2, IgG3 
and IgG4.167 IgG1 antibodies are the most abundant of the four and are consequently the 
most commonly employed therapeutic antibodies.168 An IgG1 consists of four smaller 
protein chains; two identical ~25 KDa “light” chains and two identical ~50 KDa “heavy” 
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chains. The N-termini of these chains converge to make up the antigen binding region of 
the protein and as a result considerable structural variation is seen in this region. This has 
led to the N-terminus being named the variable region, with the associated regions on the 
light and heavy chains designated VL and VH respectively. Further from the antigen binding 
region the amino acid sequence becomes more conserved on both the heavy and the light 
chain, leading to the area being designated the constant region. Each light chain contains a 
single constant region CL whereas the heavy chain is made up of three distinct constant 
regions CH1, CH2 and CH3. The individual chains are connected by disulfide bonds and 
considerable non-covalent interactions to form the characteristic symmetrical “Y” structure. 
The whole structure can be roughly divided into two distinct structures; antigen binding 
fragment (Fab) and the constant fragment (Fc, “Fragment crystallisable”). Further division 
of the Fab fragment can produce the variable fragment Fv (Figure 2).164 
 
Figure 2 
A schematic representation of an IgG1 immunoglobulin. 
 
Both Fab fragments and Fv fragments are able to successfully bind to antigens and have 
been used as therapeutics.169 The Fc region, though unable to bind to the antigen, is 
responsible for the immunological effect of antibodies and is essential for antibody-
dependent cellular cytotoxicity and complement-dependent cytotoxicity.166,170 
1.2.4.2: Antibody conjugates 
Full antibody conjugates 
By far the most well accepted antibody directed therapies are based around the full 
antibody scaffold.160,162,171 In fact, due to the immunogenic nature of the Fc region some 
success has been had in treating disease with native antibodies containing no additional 
chemical modification.172,173 Early examples of antibody based therapeutics were based 
entirely on murine monoclonal antibodies and problems of immunogenicity, efficacy and 
serum half life were frequently encountered.171 The advent of chimeric antibodies, in which 
the Fc region of a foreign antibody is replaced with that of a human antibody, has helped to 
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overcome these issues.174,175 In 1997 Rituxan, used for the treatment of B-cell non-
Hodgkin’s lymphoma,171,172,176 became the first chimeric antibody to be awarded FDA 
approval. Since this milestone the number of monoclonal antibodies with clinical approval 
in both the USA and the EU has rapidly increased.121,177 Though this impact is significant 
there are several drawbacks to using native antibodies for therapeutic purposes. The large 
size of the proteins leads to poor tumour penetration and long in vivo half-lives, which can 
lead to non-selective cell toxicity.178 These issues decrease the efficacy of the treatments 
and make native antibodies a non-ideal therapeutic choice.179  
Fortunately, these issues can be remedied through the covalent attachment of small 
chemical moieties. These attachments can be used to modulate the properties of the 
antibody or, as in the case of Antibody Drug Conjugates (ADCs), to attach a cytotoxic 
payload to improve potency.123,124,160 This latter approach has gained significant attention 
and led to the development of the area of ADC research. In designing an effective ADC 
several chemical problems must be addressed.  The attached drug must be extremely 
potent to compensate for low delivery levels. The linker between the drug and the antibody 
must be stable within the blood but labile within the cell to ensure efficient release of the 
drug occurs only at the target. In addition to this all of the components (antibody, drug, and 
linker) must have been individually assessed to eliminate any safety concerns (Figure 3).160  
 
Figure 3 
A schematic highlighting some of the criteria for a successful antibody drug 
conjugate. 
 
Within the last few years the FDA have approved two ADC based therapeutics; Kadcyla for 
the treatment of HER2-positive breast cancer and Adcetris for the treatment of Hodgkin and 
systemic anaplastic large cell lymphomas. Kadcyla consists of the cytotoxic agent DM1 
conjugated to the monoclonal antibody trastuzumab and targets the HER2 receptor which 
is over expressed in cancer cells.180 Adcetris consists of the antimitotic agent monomethyl 
auristatin E (MMAE) conjugated to the chimeric monoclonal antibody brentuximab which 
targets the CD30 antigen.181  
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Several methods for attaching drugs to antibodies have been developed, the vast majority 
relying on conjugation to native amino acids. Historically, lysine modification has prevailed 
but in recent years cysteine modification, due to the many advantageous outlined 
previously, has become the industry standard.  
Fab fragment conjugates 
Fab fragments (antigen binding fragment) are made up of the VH and VCH1 regions of the 
heavy chain attached by a single inter-chain disulfide bond to the light chain (Figure 4). 
These fragments are able to bind to the antigen, though the absence of the immunological 
effector function-mediating region, which exists on the Fc fragment, precludes any 
immunogenic effects.164,182 Though this can be a disadvantage the added benefit of 
increased tumour penetration and shorter half-life make Fab fragments an attractive target 
for conjugation.183,184 Despite being less studied several successful therapeutic examples 
have reached the market.169 The unique properties of Fab fragments (fast clearance and 
improved tumour penetration) make them ideal for the delivery of imaging agents for 
diagnostic purposes (Figure 4). Considerably better resolution between the target site and 
the background can be achieved with Fab fragments when compared to full 
antibodies.185,186   
 
Figure 4 
A schematic representation of a Fab fragment imaging agent.  
  
scFv conjugates 
Single chain variable fragments (scFvs) contain only the variable region of the antibody and 
represent one of the smallest classes of clinically employed antibody fragments. These 
fragments are termed “single chain” due to the introduction of a link between the VL and VH 
regions of the Fv fragment, covalently binding the two regions into a single fragment. This 
covalent link is necessary to improve the in vivo stability of the Fv region, which has been 
found to be too unstable for clinical use in the native form.187 Typically a peptide chain is 
introduced for this purpose, though interchain disulfide bonds have also been engineered 
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into the structure for the same effect.188,189 More recently hybrid approaches in which both 
a peptide chain and a disulfide bond have been utilised to create scFv fragments that are 
readily expressed and display excellent stability.190 An overview of the different types of 
scFv are shown below (Figure 5). 
 
Figure 5 
Schematic representations of a variable fragment (Fv) 68, a single chain variable 
fragment (scFv) 69, a disulfide stabilised variable fragment (dsFv) 70 and a 
disulfide stabilised single chain variable fragment (ds-scFv) 71. 
 
scFvs display improved tumour penetration and clearance rates, surpassing those 
demonstrated by Fab fragments.183,191–193 This makes them ideal for many of the same 
applications, and indeed scFv fragments are regularly employed as imaging 
agents.179,185,194  
1.2.5: Peptide based therapeutics 
Peptides are well studied biomolecules which generally show excellent selectivity for their 
specific cell surface receptors.195 Over 7000 naturally occurring peptides have been 
identified and implicated in crucial roles, acting as hormones,196 ion channel regulators,197 
growth factors,196 and anti-infectives,198 amongst others.195,199,200 Poor pharmacological 
properties plagued early peptide based drugs, primarily due to rapid enzymatic digestion, 
and led to a poor adoption of these therapeutics in the mid 20th century.199 A notable 
exception can be found with the polypeptide insulin, which remains one of the most utilised 
clinically available peptidic drugs. Despite these disadvantages the use of peptides in 
therapy continues to grow as formulation methods are developed to help minimise their 
negative attributes. At the time of writing over 130 peptidic therapeutics are in the clinical 
pipeline, with a further 600 in pre-clinical development.199 
1.2.5.1: Somatostatin and its analogues 
Somatostatin is a cyclic peptide expressed in both the central nervous system (CNS) and 
gastrointestinal tract. In the former the peptide acts as a neurotransmitter, and in the latter it 
is a potent inhibitor of the release of growth hormone, glucagon, insulin and gastrin.201–205 
Two forms of natural somatostatin are known, somatostatin-14 (SST-14) 72 and 
somatostatin-28 (SST-28) 73; the number relating to the length of the amino acid 
backbone. SST-28 73 contains the same core 14 amino acids as SST-14 72 with a further 
14 added on to the N-terminus (Figure 6). Both forms of the protein activate the same 
signalling pathways, though SST-28 73 displays higher potency.204 
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Figure 6 
Schematic representations of somatostatin-14 72 and somatostatin-28 73. 
 
Somatostatin receptors, of which there are currently five known human subtypes (SST1-5), 
are over-expressed in various diseases, particularly cancers related to growth hormone.203 
The relative expression of these five subtypes has been found to vary significantly 
depending on location within the body, but they all bind both forms of somatostatin with low 
nanomolar affinity.205 Binding of somatostatin to the receptor initiates signalling pathways 
which activate protein tyrosine phosphatase (PTP), inhibit adenylyl cyclase, activate 
K+/Ca2+ channels and modulate mitogen-activated protein kinase (MAPK). The combination 
of these pathways results in the characteristic effects of the peptide.203,205 The potent 
effects on cancer targets, and low nanomolar concentrations required to realise them, 
make somatostatin an ideal candidate for therapeutic investigation. Unfortunately both 
forms of the peptide suffer from a short in vivo half life of just 2-3 minutes, making them 
unsuitable for therapeutic applications in their native form.201 
Octreotide  
Significant effort has been made to overcome the poor pharmacokinetics of somatostatin 
and has resulted in the generation of several analogues. Structure-activity relationship 
studies discovered that several changes to the structure of somatostatin-14 72 were well 
tolerated and helped to improve its pharmacokinetic properties. Reversing the chirality of 
the tryptophan residue from L to D significantly improved the half life without reducing the 
potency.206 It was found that the binding of the peptide to the receptor was predominantly 
through a -turn at amino acid residues 7-10 (Phe-Trp-Lys-Thr) and modifications to this 
region resulted in a significant loss in potency.206,207 With this in mind the amino acids distal 
to the pharmacophore were substituted or removed (though the disulfide bridge was 
conserved out of necessity) resulting in several analogues.206 This work culminated in the 
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generation of several highly potent somatostatin analogues that displayed greater in vivo 
half life and selectivity for one SST receptor over the others. Of these Octreotide 74 (SST2 
selective),208 Lanreotide 75 (SST2/SST5 selective)209 and Vapreotide 76 (SST5 
selective)202 have obtained FDA approval (Figure 7). 
 
Figure 7 
Somatostatin analogues currently on the market. Underlined = D enatiomer. 
 
Of these analogues Octreotide 74 is perhaps the most well utilised. This analogue was 
originally reported by Wilfried Bauer208 and is today marketed under the trade name 
Sandostatin by Novartis Pharmaceuticals.200 The peptide has FDA approval for the 
treatment of neuroendocrine tumours, which have been found to over-express the SST2 
receptor.203  Octreotide 74 has been found to be nearly 20 times more potent than native 
somatostatin and displays exquisite selectivity for the SST2 receptor, making it an ideal 
therapeutic for the treatment of neuroendocrine tumours. Additionally, the in vivo stability 
was found to be significantly improved compared to somatostatin.208 Octreotide 74 is still 
receiving significant research interest, with recent work focused on increasing the half-life 
of the drug through formulation within a biodegradable polymer.210 The excellent potency 
and improved pharmacokinetic properties of Octreotide 74 make it a highly desirable 
therapeutic drug and an excellent candidate for further study.  
1.3: Photochemistry and Chemical Biology 
The marriage of photochemistry and protein modification perfectly exemplifies the power of 
interdisciplinary research. Advances in both fields over the last 20 years have led to the 
rapid rise of photochemical probes being used to observe, influence or exploit biological 
processes.211–217 These photochemical probes can be broadly split into two categories; 
photoswitches and phototriggers. Whilst both have the power to initiate dynamic biological 
processes, photoswitches refer to reversible photochemical processes whereas 
phototriggers generally refer to irreversible systems.212 Reversible photochemical control 
over biological mechanisms has proven to be a valuable tool for studying time sensitive 
cellular processes218,219 and protein interactions.220,221 Sadly photoswitches often display 
slow reaction kinetics, and incomplete conversions are common. Additionally, thermal 
reversion from one form to the other can occur. The combination of these problems often 
leads to poor contrast between the “on” and “off” forms of the switch, limiting their utility. 
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For situations where reversibility is not required it is often more prudent to employ 
phototriggers, which typically display more favourable reaction kinetics and greater 
conversions.  The two are compared in the schematic representation below (Scheme 24). 
 
Scheme 24 
A comparison of photoswitches and phototriggers.  
 
A large body of work exists on both photoswitches and phototriggers being employed to 
release biologically active organic molecules and thus gain spatio-temporal control over 
biological processes. This is especially prevalent in neuroscience where these techniques 
have been employed to gain exquisite control over the concentrations of neurologically 
important chemicals such as glutamate, nitrous oxide, and calcium. Indeed photouncaging 
of glutamate has become so popular that compounds for this purpose are now 
commercially available (Figure 8). 96,212,222 
 
Figure 8 
Commercially available photocaged glutamate analogues. 
 
Whilst this approach of releasing an organic substrate to elicit a desired effect on a protein 
is common, less work has been reported on directly initiating phototriggered reactions on 
proteins.96,215–217,223 This is unsurprising as the increased size and complexity of proteins 
complicates this approach. Part of the work described in this thesis falls into this category, 
thus the remainder of this section will be spent introducing this area.  
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1.3.1: Photochemical protein uncaging 
The applications of photoactivatable peptides and proteins fall generally into two 
categories: photochemical protein uncaging and photochemical targeted small molecule 
delivery. Photochemical protein uncaging describes a system in which a protein is 
deactivated through the covalent attachment of a suitable photolabile chemical “cage”. 
Subsequent irradiation releases the protein or peptide from the cage and restores the 
biological activity. Typically a cage is installed at a topologically sensitive location to cause 
the greatest detrimental effect to the activity, leading to a greater contrast before and after 
irradiation. The choice of cage can be tailored to the protein or peptide under study and 
numerous photocleavable protecting groups have been found to be suitable for these 
applications.215,216 This approach has gained significant interest over the last few decades 
for research purposes, though clinical applications are only now being fully realised.215,216 A 
general scheme demonstrating this approach is shown below (Scheme 25).  
 
Scheme 25 
A schematic demonstrating the concept of photochemical protein uncaging.  
 
Photochemical Ion Channel Control 
An excellent early example of photochemical protein uncaging was reported by Lester et al. 
on the “optochemical” control of a nicotinic acetylcholine receptor (nAChR) ion channel. By 
introducing an o-nitrobenzyl photocage to essential tyrosine residues at the extra-cellular 
N-terminus of the protein, the potential difference across the cell was eliminated. Irradiation 
at 365 nm resulted in cleavage of the photocages and reintroduction of the desired cross-
membrane current (Scheme 26).224  
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Scheme 26 
Using an o-nitrobenzyl photocleavable protecting group to gain control over an ion 
channel.224 
 
More recently a similar approach using a dimethoxynitrobenzyl caged cysteine residue to 
gain photochemical control of a potassium ion channel both in vitro and in vivo was 
reported.225 Some excellent reviews have been written on this area.219,226,227  
Photochemical Enzyme Control 
Gaining photochemical control over enzymatic reactions has greatly expanded our 
understanding of the processes in which they are implicated. An early example of using 
photocaging to activate an enzyme was provided by Schultz et al. The team engineered an 
o-nitrobenzyl protected cysteine residue into the human proapoptotic protein caspase 3, 
preventing conversion to the active enzyme and thus inhibiting catalytic activity. Irradiation 
at 365 nm to remove the photocage resulted in the generation of the active enzyme and a 
subsequent reformation of catalytic activity was observed.228 
Though the photochemically uncaged enzyme did not achieve the same catalytic activity as 
the native enzyme, significant contrast between the caged and uncaged enzymes was 
observed. The same team employed a similar approach to gain photochemical control over 
the enzyme -galactosidase both in vitro and in vivo.229 More recently photocaging has 
been applied to photoregulate a variety of enzymes, including proteases,230 luciferase231 
and DNA polymerase.232 
Light activated protein dimerisation 
Selenocysteine is a highly reactive cysteine analogue which has been shown to impart 
unusual chemical reactivity to engineered proteins. Though the expanded chemical 
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reactivity is advantageous installing selenocysteine residues is non-trivial due to the 
amplified chemical reactivity of the group under aerobic and physiological conditions. A 
method for incorporating 4,5-dimethoxy-2-nitrobenzyl (DMNB)  photocaged selenocysteine 
into a green fluorescent protein (GFP) mutant 77 to alleviate these installation problems 
was recently reported. Klimašauskas et al. exploited the photolabile nature of DMNB to 
gain photochemical control over protein dimerisation (Scheme 27).233   
 
Scheme 27 
Using photocaged selenocysteine to gain control over protein dimerisation.233  
 
This work could be used to control the assembly of multi-domain proteins by combining the 
unique reactivity of selenocysteine and spatiotemporal control of phototriggers.  
In addition to the applications highlighted above photochemical protein uncaging has also 
been utilised to modulate kinases,234 recombinases235 and nucleases,236 and exploited to 
achieve spatiotemporal control over protein phosphorylation sites237 and cellular protein 
translocation.238 These applications demonstrate the power of combining photochemistry 
with chemical biology and highlight the importance of developing chemical reactions to 
further explore this area. It is worth noting in each of the cases above the unnatural amino 
acid phototrigger was introduced using sited directed mutagenesis. This is necessitated by 
a lack of reliable means for introducing photocages site selectively to the natural amino 
acid backbone.216 Site directed mutagenesis complicates the preparation of these 
biomolecules and is a significant drawback. Methods to site selectively introduce a 
photocage to a natural amino acid without the need for mutagenesis would represent a 
significant contribution to the field.  
Protein photocages in antibody photoimmunotherapy 
Protein photocages have been employed successfully in antibody based 
photoimmunotherapy (PIT). In this approach a therapeutic immunoglobulin is deactivated 
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through the covalent attachment of photolabile cages and subsequently activated by 
irradiation (Scheme 28).  
 
Scheme 28  
A scheme depicting the premise behind photochemical uncaging in antibody 
photoimmunotherapy.   
 
This process was described as early as 1996239 though has been exploited with greater 
success more recently.240,241 Work by Self et al. describes how attachment of o-nitrobenzyl 
photocleavable cages to anti-CD3 antibodies reduces the binding affinity of the antibody to 
the antigen. Subsequent irradiation with UV-A removes the photocages and restores the 
activity of the antibody.241  
1.3.2: Photochemical release from proteins 
An alternative use for the combination of photocages and protein conjugation is to utilise 
the protein as a vehicle to deliver a chemical payload to a particular target, and 
subsequently release the compound photochemically. This approach differs in the sense 
that in general the activity of the protein must be retained upon attachment of the “cage” to 
observe the desired effect. For this reason the site of attachment is often chosen to be 
distal from any functionally important regions on the protein.  Considerably less research 
has been done in this area when compared to photochemical protein uncaging, though 
several excellent pieces of work (highlighted below) demonstrate the potential of this 
approach.  
1.3.2.1: Photocleavable antibody drug conjugates (pADCs) 
One of the first examples of targeted drug delivery using a photolabile protein-drug 
conjugate was provided by Senter et al. The group conjugated the toxin PAP-S (pokeweed 
antiviral protein S) to a murine monoclonal antibody (J5) via an o-nitrobenzyl based 
photolabile linker (Figure 9).242 Subsequent irradiation released the active drug in yields of 
up to 90%. Though the toxic effect of the antibody drug conjugate was significantly less 
than the native PAP-S this work provided the earliest known example of a photocleavable 
ADC.  
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Figure 9 
The earliest reported photocleavable ADC J5-PAP-S 78.  
 
The next example of a photocleavable ADC found within the literature was provided by 
Pegram et al. in 2003.243 The group used Paclitaxel linked to the therapeutic antibody 
Herceptin via a proprietary photocleavable linker (Figure 10). Though the group did not 
release details of the linker the results suggest that non-photochemical release of the drug 
was occurring. Despite this a significant increase in toxicity was observed after irradiation 
when compared to the non-irradiated control.243 Whilst the non-specific release of drug 
decreases the appeal of this work it does exemplify the premise and provide further 
validation for this technique.  
 
Figure 10 
The photocleavable ADC Her-Paclitaxel 79.  
 
The most robust photocleavable ADC reported thus far was by Schnermann et al. who 
used a novel cyanine based photocage244 to release a highly potent microtubule 
polymerisation inhibitor combretestatin A-4 (CA4) from the clinical monoclonal antibody 
panitumumab.245 Photoexcitation of the cyanine cage results in photooxidative cleavage of 
the C-N bond between the cage and the linker. Subsequent intramolecular cyclisation of 
the amine onto the carbamate bond results in cleavage of the toxic CA4. The work 
describes both the in vitro and in vivo application of this photocleavable ADC which 
displays excellent contrast in toxicity before and after irradiation (Figure 11). However, the 
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approach does have several drawbacks, particularly the long winded synthesis of the linker 
and the time taken for the drug to reach maximum concentration after irradiation (18 hours). 
This work provides the first true in vivo demonstration of the power of photocleavable-ADCs 
and provides a benchmark for future work in the area. 
 
Figure 11 
The recently reported photocleavable ADC CY-Pan-CA4 80. 
 
1.3.2.2: Antibody-directed photodynamic therapy 
Photodynamic therapy (PDT) utilises photosensitising drugs typically made up of extended 
porphyrin ring systems. Upon absorption of light the drug is able to undergo an intersystem 
crossing with triplet oxygen to produce singlet oxygen which can cause significant damage 
to surrounding tissue (Figure 12).246,247 
 
Figure 12 
A schematic representation of photodynamic therapy (PDT) and the porphyrin 
based PDT agent meso-tetra-hydroxyphenyl-chlorin (mTHPC) 81.   
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In traditional PDT selectivity for the disease target is achieved through targeted irradiation  
of the disease location using lasers, though off-target side effects are still common. 
Antibody directed PDT is a subset of photoinduced immunotherapy (PIT) which adds an 
extra layer of defence against side effects by exploiting the targeted nature of 
immunoglobulins to deliver the photosensitiser specifically to the disease target. Though 
early attempts at this ideal system produced only minor therapeutic advantages, more 
recent work has produced antibody-photosensitiser conjugates which display selective 
toxicity in vivo.248 A particularly promising example is provided by the work of Kobayashi et 
al. The group utilise a hydrophilic phthalocyanine photosensitiser (IR700) attached to the 
monoclonal antibody panitumumab (Figure 13). Irradiation with deep penetrating near-IR 
light results in selective destruction of the target tumour cells and a significant reduction in 
total tumour volume  when compared to the non-irradiated control.249  
 
Figure 13 
The antibody directed photodynamic therapy agent Pan-IR700 82. 
 
1.3.3: Photochemical manipulation of peptides 
As with larger proteins, the photochemical manipulation of peptides has gained significant 
research interest over the last two decades. The smaller size of peptides makes them more 
sensitive to topological changes and thus easier to deactivate through installation of 
photoremoval protecting groups.250 This makes them ideal candidates for photochemical 
manipulation.  
1.3.3.1: Photochemical switches  
Azobenzene photoswitches 
The majority of photochemical peptide manipulation has revolved around the use of 
photoswitches to gain reversible control over peptide conformation and function.250,251 An 
early example of this approach was reported by Chmielewski et al. who incorporated an 
azobenzene photoisomerisable switch into the backbone of a short cyclic peptide (83). 
Irradiation of the peptide resulted in isomerisation of the azobenzene from trans to cis and 
consequently a change in the peptides conformation was observed (Scheme 29).252  
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Scheme 29 
Photochemical control over peptide conformation using an azobenzene switch. 
 
In this first instance the group did not employ this technique towards any particular 
application, though they have since gone on to adapt this work for other peptides.  A 
particularly relevant application of this work is the photomodulation of the comformation of a 
modified somatostatin analogue 84. Knowing the importance of the -turn centred around 
the Phe-Trp-Lys-Thr region the group installed an azobenzene switch on either side of the 
pharmacophore. Using elegant NMR experiments the group concluded that the trans form 
of the peptide contained no -turn conformation. Irradiation to the cis isomer formed a type 
II’ -turn, demonstrating considerable contrast in peptide conformation between the two 
isomers. A consequent decrease in IC50 was also observed upon irradiation; 1.7 M for the 
cis form compared to 3.6 M for the trans form (Scheme 30).253 Whilst this change is very 
minimal it highlights the potential of photochemical switches for the modulation of peptide 
conformation.  
 
Scheme 30 
The photoisomerisation of somatostatin analogue 84. 
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Since this study photoswitches have been applied to peptides for a variety of applications, 
including photomodulation of redox active peptides,254,255 membrane-binding peptides,256 
and peptides involved in muscle contraction.257 An excellent review on this subject has 
been written by Feringa et al.250 
S,S-Tetrazine phototriggers  
Another photochemical reaction which has been explored for the photochemical 
manipulation of peptides is the photolytic degradation of S,S-Tetrazine analogues. In this 
approach the peptide is bound into a cyclic conformation through the introduction of a 
cysteine selective tetrazine moiety (85). Irradiation at 355 nm results in rapid photolysis of 
the N-N bonds of the S,S-Tetrazine and formation of an acyclic peptide (86). This reforms 
the non-cyclic native structure of the peptide and in this way could theoretically be used to 
photochemically control function (Scheme 31).258,259  
 
Scheme 31 
Irradiation of a S,S-Tetrazine bridged peptide 85  to form open chain peptide 86.258 
 
This reaction displays unprecedented kinetics, with photolysis times in the picosecond 
range.259 To the best of our knowledge this technique has not yet been employed towards 
any therapeutic purpose though speculative applications for studying protein 
folding/unfolding dynamics have been put forward.258,260 
1.3.3.2: Phototriggers  
Photolabile protecting groups have been employed to cage peptides in much the same way 
as caging proteins. A photocleavable chemical moiety is attached to the peptide at a 
structurally important position to block the function (87). Upon photolysis of the cage the 
activity of the peptide (88) is reinstated (Scheme 32). 
 
Scheme 32 
A schematic representation of photochemical peptide uncaging. 
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Though caged peptides have not been as widely adopted as caged proteins several 
excellent studies have been reported. This technique has been employed to gain control 
over cell-binding peptides,261,262 peptidic vasoconstrictors,263,264 and a peptide involved in 
neurotransmission.265 A small review on this subject has been written by David 
Lawrence.213    
1.4: Research overview 
The research discussed in this chapter clearly highlights photochemical transformations as 
powerful tools for studying and manipulating biological systems. This thesis explores the 
use of novel thiomaleimide based photochemical transformations as tools for 
photochemical protein and peptide modification. Through this work we hoped to make a 
contribution to the ever expanding toolbox of chemical reactions which can be employed for 
the manipulation of biological processes.  
Chapters 2.1 and 2.2 explore the use of a recently reported thiomaleimide [2+2] 
photocycloaddition as a novel “photoswitch”. The application of this reaction towards 
peptide photoactivation and photochemical disulfide rebridging is described. Chapters 2.3 
and 2.4 describe the discovery of novel photochemical decarboxylation reactions and their 
application towards novel cysteine selective photocleavable linkers. Each individual section 
is accompanied by research aims, conclusions and future directions.   
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2: Results and Discussion 
2.1: Photochemical peptide activation 
2.1.1: Aims and introduction 
The first aim of this work was to expand on the recently discovered thiomaleimide 
photochemistry to develop a method for photochemically activating peptides. We originally 
envisioned a system in which a small therapeutic peptide could be deactivated through the 
installation of cysteine selective photoactive tags, and subsequently reactivated through 
reformation of the cysteine bridge via irradiation at a specific wavelength (Scheme 33). This 
method could exploit the unique spatial and temporal control offered by photochemistry to 
develop a new type of targeted chemical tool.  
 
Scheme 33 
Photochemical peptide activation via the installation of cysteine selective 
photoactive tags. 
 
Though conceptually simple this approach does require a specific set of conditions to reach 
full potential. The peptide must contain a disulfide bond which is easily modified and 
functionally important. This will allow for simple installation of the photoactive tags and also 
ensure installation is accompanied by a decrease, or preferably complete nullification, of 
activity. A greater conformational change between “open” and “bridged” forms of the 
peptide would lend more power to this technique. Additionally, the photoactive tag must be 
able to target cysteine residues efficiently, selectively, and without causing unnecessary 
steric perturbation. This last point is particularly important, as upon irradiation the peptide 
must be able to reform its active conformation. Finally, the photochemical reaction itself 
must be rapid, highly efficient, and selective for the photoactive tags i.e. unreactive with 
naturally occurring amino acids. With these criteria in mind we set towards finding a 
suitable peptide and photoactive tag to explore this method.  
Octreotide 
Octreotide 74 (Figure 14) is a synthetic octapeptide based on the natural hormone 
Somatostatin used for the treatment of neuroendocrine tumours.266 The therapeutic use of 
Octreotide was previously covered (Section 1.2.5.1, page 36) and an excellent review on 
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the use of Somatostatin analogues, including Octreotide 74, in neuroendocrine tumour 
therapy has been written by Modlin et al,202 so this subject will not be covered further here. 
Octreotide 74 contains a single essential disulfide bond, which has been shown as 
essential to the activity of Somatostatin analogues,157 and previous work has demonstrated 
the ease in which the cysteine residues can be modified.152  
 
Figure 14 
A schematic representation of Octreotide 74. 
 
Maleimides as Photoactive Tags 
As previously described (Section 1.2.3.1, page 31), monobromomaleimides (89) react in a 
highly efficient and selective manner with cysteine residues to produce cysteine-maleimide 
conjugates. More recent work has highlighted the ability of cysteine-maleimides to undergo 
highly efficient [2+2] photodimerisations (Section 1.1.2.1, page 21).63 This dimerisation 
proceeds quantitatively within five minutes of irradiation and is able to out-compete [2+2] 
cycloadditions between the maleimide and other olefins. Thus in substituted maleimides we 
have discovered a reagent which fulfils the criteria listed previously. We hypothesised that 
Octreotide 74 could be successfully deactivated through the installation of two maleimide 
moieties to generate bis-modified Octreotide 90, and then subsequently reactivated via the 
highly efficient [2+2] dimerisation to generate bridged Octreotide 91 (Scheme 34). 
 
Scheme 34 
A proposed strategy to photochemical rebridge cysteine residues using 
thiomaleimide photochemistry.   
 
2.1.2: Modification and irradiation of Octreotide 
Octreotide was reduced and modified according to a previously optimised protocol 
(Scheme 35). Tris(2-carboxyethyl)phosphine (TCEP) was chosen as a reducing agent due 
to its limited cross reactivity with substituted maleimides. It is more common to use thiol 
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containing reducing agents, such as dithiothreitol (DTT), -mercaptoethanol (BME) and 
glutathione (GSH). However, these readily react with substituted maleimides so must be 
removed before the modification step of any protocol, a time consuming process with small 
peptides. Bis-modification of the peptide with monobromomaleimide 93, which was 
synthesised using a known protocol,267 proceeded smoothly. A large excess of 
monobromomaleimide 93 was used to prevent unwanted succinimide formation that results 
from attack of both cysteine residues onto a single maleimide.267 Success at each step was 
evidenced using LCMS (Figure 15). 
 
 
 
Scheme 35 
The reduction and modification of Octreotide 74. 
Figure 15 
LCMS spectra of Octreotide 74, reduced Octreotide 92 and modified Octreotide 90. 
See experimental section for full spectra (Section 3.2.2.1, page 178, Figure 62 & 
Figure 64).  
 
Irradiation of bis-modified conjugate 90 was carried out to attempt [2+2] cyclisation of the 
peptide (Scheme 36). However, as no mass change accompanies this reaction 
confirmation by LCMS was not possible. To compensate for this a chemical test was 
devised which exploited the maleimide conjugate acceptors. Before irradiation the double 
bond of the maleimide is susceptible to thiol attack,146,151  so conjugate 90 yields a positive 
reaction with ethanedithiol 94 (EDT). Interestingly only mono-addition of EDT 94 was 
observed, suggesting that a single molecule of EDT bridges the two thiomaleimides to form 
Octreotide conjugate 95. This was unexpected as an excess of EDT was employed thus 
some di-addition, i.e. addition of EDT to both thiomaleimides, was anticipated. Upon 
irradiation to form bridged conjugate 91 the conjugate acceptors are removed and EDT 94 
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can no longer react via addition-elimination. After five minutes of irradiation no reaction with 
EDT 94 was observed by LCMS, providing evidence for successful [2+2] cycloaddition and 
rebridging of the peptide to form bridged Octreotide conjugate 91.   
 
Scheme 36 
A chemical test to demonstrate the success of the photochemical [2+2] 
cycloaddition. See experimental section for mass spectra (Section 3.2.2.2, page 
181, Figure 65 & Figure 66). 
 
2.1.2.1: HPLC data 
Though the chemical test with EDT 94 (Scheme 36) provided evidence for the success of 
the photochemical [2+2] dimerisation, further data was sought for corroboration. We also 
wished to obtain as much structural information as possible, since any conformational 
changes occurring upon irradiation would undoubtedly affect binding affinity and potency of 
the peptide. High performance liquid chromatography (HPLC) is well established as a tool 
for studying peptide modification and can also reveal important changes in polarity. Each 
step of the newly optimised reaction sequence was repeated and studied using analytical 
HPLC. Analysis of the bis-modification step is shown below (Scheme 37) (Figure 16). 
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Scheme 37 
The modification of Octreotide 74 using an optimised protocol.  
Figure 16 
HPLC of Octreotide 74 and the crude mixture of conjugate 90. For HPLC conditions 
see experimental (section 3.2.1.1, p 175) 
 
Analysis of the crude solution of bis-modified conjugate 90 revealed that the conjugation 
step results in a major product and several minor products. Analysis of the individual peaks 
by MALDI-TOF revealed them to have identical masses of 1211 Da, corroborating the 
previously obtained LCMS data. This suggests that the peaks correspond to different 
isomers of the desired peptide. This was unexpected and, due to limited data, identification 
of the peaks was not possible. It seems unlikely that the peaks correspond to 
conformational isomers of the desired product as any non-covalent interactions would be 
removed under the acidic HPLC conditions. Another possibility is that isomers are forming 
upon intramolecular reaction of the Octreotide lysine with the generated thiomaleimides.  
However, the fact that the lysine residue appears to be inert towards the large excess of 
the more reactive monobromomaleimide 93 discourages this hypothesis. Evidence against 
both of these theories was obtained upon isolation and incubation of the major product 
(peak D) under the reaction conditions, which upon reanalysis by HPLC showed no 
change. If the minor products result from isomerisation of the major product it is reasonable 
to assume incubation and reanalysis by HPLC would reveal multiple peaks. Further 
exploration of these results was not deemed pertinent to the overall aim. Isolation and 
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irradiation of the most prominent by-product (peak C) resulted in no change to the HPLC 
trace upon analysis, indicating the unidentified species was not photoactive.   
The major product was isolated and subsequently irradiated under the optimised irradiation 
conditions (Scheme 38). HPLC of the resulting crude solution revealed a complex mixture 
of products with at least four dominant species (Figure 17). Analysis of each of the major 
peaks, as well as a collection of the eluent between 15.0 and 20.0 minutes, by MALDI-TOF 
revealed the desired mass of 1211 Da (see experimental section 3.2.2.1, page 179, Figure 
63). This suggests that the mixture consists of several isomeric species. 
 
 
Scheme 38 
The optimised irradiation of bis-modified Octreotide 90. 
Figure 17 
HPLC data of the mixture resulting from the irradiation of Octreotide conjugate 90. 
(A) Pure Octreotide conjugate 90; (B) Pure Octreotide conjugate 90 irradiated for 
five minutes. 
 
In this instance this was somewhat expected, as [2+2] cycloadditions are known to produce 
several isomers; endo head-to-head, endo head-to-tail, exo head-to-head and exo head-to-
tail. This is further complicated by the diastereoisomers of these forms caused by the 
chirality of the amino acid backbone.  However, the generation of such a complex mixture 
was not anticipated due to the stereoselective nature of the previously studied 
cysteine-maleimide photochemical [2+2] dimerisation which produced only the exo head-to-
head products (section 1.1.2.2, page 20).63 This selectivity was reasoned using both 
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Frontier Molecular Orbital theory and steric arguments. For a favourable orbital interaction 
the thiomaleimide moieties must approach each other in a suprafacial manor. In addition to 
this, a head-to-head configuration is favoured due to the complimentary overlap between 
SOMO and LUMO, as is often the case with [2+2] cycloadditions, and an exo transition 
state minimises steric clash between cysteine residues (Scheme 39). 
 
Scheme 39 
Electronic and steric arguments for the stereoselectivity of the thiomaleimide [2+2] 
cyclisation. 
 
This level of stereoselectivity is clearly not occurring with the photochemical [2+2] 
cycloaddition of bis-modified Octreotide conjugate 90. The HPLC data reveals at least four 
major products and several minor products, highlighting a decrease in the stereoselectivity 
of this reaction when applied to Octreotide. This decrease can be rationalised by taking into 
account the inherent structure of the peptide. Though only eight amino acids in length 
Octreotide 90 still holds tertiary structure that could affect the orientation of the two 
thiomaleimides during the cyclisation. The propensity of the peptide to obtain a particular 
conformation, perhaps to maximise its intramolecular forces or avoid steric clashes 
elsewhere, could be competing with the orbital or steric considerations of the 
photochemical [2+2] cycloaddition. The possible outcomes from the photochemical [2+2] 
dimerisation are shown below (Scheme 40). 
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Scheme 40 
The eight possible isomers (96a-h) resulting from the photochemical [2+2] 
cyclisation. 
 
In order to rationalise the probability of each of the isomers it is necessary to have some 
idea of the three-dimensional structure of Octreotide conjugate 90. Knowledge of the 
relative position of the two maleimides in the transition state could provide important 
information regarding the structure of the product. Unfortunately, this requires detailed 
knowledge of the exciplex, particularly the intermolecular distance between the bonding 
carbons, which we do not possess. Thus any attempt to draw structural information from 
the current evidence would be mostly conjecture and any conclusions inherently flawed. A 
lack of preparative scale HPLC inhibited large scale isolation of the products and it was 
decided that isolation and identification of each individual peak was not a priority.  
2.1.2.2: Tandem-MS data 
Though the HPLC data provided valuable information regarding the stereoselectivity of the 
reaction it did not conclusively confirm the reformation of the bridge between the two 
cysteine residues. It was envisaged that this information could be obtained by studying the 
fragmentation patterns of bis-modified Octreotide conjugate 90 before and after irradiation 
using tandem mass spectrometry. A bridge between the cysteine residues should inhibit 
fragmentation, giving rise to several unique peaks when compared to the acyclic form. The 
results of the fragment analysis of both conjugates 90 and 91 are shown below (Figure 18) 
(Figure 19).  
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Figure 18 
A fragment assigned tandem mass spectrum of conjugate 90.  
 
 
 
Figure 19 
A fragment assigned mass spectrum of conjugate 91. 
 
Unfortunately, the results proved inconclusive. Analysis of the B and Y” fragments (CO+ 
and NH3+, respectively) of conjugate 90 before irradiation confirmed the lack of bridge 
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between cysteine residues. Fragments of 679.11 and 533.21 Da evidenced cleavage 
between the tryptophan and lysine residues, whilst a fragment of 807.12 Da was indicative 
of cleavage between lysine and threonine. If the cysteine residues were bridged cleavage 
at these positions would not cause fragmentation. However, analysis of the bioconjugate 
after irradiation showed that fragmentation at these positions was still occurring. Fragments 
at 908, 807, 679 and 533 Da suggest extended fragmentation which would not be possible 
in the presence of a stable bridge between cysteine residues. Ideally only the 1106 and 
1064 Da fragments would be observed after formation of the cyclobutane bridge. Though 
these peaks have increased relative to the other fragment ions, the results are not 
conclusive enough to confirm the success of the reaction. These results initially suggest 
that the photochemical [2+2] dimerisation did not proceed as expected, though it is possible 
the cyclobutane bridge is simply unstable under the conditions of the electrospray 
ionisation. Cleavage of the c-c bonds in the ring would destroy the bridge between the 
cysteine residues and nullify the results. There is a literature precedent for the cleavage of 
cyclobutane rings under ionising conditions with c-c cleavage on opposing sides of the ring 
a common occurrence.268 Cleavage at this position would not be entirely unexpected given 
the significant ring strain of cyclobutane systems, a problem potentially exacerbated by the 
neighbouring succinimide ring systems and sulfur atoms. If ring cleavage is occurring this 
represents a significant drawback in using MS-MS for studying these constructs.  
2.1.2.3: NMR data 
To try and provide conclusive evidence for the formation of bridged Octreotide 91 it was 
decided to analyse Octreotide conjugates 90 and 91 using NMR. Unfortunately attempts to 
purify the mixtures obtained from modification and irradiation by preparative scale HPLC 
were unsuccessful due to the difficult separation caused by the isomeric nature of the 
products.  However, additional information was found by analysing the crude NMR of 
Octreotide conjugate 90 before and after irradiation (Figure 20). Though the NMR of 
conjugate 90 was crude the addition of the maleimides was clear, evidenced by the 
appearance of two alkene singlets. The disappearance of these peaks upon irradiation and 
the formation of characteristic cyclobutane singlets between 3.40 and 3.55 ppm63 indicate 
successful [2+2] cycloaddition. Two unknown non-peptidic impurities were also observed 
(2.20 + 2.51 ppm and 3.65 +3.75 ppm) but could not be removed from the peptide product. 
The spectrum after irradiation was further complicated by the number of stereoisomers 
produced during the reaction, a feature which will be discussed in detail later in this section.  
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Figure 20 
NMR data showing the appearance of characteristic maleimide alkene singlets 
upon modification of Octreotide 74, and the disappearance of these peaks upon 
irradiation of modified Octreotide 90. The appearance of cyclobutane singlets is 
also observed. 
 
Though these spectra are crude they do provide additional evidence for the formation of a 
cyclobutane ring, and when coupled with the HPLC data, previously published small 
molecule study,63 and chemical test with EDT, suggest the thiomaleimide [2+2] 
photocycloaddition was successful.  
2.1.3: Determining the binding affinity of Octreotide conjugates  
2.1.3.1: Dose-Response curve 
*The cell work and patch clamping described in this section was completed by Dr Sally 
Fletcher and Dr Muriel Nobles, with my intellectual input and guidance. All peptide 
conjugation and irradiation was completed by me.* 
As the balance of evidence suggested the photochemical [2+2] cycloaddition was 
successful, it was decided to proceed to test the hypothesis that the dimerisation could be 
used to activate a small therapeutic peptide. This required a reliable method for measuring 
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the binding affinity of conjugates 90 and 91 to the SST2 receptor. Previous work with 
collaborators at Queen Mary University of London had already utilised whole cell patch 
clamping for this purpose.152 Whole cell patch clamping is a technique used to measure the 
voltage across a cell membrane, working on the premise that ligand binding opens up an 
ion channel, consequently increasing the potential across the membrane. The greater the 
affinity and potency of the ligand the larger the current across the cell membrane. Detailed 
descriptions of the patch clamping method are abundant in the literature so this technique 
will not be discussed here.269  
In order to study the binding of Octreotide 74, and analogues 90 and 91, to the SST2 
receptor it was necessary to acquire a suitable cell line with an appropriate ion channel. 
Analogues of Somatostatin, such as Octreotide 74, have been reported to activate G 
protein-coupled inwardly-rectifying potassium (GIRK) channels causing hyperpolarisation of 
cell membranes.270 Consequently cells which express GIRK channels can be transfected 
with the SST2 receptor and utilised for patch clamping. The SST2 receptor is coupled to 
the GIRK channel by G-protein, therefore activation of the SST2 receptor leads to 
activation of the GIRK channel and an influx of potassium ions.270 Fortunately a HEK293 
cell line transfected with SST2 and stably expressing the GIRK1/2a channel had already 
been engineered by our collaborators for a related project. Octreotide 74, bis-modified 
conjugate 90 and bis-modified Octreotide 91 irradiated for five minutes to produce bridged 
conjugate 91 were prepared in a series of dilutions (10−12 - 10−6 M) and tested for current 
activation against SST2. Because potential applications would rely on in situ generation of 
the bridged conjugate, Conjugate 91 was not purified further before being applied to the 
cells (Figure 21).  
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Figure 21 
Dose response curves for Octreotide 74, and conjugates 90 and 91. Curve 
parameters for native Octreotide 74 are in the blue box, and for modified Octreotide 
90 in the green box.  Due to the large error bars R2 and Chi2 tests for bridged 
Octreotide 91 could not be determined. Five readings were taken at each 
concentration.  
 
Native Octreotide 74 behaved as expected and produced a sigmoidal dose response curve 
with a high R2 value, demonstrating a good data fit. It is apparent that at high 
concentrations the current activation reaches a plateau as maximum current activation is 
reached. From this curve we obtain an EC50 value, the concentration at half maximum 
current, of 1.58 nM. This is slightly higher than the previously obtained literature value of 
0.66 nM152 though still remains in the nM range.  Open conjugate 90 was tested several 
times at the highest concentration (1 M) and found to elicit only negligible current 
activation, demonstrative of a lack of binding to the SST2 receptor. For this reason, and 
due to time restraints, a full range of dilutions were not tested for this conjugate. This 
confirmed that installation of the maleimide tags deactivated the peptide towards the SST2 
receptor. Bridged conjugate 91, though eliciting a current response upon application to the 
cell, produced erratic data. Repeated application of the construct to the cell at identical 
concentrations produced a wide range of current response, e.g. a concentration of 10−12 M 
could elicit the same response as 10−6 M and vice versa (see error bars). In addition to this 
increasing the dose of the peptide did not produce the expected response in current 
activation leading to a very shallow non-sigmoidal dose response curve. The shallow curve, 
coupled with the large margins of error, made calculating an accurate EC50 for the bridged 
construct impossible.  
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2.1.3.2: Measuring maximum current activation  
An alternative measure of the ability of the peptide to bind to the receptor is to measure the 
peptide concentration at which maximum activation is achieved. Cells identical to those 
previously described (section 2.1.3.1, page 60) were exposed to solutions of native 
Octreotide 74, and conjugates 90 and 91 of varying concentrations (10−12 - 10−6 M) until 
maximum current activation was achieved.  Native Octreotide 74 demonstrated a large 
maximum current at a concentration of only 0.01 M (pA/pF = -73.7 ± 5.9), open conjugate 
90 showed negligible current activation as high as 1 M (pA/pF = -2.1 ± 1.0), and bridged 
conjugate 91 showed significant restoration of activity at 0.1 M (pA/pF = -16.1 ± 4.7) 
(Figure 22). 
 
 
 
 
 
 
 
Figure 22 
Maximum current activation for Octreotide 74 (0.01 M), conjugate 90 (1 M) and    
conjugate 91 (0.1 M). Values shown are an average of 10 readings at each 
concentration (9 for conjugate 90).  
 
This data highlights the complete loss of activity upon installation of the maleimide tags, 
and then restoration of activity after irradiation. Significant attenuation in both binding 
affinity and agonist efficacy is observed compared to the native peptide, evidenced by the 
required increase in concentration to reach a lower maximum current activation. This was 
expected due to the small size of Octreotide 74 and the proximity of the modification to the 
peptides pharmacophore (Phe-Trp-Lys-Thr).271 Previous work has highlighted that addition 
of a maleimide bridge into to the disulfide bond of Octreotide 74 can elicit a dramatic 
change in both affinity and efficacy.152 It is also likely that only a small number of the 
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possible diastereo and regioisomers obtained from the photochemical [2+2] cyclisation 
result in active conformations, leading to a relative decrease in the concentration of the 
active peptide (Figure 23). 
 
Figure 23 
Explanations for the attenuation in activity after photochemical rebridging. Bond 
distances were calculated in ChemBio3D after energy minimisation using the MM2 
algorithm with an RMS gradient of 0.01. 
 
The presence of multiple isomers in the solution poses the question as to which is most 
active.  Regrettably no crystal structure of the SST2 receptor exists, precluding our ability to 
undertake computational docking studies. Nevertheless, it is worth noting that the 
conformation favoured in the small molecule study, exo head-to-head, would seemingly 
cause a larger perturbation in structure than the disfavoured endo head-to-head product. 
Exo structures place the sulfur atoms trans to each other at a distance of approximately 
4.1 Å, potentially causing a large perturbation in the structure. Endo structures place the 
sulfur atoms cis to each other at a distance of approximately 3.1 Å, creating a structure in 
which the sulfur atoms are placed a less perturbed conformation (Figure 24).  
 
Figure 24 
Ball and stick 3D models showing the difference between exo and endo 
conformations of bridged Octreotide 91. Lowest energy conformations were fitted 
using the MM2 algorithm in ChemBio3D with an RMS gradient of 0.01. 
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Regardless of this, we are presently unable to influence the stereochemistry of the 
photochemical [2+2] cyclisation, which appears to be directed by the conformational 
considerations of the protein. It is entirely possible that this reaction will exhibit protein 
dependent stereoselectivity, with larger proteins undergoing less overall perturbation and 
thus suffering only a minimal loss in affinity and efficacy. 
2.1.4: Conclusions and future work 
The initial aim of this work was to test the applicability of the thiomaleimide photochemical 
[2+2] cycloaddition towards the photoactivation of a small therapeutic peptide. By using the 
SST2 receptor agonist Octreotide 74 as a model system we successfully demonstrated this 
concept. HPLC, MS-MS, MALDI, LCMS and chemical tests were utilised to optimise the 
modification and irradiation of the peptide. Previously unknown information regarding the 
influence of peptide conformation on the key photochemical reaction was obtained through 
this careful analysis. Finally, binding affinity and peptide efficacy data obtained through 
whole cell patch clamping demonstrated the capability of the reaction for reforming the 
active conformation of the peptide. Though a significant drop in both binding affinity and 
efficacy is observed the overall aim was achieved, providing the first example of peptide 
photoactivation through photochemical manipulation at the site of a disulfide bond  
(Scheme 41).  
 
Scheme 41 
The optimised protocol for photochemically activating Octreotide 74. 
 
Future work could focus on developing stereoselective variants of this reaction. With 
sufficient knowledge of the target receptor a stereospecific cycloaddition could be incredibly 
powerful, as the desired peptide conformation for the active site could be selected for and 
achieved in a higher yield than currently possible. Presently the preference for exo 
products is attributed to the desire to avoid a steric clash between cysteine residues in the 
transition state. If a modification could be found which provides sufficient reason to 
overcome these steric factors this preference could be flipped and endo would be 
preferred. A possible route towards this would be to functionalise the imide nitrogen with 
groups which stack efficiently through extensive intermolecular forces and steric attraction 
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(Scheme 42). Similar methods have been employed with some success for asymmetric 
[2+2] cycloadditions.272–274 
 
Scheme 42 
A potential method for asymmetric thiomaleimide photochemical [2+2] cyclisation 
reactions.  
 
It would also be worthwhile to demonstrate the general applicability of this method by 
testing it on a variety of peptides or proteins with essential disulfide bonds. Of particular 
interest would be the photochemical activation of enzymatic processes. By targeting 
disulfide bonds near the active site of an enzyme photochemical control of enzymatic 
processes could be achieved.   
 
Scheme 43 
Photochemically activating enzymes using the thiomaleimide photochemical [2+2] 
cyclisation. 
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2.2: Thiomaleimide [2+2] cyclisations on antibody 
fragments 
2.2.1: Aims and introduction 
After the success of the thiomaleimide [2+2] cyclisation on a small peptide we wanted to 
test the scope of the reaction through its application to more complex proteins. Recent work 
in the field of protein modification has utilised next generation maleimides to insert chemical 
functionality into the disulfide bonds of antibodies to generate functional antibody 
conjugates.146,149,153,156 Most recently this technology has been used to develop a functional 
Antibody Drug Conjugate (ADC) by targeting disulfide bonds with a monomethyl auristatin 
E (MMAE) functionalised disubstituted maleimide.153 By retaining the bridge between the 
heavy and light chain the conjugates are able to maintain the thermal stability of the native 
antibody, which is lost upon removal of the interchain covalent bond.158 Though highly 
selective and efficient the modification suffers from thiol instability. The installed maleimide 
bridge is susceptible to thiol attack which can lead to premature cleavage of the payload, 
decreasing the efficacy and potentially leading to off-target side effects (Scheme 44).146 
More recently issues of thiol mediated maleimide transfer between the ADC and Human 
Serum Albumin (HSA) within the blood have reinforced this problem.153  
 
Scheme 44 
The thiol instability of maleimide-bridged ADCs. 
 
Methods to address this unwanted reactivity by hydrolysing the maleimide to the unreactive 
maleimic acid have been very successful.153 We hypothesised that the thiomaleimide 
photochemical [2+2] cycloaddition could also be employed for this purpose. Upon 
successful cycloaddition the maleimide conjugate acceptor is removed and the 
susceptibility to thiol attack eliminated, as evidenced by lack of reactivity towards EDT 
described in the previous chapter. By applying the thiomaleimide [2+2] cyclisation we could 
demonstrate the scope of this reaction on larger proteins whilst simultaneously addressing 
the issues related to thiol instability (Scheme 45).  
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Scheme 45 
The proposed photochemical thiomaleimide [2+2] cyclisation to stabilise 
maleimide antibody conjugates towards thiols. 
We aimed to apply the photochemical thiomaleimide [2+2] cycloaddition to an 
immunoglobulin and a selection of associated antibody fragments. Through this the scope 
of the reaction on a range of proteins of various sizes could be tested, whilst 
simultaneously generating a small library of thiol stable functional antibody conjugates. 
Towards this aim the reaction would be tested on scFv and Fab antibody fragments, as well 
as a full antibody (Figure 25).  
 
Figure 25 
The proposed protein models; full antibody, Fab fragment and scFv fragment. 
 
2.2.2: Modification of an anti-CEA scFv 
As discussed earlier (Section 1.2.4.1, page 32) an scFv is an antibody fragment comprising 
of the antigen binding region (Fv) stabilised through the addition of covalent interchain VL - 
VH peptide linkages and disulfide bonds.188,189 Previous work has shown a mutant form of 
the anti-carcinoembryonic antigen (Anti-CEA) scFv 97, engineered by the Chester group at 
UCL Cancer Research, is a good candidate for conjugation with maleimide.150 Protocols for 
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the reduction and modification of the disulfide bond are well established150 and as a 
relatively small antibody fragment scFv 97 presented the sensible next step in establishing 
the scope of the photochemical thiomaleimide [2+2] cycloaddition. Reduction and 
bis-modification of the fragment was performed using DTT and a large excess of 
monobromomaleimide 93. In this instance TCEP proved ineffective as a reducing agent, 
possibly due to the more buried nature of the disulfide bond within the protein structure. 
Due to the aforementioned cross reactivity DTT was removed by size exclusion filtration 
before bis-modification with monobromomaleimide 93. The addition of EDTA to the buffer 
systems minimises disulfide reoxidation by chelating redox active metal impurities. Under 
these conditions bis-modification proceeded smoothly and no further optimisation was 
required. scFv conjugate 98 was subsequently irradiated using a single 5W LED system for 
ten, thirty and sixty minutes (Scheme 46) (Figure 26) (Figure 27). 
As with irradiating Octreotide conjugate 90 no mass change can be seen upon successful 
photochemical [2+2] cyclisation. However, previous work has shown that changes in the 
protein structure between the bridged (99) and unbridged (98) forms of this scFv are 
sufficiently large to be resolved by SDS-PAGE (Figure 27).150,275 SDS-PAGE analysis 
shows destruction of the bridge upon reduction and modification (lanes 2 and 4), and 
subsequent reformation upon irradiation (lanes 6 - 8). Though the change is small there is 
a clear transformation taking place which results in the protein moving further down the gel, 
consistent with a structure more similar to native scFv 97 with the disulfide bridge intact.275 
The results suggest that maximum bridging was obtained within ten minutes of irradiation, 
with extended irradiation providing no further benefit. Quantification by densitometry gives 
a yield of 71% for the photochemical bridging of the cysteine residues. 
 
Scheme 46 
The modification and irradiation of scFv fragment 97. 
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Figure 26 
MS data: (A) Pure scFv 97, (B) bis-modified scFv 98, (C) Rebridged scFv 99. See 
experimental section for full spectra (Section 3.2.3.1, page 183, Figure 68). 
Figure 27 
SDS-PAGE (12%) analysis of the modification and irradiation of scFv 97. 
 
It is postulated that the retention difference observed with SDS-PAGE results from the 
bridged protein forming a more tightly packed three dimensional-structure. This provides a 
smaller surface area for the SDS to bind, generating a lower overall charge and lowering 
the retention factor of the protein on the gel. Analysis by LCMS highlighted purity issues of 
the native protein, which are a result of the post-expression purification protocol employed 
during expression of the protein. Enzymatic cleavage of the leader sequence after 
expression gives rise to multiple species with pendant N-terminal amino acids in addition to 
the desired protein. Though complicating the LCMS spectra these modifications cause no 
adverse effects with regards to the behaviour of the protein.                             
Whilst SDS-PAGE seems to indicate that consumption of the starting material is incomplete 
we must assume this is not the case, as extended irradiation times do not increase the 
bridging yield. LCMS does not indicate any additional mass fragments, though the 
previously mentioned issues with quality prevent confident interpretation of the spectra. 
Analysis of the amino acid sequence of the peptide reveals the amino acids proximal to the 
cysteine residues as glycine, threonine, phenylalanine, alanine, and histidine. There is no 
obvious explanation as to how these residues could adversely affect the photochemical 
[2+2] cyclisation between the cysteine-maleimides. Of course considering only 
neighbouring residues is insufficient, and it is entirely possible that an aspect of the 
quaternary structure of the protein is interfering with the reaction. Without detailed structural 
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information further reasoning behind the reduction in efficiency of the photochemical 
thiomaleimide [2+2] cyclisation is not possible.   
2.2.2.1: Thiol stability of a rebridged anti-CEA scFv conjugate 
To test the hypothesis that the cyclobutane bridge would be resistant to thiol attack bridged 
scFv conjugate 99 was incubated with an excess of -mercaptoethanol (BME) (Scheme 
47). SDS-PAGE analysis showed no change, indicating the bridge was retained (Figure 
28). LCMS data also showed no change, supporting this result. Bis-modifed scFv 98 was 
subjected to the same conditions and cleavage of the maleimides was observed by LCMS, 
though as expected no change could be seen by SDS-PAGE. As a control reaction native 
scFv 97 was subjected to the same conditions to demonstrate that BME was capable of 
reducing this particular scFv.  
 
 
Scheme 47 
Testing the thiol stability of rebridged scFv conjugate 99. 
Figure 28 
SDS-PAGE (12%) showing the thiol stability of scFv conjugate 99 (lane 8). 
 
As a model system anti-CEA scFv 97 demonstrated the potential of this reaction for 
bridging cysteine residues on larger proteins and also validated the hypothesis regarding 
thiol stability.  
2.2.3: Modification of Rituxan Fab 
2.2.3.1: Preparation of Rituxan Fab 
Given the success of the thiomaleimide [2+2] photocycloaddition on anti-CEA scFv 97 it 
was decided to attempt the reaction on a larger antibody fragment. Fab fragments consist 
of the heavy and light chains of the antibody connected by a single disulfide bond, thus 
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offer a unique chance to test the scope of the photochemical thiomaleimide [2+2] 
cycloaddition. Upon removal of the disulfide bridge the two chains are no longer covalently 
connected, though intramolecular forces keep them tightly associated, so in the strictest 
sense rebridging via a [2+2] cycloaddition could be considered an intermolecular reaction. 
As discussed in the introduction, Rituxan is a clinically relevant chimeric monoclonal 
antibody which has attracted significant interest in the ADC field.172,176 Rituxan Fab 101 
was produced through an enzymatic digest of the full antibody 100. The hinge region of the 
antibody is selectively targeted by the thiol-endopeptidase enzyme papain to cleave the 
two Fab fragments 101 from the Fc region. The Fc and Fab fragments are then separated 
using a protein A column, which selectively binds the Fc region and allows for efficient 
purification. Using this protocol Rituxan Fab 101 was prepared in an overall yield of 43% 
(Scheme 48). Characterisation by SDS-PAGE and LCMS showed the protein was obtained 
in excellent purity (Figure 29) (Figure 30). 
 
Scheme 48 
Preparation of Rituxan Fab 101. 
 
2.2.3.2: Modification of Rituxan Fab 
Reduction of Rituxan Fab 101 using TCEP in EDTA containing buffer proceeded smoothly 
and subsequent bis-modification using monobromomaleimide 97 produced bis-modified 
Rituxan Fab 102. Attempts to reduce the equivalents of maleimide showed some promise, 
with both thirty equivalents and fifty equivalents producing bis-modified Rituxan Fab 102 as 
the major product. However, evidence of trace succinimide formation was found in both 
LCMS and SDS-PAGE data, demonstrating the negative effect of lowering the equivalents 
of monobromomaleimide 93. Irradiation of bis-modified Rituxan Fab 102 affected 
successful bridging to rebridged Rituxan Fab 103 within ten minutes (Scheme 49). It is 
worth noting that the lack of a covalent link between the two fragments in bis-modified 
Rituxan Fab 101 can be seen in the mass spectrum (Figure 29B) and in the SDS-PAGE 
(Figure 30, lane 6+7), providing unambiguous evidence for the success of the 
photochemical thiomaleimide [2+2] cycloaddition on a protein.  As with the photochemical 
thiomaleimide [2+2] cycloaddition on the scFv the reaction does not produce complete 
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rebridging, with gel densitometry giving a bridging yield of 85%; this will be discussed later 
in this chapter.  
 
 
 
 
Scheme 49 
The reduction, modification and irradiation of Rituxan Fab 101. 
Figure 29 
LCMS data: (A) Rituxan Fab 101, (B) bis-modified Rituxan Fab 102, (C) Bridged 
Rituxan Fab 103. See experimental section for full spectra (Section 3.2.4, page 186, 
Figure 71 & page 190, Figure 76). 
Figure 30 
SDS-PAGE (12%) analysis of the modification and irradiation of Rituxan Fab 102. 
 
The novel nature of this work necessitates careful control reactions to rule out secondary 
reactions which could contribute to the observed rebridging. In the case of the Rituxan Fab 
work we primarily wanted to rule out non-photochemical rebridging of the two chains. Bis-
modified Rituxan Fab 102 was incubated both at room temperature and 37 °C for one hour. 
Analysis by SDS-PAGE (see experimental section 3.2.4.2, page 193, Figure 81) and LCMS 
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showed no change, suggesting that the observed reactivity upon irradiation is purely 
photochemical.  
2.2.3.3: Thiol stability of Rituxan Fab conjugates 
As with the scFv conjugate 98 we wanted to demonstrate the thiol stability of the 
cyclobutane bridge of Rituxan Fab conjugate 103. To test for stability against a wide range 
of thiols we incubated bridged Rituxan conjugate 103 with up to 500 equivalents of BME, 
DTT and GSH (Scheme 50). As a control pure Rituxan Fab 101 was subjected to the same 
conditions. As expected the SDS-PAGE shows the cyclobutane bridge was unaffected by 
the excess thiol. No difference can be seen between the negative control (Figure 31, lane 
6) and the lanes containing bridged Rituxan Fab 103 incubated with excess thiol (Figure 
31, lanes 7-9). LCMS data once again supports this conclusion as no change can be seen 
in the spectra after incubation. Interestingly pure Rituxan Fab 101 proved much less robust, 
with high molecular weight bands appearing at the top of the gel, suggesting significant 
aggregation (Figure 31, lanes 3-5). 
 
 
Scheme 50 
Testing the thiol stability of bridged Rituxan Fab 103. 
Figure 31 
SDS-PAGE demonstrating the thiol stability of the bridged Rituxan Fab fragments.  
 
This work provided the most conclusive evidence yet for both the success of the 
photochemical thiomaleimide [2+2] cycloaddition on larger proteins and also the thiol 
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stability of the resulting cyclobutane bridge. To demonstrate that the conjugates before 
irradiation are unstable under the same conditions bis-modified Rituxan Fab conjugate 102 
was subjected to the same conditions. Complete cleavage of the maleimide from both the 
heavy and light chain with only 100 equivalents of thiol demonstrates the thiol instability of 
the maleimide structure and highlights the importance of forming the cyclobutane ring 
(Scheme 51).  
 
Scheme 51 
Reacting bis-modified Rituxan Fab conjugate 102 with thiol leads to complete 
cleavage of the maleimide. Evidence of this transformation was shown using 
LCMS. See experimental section for full spectra (Section 3.2.4.3, page 194, Figure 
82). 
 
2.2.3.4: Synthesis of functionalised bromomaleimides 
Whilst chemically interesting the photochemical thiomaleimide [2+2] cyclisation reaction of 
unfuctionalised maleimides on antibody fragments serves a limited purpose. Though a 
covalent link between heavy and light chains is beneficial for stability, binding to the antigen 
is not affected upon removal of the bridge. Thus, unlike with Octreotide 74, the 
photochemical thiomaleimide [2+2] cyclisation cannot be used for photochemical activation 
of the protein. It was decided that the best way to exploit the stabilising nature of this 
reaction would be to generate functionalised thiol-stable Rituxan Fab fragments. By placing 
functional groups such as PEG, Biotin, fluorophores, or cytotoxic drugs onto the imide 
nitrogen of the maleimide a small library of thiol stable bis-modified Fab fragments could be 
generated. Through this work valuable information regarding the scope of the reaction 
could also be ascertained.   
Synthesis of N-dansyl-bromomaleimide 
Dansyl analogues are well established fluorescence probes for protein modification, often 
attached directly to lysine residues via reaction with dansyl chloride.276–278 More recent 
work has highlighted the ability of maleimide to quench this fluorescence through photo-
induced charge transfer (PET) or intramolecular charge transfer (ICT), leading to the 
development of thiol-mediated “switch on” fluorescent probes.151 For these reasons it was 
decided that a dansyl analogue would be synthesised for the functionalisation of Rituxan 
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Fab 101. N-dansyl-bromomaleimide 110 was synthesised simply over three steps. 
Reaction of mono-Boc protected amine 106 with dansyl chloride 107 followed by Boc 
deprotection afforded intermediate 108. Subsequent condensation with bromomaleic 
anhydride 109 produced the desired compound in a 46% yield over two steps (Scheme 
52).  
 
Scheme 52 
The synthesis of N-dansyl-bromomaleimide 110. 
 
Synthesis of N-OEG-bromomaleimide 114 
Though the low molecular weight of Fab fragments can be advantageous for tumour 
penetration, the lower half life is often problematic for clinical applications.279 This can be 
overcome by PEGylation i.e. the covalent attachment of high molecular weight PEG 
chains.280 Compatibility of PEG-maleimides with the photochemical thiomaleimide [2+2] 
cycloadditions is desirable as it will provide a method for thiol-stable antibody PEGylation. 
A small OEG “mini PEG” bromomaleimide 114 was synthesised for this purpose. The 
smaller three unit polymer was chosen for ease of synthesis and availability. Activated 
carbamate 112, quantitatively synthesised from bromomaleimide 93, was reacted with 
OEG-amine 113 to produce the desired OEG-bromomaleimide 114 in a 71% yield (Scheme 
53). 
 
Scheme 53 
The synthesis of N-OEG-bromomaleimide 114. 
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Synthesis of N-biotin-bromomaleimide 117 
D-Biotin, or vitamin B7, is a coenzyme complicit in a number of biological processes.281 
However, its utility as a tool for covalent protein modification results from the ability to bind 
strongly to the protein avidin.282 This affinity is regularly exploited for immobilising proteins 
onto solid resins for diagnostic or purification purposes. Incorporation of a biotin 
functionalised Fab fragment into the Rituxan Fab library could expand this work into these 
areas. Biotin-Boc-amine 116 was synthesised via HBTU mediated amide coupling. 
Deprotection of the amine and subsequent condensation with bromomaleic anhydride 
produced N-biotin-bromomaleimide 117 in an overall yield of 47% (Scheme 54). 
 
Scheme 54 
The synthesis of N-Biotin-bromomaleimide 117. 
 
2.2.3.5: Generating functionalised Rituxan Fab fragments 
The successful synthesis of N-dansyl-bromomaleimide 110, N-OEG-bromomaleimide 114 
and N-biotin-bromomaleimide 117 paved the way for the generation of the desired library of 
functionalised Rituxan Fab fragments. In addition to the synthesised bromomaleimides an 
N-rhodamine bromomaleimide was provided by Cristina Marculescu283 to test under these 
reaction conditions. The previously employed protocol for reduction, modification and 
irradiation of the Rituxan Fab was utilised to generate the desired conjugates (Scheme 55). 
Reduction and modification of Rituxan Fab 101 with the N-functionalised bromomaleimides 
went smoothly and LCMS confirmed successful bis-modification in each case (Figure 33, 
A-D). Upon irradiation successful photochemical thiomaleimide [2+2] cycloaddition was 
seen with the N-OEG and N-Biotin functionalised Fab fragments 188b and 118c (Figure 33, 
B, C), though irradiation times were increased to 30 minutes to achieve maximum 
conversion. As with the non-functionalised Rituxan Fab conjugate 102 complete conversion 
to the bridged form was not seen, and extended irradiation times did not improve this. 
Irradiation of the N-dansyl and N-rhodamine functionalised Fab fragments 118a and 118d 
did not proceed as anticipated. Upon extended irradiation no conversion to the bridged 
product was observed by either SDS-PAGE (Figure 32) or LCMS (Figure 33, A, D), though 
a loss of mass from the light chain of the Fab fragment was noted. This will be discussed 
later in this chapter.  
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Scheme 55 
The modification and irradiation of functionalised Rituxan Fab fragments 118a-d 
Figure 32 
SDS-PAGE (12%) analysis of the modification and irradiation of functionalised 
Rituxan Fab fragments 118a-d.  
79 
 
 
Figure 33 
LCMS data for the modification and irradiation of Rituxan Fab with functionalised 
maleimides; (A) bis-modified conjugate 118a, (B) bis-modified conjugate 118b, (C) 
bis-modified conjugate 118c, (D) bis-modified conjugate 118d, (E) bis-modified 
conjugate 118a irradiated for 30 minutes, (F) bridged conjugate 119b, (G) bridged 
conjugate 119c, (H) bis-modified conjugate 118d irradiated for 30 minutes. See 
experimental section for full spectra (Section 3.2.4.2, page 185). 
 
Possible explanations for the lack of reactivity of fluorophore conjugates 118a and 118d are 
that the steric bulk caused by the large fluorophores so close to the maleimide discourages 
the [2+2] cyclisation. It is also possible that the excitation of the maleimide is quenched by 
the presence of the fluorophore through a charge transfer mechanism. However, small 
molecule studies of thiomaleimides have shown that [2+2] photocycloadditions of dansyl-
linked thiomaleimides proceed efficiently, so this hypothesis is discouraged.151 
Nevertheless, these results provide valuable information regarding the limitations of this 
approach. 
2.2.4: Modification of Rituxan 
Following the success on smaller antibody fragments it was decided to test the applicability 
of the thiomaleimide [2+2] photocycloaddition on the full antibody. This was an ambitious 
task considering the additional complexity of the full antibody when compared to the 
smaller scFv and Fab fragments. Complete rebridging of the antibody is contingent on the 
success of four thiomaleimide [2+2] photocycloadditions, which is made possible only after 
successful modification of the eight cysteine residues liberated from the solvent accessible 
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interchain disulfide bonds. Rituxan 100 was reduced according to a known protocol and 
reacted with an excess of monobromomaleimide 93 to tag each resulting cysteine residue 
and produce modified Rituxan 120, which was subsequently irradiated for sixty minutes, 
with a sample taken at thirty minutes (Scheme 56).  Analysis by SDS-PAGE revealed a 
complex mixture corresponding to incomplete bridging upon irradiation (Figure 34). Single 
light chain 122, single heavy chain 123, half antibody 124 and a heavy-heavy-light 
fragment 125 could be identified in addition to the fully rebridged antibody 121 (Figure 35). 
A previously unobserved species was also apparent on the SDS-PAGE, appearing just 
beneath the heavy chain, though could not be identified.  
 
                       
 
Scheme 56 
The modification and irradiation of Rituxan 100. 
Figure 34 
SDS-PAGE (12%) analysis of the modification and irradiation of Rituxan 100. 
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Figure 35 
The different fragments produced from the attempted photochemical 
thiomaleimide [2+2] cyclisation on the modified full Rituxan antibody 120.  
 
The prevalence of these peaks after irradiation indicates that the photochemical 
thiomaleimide [2+2] cyclisation is considerably lower yielding on the full antibody than it is 
on the smaller fragments. Reasons for this decreased reactivity could be secondary 
interactions within the larger quaternary structure of the protein or “intramolecular” bridging 
between cysteines in the hinge region i.e. cysteine bridging between residues on the same 
heavy chain. Incomplete bridging is a common occurrence even with next generation 
maleimide reagents,156 which avoid the additional photochemical step, so the complex 
mixture obtained from this reaction was not entirely unanticipated.  Due to these problems 
work with the full Rituxan antibody was not taken further. 
2.2.5: Modification of Herceptin Fab 
2.2.5.1: Preparation of Herceptin Fab fragments 
In addition to testing the scope of the reaction with regards to the maleimide 
functionalisation it was also desirable to test its applicability to the antibody fragments of a 
different parent immunoglobulin. Herceptin is a humanised monoclonal antibody commonly 
utilised in antibody therapy,173,284,285 and thus a desirable candidate for the photochemical 
thiomaleimide [2+2] cyclisation. Due to the problems associated with the reaction on the 
larger full Rituxan antibody 100, and the success of the reaction on Rituxan Fab 101, it was 
decided the Herceptin Fab fragment 127 would be used. Preparation of Herceptin Fab 127 
from a sequential enzymatic digestion of full Herceptin 126 proceeded in a high yield. 
Herceptin 126 was digested first with the enzyme pepsin, which targets sites on the Fc 
region below the “hinge”, producing a Herceptin F(ab`)2 fragment and multiple smaller 
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protein fragments. Subsequent digestion with papain cleaves the hinge region, yielding 
pure Herceptin Fab 127 after size exclusion filtration (Scheme 57).  
 
Scheme 57 
Production of the Herceptin Fab 127 through sequential enzymatic digest. 
 
2.2.5.2: Modification of Herceptin Fab 
Using the optimised protocol developed during the work with Rituxan Fab 101, Herceptin 
Fab 127 was reduced, bis-modified and irradiated. Borate buffered saline (BBS) at pH = 8 
was used in place of PBS as this was found to improve reduction efficiency. The decision to 
perform irradiation at pH = 6 will be discussed later in this chapter. Bromomaleimides 93, 
114, and 117 (N-H, N-OEG and N-Biotin respectively) were chosen for conjugation based 
on the previous success of their photochemical thiomaleimide [2+2] reactions. Irradiation in 
this case was performed using the more powerful UVG-2 torch resulting in decreased 
irradiation times (Scheme 58).  Successful photochemical [2+2] cyclisation and rebridging 
in each case was shown using SDS-PAGE (Scheme 58) and LCMS (Figure 37). The 
results mirrored those obtained with Rituxan Fab 101 demonstrating the applicability of this 
reaction towards different antibodies. Analysis of the SDS-PAGE gel by densitometry gave 
a bridging conversion of 85% for Herceptin Fab conjugate 129a, and 80% for conjugates 
129b and 129c. LCMS analysis of bridged conjugate 129b and 129c revealed additional 
peaks which could not be identified, though did contain an intact bridge between cysteine 
residues. The relative intensity of these peaks was found to vary considerably between 
repeated injections onto the LCMS, suggesting they resulted from fragmentation or addition 
during ionisation.  
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Scheme 58 
The modification and irradiation of Herceptin Fab 127. 
Figure 36 
SDS-PAGE analysis of the generation and irradiation of Herceptin Fab conjugates 
128a-c. 
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Figure 37 
LCMS data for the modification and irradiation of Herceptin Fab 127 with 
functionalised maleimides; (A) bis-modified conjugate 128a, (B) bis-modified 
conjugate 128b, (C) bis-modified conjugate 128c, (D) bridged conjugate 129a, (E) 
bridged conjugate 129b, (F) bridged conjugate 129c.  For full spectra see 
experimental section (Section 3.2.5.2, page 196). 
 
The success of these reactions on the Herceptin Fab fragment was expected, given the 
structural similarities between Rituxan and Herceptin. Bridged Herceptin-Fab fragment  
129a was tested in the same thiol stability assay employed for Rituxan Fab 103 (Scheme 
50, Figure 31) and showed complete thiol stability. As a result, the general applicability of 
this method for generating thiol stable bis-modified Fab fragments has been demonstrated.  
2.2.6: C-terminal decarboxylation of Fab Fragments 
Throughout the work with Fab fragments incomplete bridging was observed in all cases, 
particularly with bis-modified Rituxan Fab conjugates 118a and 118d. Extended irradiation 
did not increase the bridging yield, hinting at a competing side reaction. Appearance of a 
common peak, independent of the functionalisation on the maleimide, in the LCMS spectra 
after irradiation suggested this side reaction resulted in loss of the maleimide. In each case 
the mass of the peak corresponded to a loss of the maleimide and a further 76 Da from the 
light chain of the maleimide. This was particularly obvious in the case of Rituxan Fab 118d, 
as a change in mass of the light chain could be seen on the SDS-PAGE (Figure 32) and 
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the LCMS (Figure 33E). Both Rituxan Fab 101 and Herceptin Fab 127 form disulfide bonds 
between the C-terminus of the light chain and an internal cysteine on the heavy chain; a 
feature shared amongst all Kappa type immunoglobulins. Thus the light chains on the Fab 
conjugates all contain C-terminal cysteine-maleimides, opening up decarboxylative reaction 
pathways. Based on the LCMS and SDS-PAGE data a photochemical decarboxylation was 
proposed (Scheme 59). 
 
Scheme 59 
A proposed mechanism for the loss of mass from the light chain and formation of a 
decarboxylated Fab fragment, demonstrated using Herceptin Fab conjugate 128a. 
 
Similar photochemical processes have been extensively studied on carboxyl containing 
phthalimides (Section 1.1.3.1, page 23).81,286–289 Based on this hypothesis it was decided to 
test the effect of pH on the irradiation of bis-modified Herceptin Fab conjugate 128a. 
Solutions of Herceptin Fab conjugate 128a at pH 6 and pH 8 were irradiated for two 
minutes and compared (Scheme 60). LCMS analysis suggests that increasing the pH 
increases the formation of the side product, evidenced by an increase in the relative height 
of the peak corresponding to the proposed decarboxylative side product 130. However, it is 
important to note that quantification by mass spectrometry is not possible due to the 
differences in ionisation of the two products. This problem is particularly highlighted in the 
LCMS of bis-modified Herceptin Fab 128a irradiated at pH = 8, which suggests that 
decarboxylated Herceptin Fab 130 is the major product (Figure 38). Analysis by SDS-
PAGE clearly contradicts this and in fact suggests that the difference between irradiation at 
pH = 6 and pH = 8 is minimal (Figure 38). Due to the simplified LCMS spectra irradiation of 
bis-modified Herceptin fragments 128a-c in the optimised protocol was performed at pH = 6.  
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Scheme 60 
Testing the affect of pH on the formation of proposed side product 130. 
Figure 38 
Analysis by SDS-PAGE and MS showing the difference in the photochemical [2+2] 
cycloaddition of bis-modified Herceptin Fab 128a at pH = 6 and pH = 8. The red box 
highlights decarboxylated Herceptin Fab 130. 
 
In order to rule out non-photochemical pathways for the reaction bis-modified conjugate 
128a was incubated both at room temperature and 37 °C for one hour. No change in LCMS 
trace was seen, suggesting the side reaction was purely photochemical in nature. That 
being said a peak corresponding to the same loss of mass from the light chain has been 
observed with dibromomaleimide bridging reagents under non-photochemical conditions.275 
This suggests there may also be a considerably slower thermal route to the product. 
Further exploration of this reaction is described in the following section (Section 2.3, page 
90). 
2.2.7: ELISA data for Herceptin Fab conjugates  
After demonstrating the success of the photochemical thiomaleimide [2+2] cycloaddition on 
antibody fragments it was necessary to demonstrate that the reaction does not have a 
87 
 
negative impact on the antigen binding ability. ELISAs (Enzyme Linked Immunosorbent 
Assays) are regularly employed for detection and quantification of antibody binding.290 The 
antigen against the antibody of interest is typically immobilised on the surface of a 
polystyrene plate before being incubated with a solution containing the antibody to be 
studied. Binding of the antibody to the antigen is then quantified by addition of a secondary 
antibody which is linked to an enzyme that catalyses a colourimetric reaction. Due to the 
specificity between the enzyme and the antibody the intensity of the colour is proportional 
to the amount of antibody bound to the plate. Protocols for ELISA affinity testing for 
Herceptin have been previously described,144 thus Herceptin was chosen over Rituxan for 
affinity testing. Both Herceptin conjugates, bis-modified 128a and bridged 129a, showed a 
strong affinity for the HER2 antigen, as did the native Herceptin Fab 127. A slight drop in 
binding affinity is seen in bridged Herceptin Fab 129a though this was not large enough to 
cause major concern (Figure 39).  
 
Figure 39 
An ELISA against HER2 antigen for native Herceptin Fab 127 and Herceptin Fab 
conjugates 128a and 129a.  See section 3.2.5.3, page 201 for details.  
 
Retention of the binding capability of Herceptin Fab conjugates 128a and 129a was 
expected as the modification occurs distal to the binding site of the protein. Any topological 
changes to the protein at the modification site have a negligible effect on the structure of 
the antigen binding region. These positive results further demonstrate the suitability of this 
reaction for antibody conjugation. 
2.2.8: Conclusions and future work 
The thiomaleimide photochemical [2+2] cyclisation was successfully applied to an scFv 
fragment and the Fab fragments of two clinically relevant antibodies, Rituxan and 
Herceptin. A small library of functionalised thiol-stable Fab conjugates was generated 
through a three step protocol which includes a highly efficient thiomaleimide [2+2] 
photocycloaddition (Scheme 61). The reaction was also attempted on the full antibody 
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Rituxan, though the additional complexity of the protein reduced the rebridging efficiency of 
the reaction. 
 
Scheme 61 
An optimised protocol for the generation of thiol stable Fab fragments. 
The next logical step in this work would be to attach a drug to the imide nitrogen and 
generate a thiol-stable Fab ADC. This construct could then be compared to both traditional 
maleimide ADCs and also bridged maleimide ADCs for in vivo stability and efficacy against 
a target disease.  
A different use for the photochemical thiomaleimide [2+2] cyclisation could be in the 
development of a novel bioorthogonal “photo click” reaction. By finding a suitable olefin to 
act as an electron acceptor the reaction could be used as a reagent free method for 
clicking chemical payloads to proteins of interest (Scheme 62). 
 
Scheme 62 
A proposed photochemical “click” reaction utilising the photochemical 
thiomaleimide [2+2] cyclisation. 
 
The success of this reaction depends entirely on the efficiency of the intermolecular 
photochemical [2+2] cyclisation. Typically, very high concentrations are required for 
intermolecular photochemical transformations due to the short lived nature of the excited 
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state. At low concentrations a successful collision between an excited state molecule and 
its reactive partner is statistically unlikely. For these reasons historical methods for 
photochemical “click” reactions have relied on using photoactive cages to mask reactive 
species which can become active upon irradiation.291,292 Excellent work based on tetrazole 
constructs utilises this approach to great effect.293–295 However, typical yields of less than 
60% limit the utility of this approach. Other methods such as the thiol-ene photoclick are 
limited by the necessity of a photosensitiser.296. Highly efficient intermolecular 
photochemical cyclisations, such as the photochemical thiomaleimide [2+2] cyclisation, 
could prove a valuable addition to this field.  
The photochemical thiomaleimide [2+2] reaction could also be employed for photochemical 
surface patterning. We envisage a system in which a solid support is modified with a 
suitable olefin to act as an electron acceptor for the maleimide. The support could then be 
incubated in a solution containing a thiomaleimide-modified structure of interest. Selective 
irradiation at a particular location on the support would form a covalent cyclobutane bridge 
between the structure and the support, while the remaining non-bound structure could be 
easily removed. Of particular interest would be the site selective immobilisation of 
antibodies onto surfaces. By repeating the process above with multiple antibodies against 
different antigens a multi-functional patterned surface could be generated for diagnostic 
purposes (Scheme 63).  
 
Scheme 63 
A conceptual method for photochemically modifying surfaces with antibody 
fragments. 
 
The success of this technique depends upon the same parameters as the photochemical 
click technique mentioned above. Photochemical surface derivatisation has been 
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extensively researched and several excellent methods exist based on the photoclick 
reactions listed above. That being said, the high efficiency, biocompatibility and simplicity of 
the photochemical thiomaleimide [2+2] cyclisation could arguably make a useful 
contribution to the field.    
2.3: C-terminal cysteine thiomaleimide decarboxylations 
2.3.1: Aims and introduction 
Whilst studying the photochemical thiomaleimide [2+2] cyclisation on antibody Fab 
fragments an interesting side reaction was observed. This reaction led to cleavage of the 
maleimide from the light chain of the protein and was tentatively assigned as a 
decarboxylation process initiated by photoexcitation of the maleimide (page 85, Scheme 
59). Due to the size and complexity of the protein complete structural assignment of the 
proposed side-product was not possible. 
The ability of the reaction to cleave the maleimide from the protein could provide a useful 
tool to photochemically cleave small molecule payloads from proteins, a powerful method 
for targeted therapeutics. The same reaction could also be employed for photochemical 
protein “uncaging” (Scheme 64). 
 
Scheme 64 
Applications of photocleavable linkers. 
 
Current methods for photochemical uncaging are dominated by nitrobenzyl based 
photocleavable linkers which suffer from low yields, long reaction times, and potentially 
toxic by-products.89 By studying this side reaction further we hoped to make a contribution 
to the field of photocleavable linkers and provide an alternative means of photochemical 
drug delivery and photochemical uncaging.  
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Aims 
The first aim of this work was to use traditional synthetic and spectroscopic techniques to 
explore the proposed decarboxylative reaction observed with Kappa IGg1 Fab fragments. 
Though similar reactions have been studied on phthalimides81,286–288,297,298 no such 
transformation has been reported with maleimides. Successful confirmation of the reaction 
would mean the discovery of a novel photochemical transformation and expand the 
photochemical reactivity of substituted maleimides (Scheme 65). 
 
Scheme 65 
A proposed small molecule study to confirm the theorised photochemical 
decarboxylation. 
 
The second aim of this work was to use the knowledge gained to design a novel 
photocleavable linker based around the maleimide scaffold for use in protein uncaging or 
photochemical drug delivery, with particular focus on the development of photocleavable 
antibody drug conjugates (Scheme 66). At the time of writing very few examples of 
photocleavable ADCs exists in the literature245 and any developments would represent a 
considerable contribution to the field of targeted therapeutics. 
 
Scheme 66 
A proposed photocleavable antibody drug conjugate utilising a maleimide based 
photocleavable linker. 
 
2.3.2: Small molecule models of C-terminal cysteine 
decarboxylation 
2.3.2.1: Synthesis and irradiation of a single cysteine model 
C-terminal Fmoc-L-cys-maleimide 133 was synthesised from readily available starting 
materials. Trityl deprotection of Fmoc-L-cys(Trt) 131 gave Fmoc-L-cys 132, which was 
subsequently reacted with bromomaleimide 93 to furnish the desired compound 133 in an 
excellent yield. The bulky Fmoc group was employed to discourage competing 
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photochemical [2+2] cyclisation. Irradiation of 133 at low concentration (380 M) using a 
UVG-2 365 nm torch in the presence of base resulted in complete consumption of the 
starting material and produced the suspected enecarbamate 134 in an isolated yield of 
95% within one hour. Irradiation with a medium pressure mercury lamp reduced the 
reaction time to 20 minutes with no detrimental effect on the yield (93%). As a control 
Fmoc-L-cys-maleimide 133 was irradiated in the absence of base and showed no 
decarboxylation, producing only [2+2] cyclisation product 135. This demonstrates the 
necessity of the carboxylate for this reaction and provides mechanistic insight. Stirring a 
solution of Fmoc-L-cys-maleimide 133 with base for one hour showed no reaction, ruling 
out potential non-photochemical routes to the product under these conditions (Scheme 67).  
 
Scheme 67 
The synthesis and irradiation of Fmoc-L-cys-maleimide 133. 
 
Initially isolation of enecarbamate 134 was problematic. However, this was discovered to 
be the result of degradation of the enecarbamate product to the carbamate. Attempts to 
purify the irradiated mixture by silica gel chromatography produced confusing results as the 
mildly acidic nature of the silica is sufficient to promote this conversion. By changing the 
purification protocol to a simple extraction procedure isolation of the enecarbamate was 
possible. It is of interest to note that enecarbamate 134 appears to be unstable in 
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deuterated CHCl3 with significant conversion to the carbamate observed in samples left 
overnight. To test for acid catalysed degradation isolated enecarbamate 134 was subjected 
to a mildly acidic environment. Quantitative conversion to carbamate 136 was observed, 
providing evidence for the suspected degradation pathway (Scheme 68). The most logical 
mechanism for this process is tautomerisation of the enamide to the Schiff base, followed 
by acid catalysed hydrolysis to the carbamate. 
 
Scheme 68 
The acid catalysed hydrolysis of enecarbamate 134 to carbamate 136. 
 
At the time of writing there appears to be no examples of enecarbamate hydrolysis in the 
literature, though some hydrolysis studies of structurally similar enamides can be found.299 
This is surprising as enecarbamates have been employed as synthetic building blocks.300–
302  
2.3.2.2: C-terminal decarboxylation of a dipeptide model 
To provide a second model of this reaction dipeptide-maleimide 143 was synthesised via a 
simple convergent route. This model more closely resembles the reaction on a protein due 
to the adjacent amide bond, as opposed to the carbamate bond present in Fmoc-L-cys-
maleimide 133. Thus upon irradiation an enamide, rather than an enecarbamate, would be 
produced. NHS-Ester 138 was readily synthesised in excellent yield from Fmoc-L-
phenylalanine 137 using EDC and DMAP. Subsequent coupling with L-cysteine(Trt) 140 
proceeded smoothly to furnish dipeptide 141. Removal of the trityl group followed by 
conjugate addition to bromomaleimide 93 furnished dipeptide-maleimide 143 in an overall 
yield of 33%. Irradiation of 143 in the presence of base produced enamide 144 in an 81% 
yield (Scheme 69).  
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Scheme 69 
Synthesis and irradiation of dipeptide-maleimide 143. 
 
The slightly lower yield of this reaction compared to the single cysteine model 133 could be 
due to competition from the photochemical [2+2] cyclisation. The additional distance 
between the maleimide and the bulky Fmoc group resulting from the phenylalanine residue 
provides less steric discouragement for the cyclisation. Evidence of cyclisation products 
could not be found, though the small scale of these reactions caused by the low 
concentration made isolating trace products difficult. 
In each case, though the enecarbamate/enamide was successfully identified, the 
suspected thiolate product could not be isolated. After removal of the enamide a crude gum 
remained which showed no discernible peaks in both 1H and 13C NMR. Only weak broad 
peaks could be seen suggesting the remaining material was a complex mixture of 
structurally similar compounds. Attempts to follow the irradiation of Fmoc-L-cys-maleimide 
133 in a sealed NMR tube, to rule out degradation during work up, were unsuccessful due 
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to competition from the photochemical [2+2] cyclisation caused by the necessary increase 
in concentration. Throughout the reactions the appearance of a yellow colour was clearly 
observed, suggesting the formation of a compound with extended conjugation. Increasing 
the irradiation times of Fmoc-L-cys-maleimide 133 led to the disappearance of this colour, 
though did not affect the yield of enecarbamate 134. Similarly, increasing the concentration 
of the reaction decreased the intensity of this colour. This evidence suggests that the 
compound responsible for the yellow colour is reacting with itself to produce a complex 
mixture of non-UV absorbing polymers or oligomers. Maleimides are known to be 
susceptible to polymerisation303,304 and it is entirely plausible that the released product, 
which contains a thiol and a conjugate acceptor, would react with itself. Attempts to 
separate and isolate any of the products were unsuccessful and scaling up the reaction 
was impractical due to the limiting concentration. 
2.3.3: Attempts to determine the fate of the maleimide 
2.3.3.1: Synthesis and irradiation of an N-methyl maleimide model 
In order to assess the utility of this reaction it is important to know the fate of the released 
maleimide. This is particularly important for any in vivo application, as unambiguous 
identification of any released chemical is crucial for toxicity studies. Towards this goal an 
N-methyl variant of the C-terminal cysteine-maleimide model was synthesised. It was 
hoped the addition of a methyl group to the imide nitrogen could provide a point of 
reference for NMR analysis and simplify structural assignment of any trace materials 
resulting from the irradiation. Fmoc-L-cys-N-methylmaleimide 146 was synthesised 
according to the previously employed protocol in a yield of 79%. Irradiation in the presence 
of base resulted in consumption of the starting material and appearance of the previously 
observed yellow colour within one hour (Scheme 70). 1H and 13C NMR of the crude product 
revealed enecarbamate 134 and a complex mixture of other products which could not be 
identified or isolated, though did contain peaks characteristic of N-Methyl maleimide. No 
peaks corresponding to peptidic or Fmoc impurities could be found, indicating the 
unidentifiable products resulted entirely from the released maleimide.  
 
Scheme 70 
The synthesis and irradiation of Fmoc-L-cys-N-methylmaleimide 146. 
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Repeating the experiment with immediate quenching of the reaction using HCl after 
irradiation resulted in the rapid disappearance of the yellow colour (Scheme 71). NMR 
analysis of this crude mixture revealed the suspected carbamate 136 and small amounts of 
a proposed succinimide dimer 147.  
 
Scheme 71 
Irradiation of Fmoc-L-cys-N-methylmaleimide 146 with immediate quenching. 
 
Though the complexity of the crude mixture made NMR analysis difficult, DEPT, HMBC 
(Figure 40) and HSQC techniques suggested the major impurity was dimer 147. 
Correlations between the N-methyl groups and the carbonyls show one symmetrical 
succinimide and one asymmetrical succinimide. This is supported by the HMBC 
correlations between the CH2 protons on each ring system. A quaternary carbon at  = 61.5 
is indicative of an aliphatic carbon adjacent to two hetero atoms. These assignments are 
supported by similar structures reported in the literature.148 Unfortunately no further 
structures could be identified and full characterisation of the impurity was not possible.  
 
Figure 40 
A HMBC spectrum showing long distance couplings in support of dimer 147. 
HMBC couplings between 3 and 2 and 3 and 4 are seen further downfield.  
 
This analysis confirmed that the released maleimide is able to react with itself and supports 
the polymerisation theory. Possible mechanistic explanations for the formation of dimer 147 
are provided below. Upon acidification thiolate 148 could convert to thioketone 149. 
Subsequent nucleophilic addition from thiol 150, which results from tautomerisation of 
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thioketone 149, results in intermediate 151. Intramolecular conjugate addition onto the 
remaining maleimide would then result in formation of dimer 147 (Scheme 72).  
 
Scheme 72 
Potential mechanisms for the formation of dimer 147. 
 
This mechanism does not fully explain why dimer 147 is only observed if the reaction is 
quenched with HCl. It is possible that under basic conditions the maleimide exists as 
thiolate 148 which could be more likely to undergo extended polymerisation rather than 
form dimer 147. At the present time any proposed mechanism is purely speculative and 
further study is required to truly understand this process.  
UPLC-MS studies 
With evidence suggesting that polymerisation was responsible for the loss of the released 
maleimide it was decided to analyse the reaction using UPLC-MS. The more sensitive 
technique allows reactions to be monitored at a low concentration, potentially alleviating 
issues of polymerisation. Fmoc-L-cys-N-methylmaleimide 147 was irradiated for 50 minutes 
with samples taken every 10 minutes. UPLC-MS analysis scanning at 254 nm clearly 
showed the disappearance of the starting material 147 (7.78 minutes) and the appearance 
of enecarbamate 134 (8.42 minutes). Upon addition of HCl enecarbamate 134 can be seen 
degrading to carbamate 136 (6.27 minutes). Standard solutions of enecarbamate 134 and 
carbamate 136 were injected to confirm the identity of these peaks (Figure 41). ES+ and 
ES- ionisation analysis of the peaks provided additional evidence. 
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Figure 41 
UPLC analysis of the irradiation of Fmoc-L-cys-N-methylmaleimide 146. Starting 
material 146 is observed at 7.78 minutes, with enecarbamate 134 appearing at 8.42 
minutes. Carbamate 136 appears at 6.17 minutes after addition of HCl. LC traces of 
standard solutions of 146, 134 and 136 can be found in the experimental section 
(section 3.1.2.3, page 154). 
 
After forty minutes of irradiation an additional peak at 11.08 minutes is observed. Analysis 
of this side product using ES+ ionisation identified several discrete mass peaks, though 
none correspond to a suspected polymerisation product. Ionisation using ES- mode 
produced equally inconclusive results (Figure 42).  
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Figure 42 
ES- and ES+ ionisation patterns from the peak at 11.08 minutes (Figure 41).  
 
Unfortunately, no additional peaks could be seen either by the LC trace or the mass trace. 
Scanning the ionisation trace for suspected polymer fragments, including dimer 147, was 
equally unfruitful. Several LC solvent systems were assessed, in case the polymer was 
being retained on the column, but returned no positive results. These results were 
perplexing as there is a clear formation of a yellow colour during the reaction, so it stands 
to reason that the responsible compound should be observable. In order to rule out the 
possibility that interaction with the column was affecting the results a solution of 147 
irradiated for one hour was analysed directly by ESI. Enecarbamate 134 was observed 
though no other products could be identified.  
2.3.3.2: Synthesis and irradiation of an N-dansyl maleimide model 
To attempt to ascertain further information regarding the fate of the released maleimide in 
the C-terminal photochemical decarboxylation Fmoc-L-cys-N-dansylmaleimide 148 was 
synthesised and irradiated. It was hoped that attachment of a strongly absorbing and 
fluorescing group to the imide nitrogen would help to locate the maleimide after 
photochemical cleavage. Fmoc-cysteine was reacted with previously synthesised 
N-dansylbromomaleimide 110 to produce Fmoc-L-cys-N-dansylmaleimide 148 (Scheme 
73). 
 
Scheme 73 
The synthesis of Fmoc-L-cys-N-dansylmaleimide 148. 
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Irradiation of this construct was followed using UPLC-MS for a total of 50 minutes (Scheme 
74) (Figure 43). Once again disappearance of the starting material 148 and appearance of 
enecarbamate 134 was clearly observed, though no peaks corresponding to the released 
maleimide could be detected at either 254 or 330 nm (dansyl absorbance305). Visible 
fluorescence over the course of irradiation was noticed, and TLC analysis revealed a 
complex mixture of fluorescent spots.  
 
 
 
Scheme 74 
The irradiation of Fmoc-L-cys-N-dansylmaleimide 148. 
Figure 43 
UPLC analysis of the irradiation of 148. Starting material 148 is observed at 9.95 
minutes, with enecarbamate 134 appearing at 8.53 minutes. Carbamate 136 
appears at 6.32 minutes after addition of HCl. LC traces of standard solutions of 
148, 134 and 136 can be found in the experimental section (section 3.1.2.3, page 
154). 
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The inability to confidently observe and identify the fate of the released maleimide in this 
reaction casts serious doubt on its application to photochemical drug delivery. 
Nevertheless, the reaction still represents a novel reactivity for maleimides and a high 
yielding photochemical method for producing enecarbamates and enamides.  
2.3.4: Postulated mechanism for C-terminal thiomaleimide 
decarboxylation 
Given the novelty of this reaction it is interesting to postulate a mechanism. A considerable 
body of research exist on the decarboxylation reactions of phthalimides and mechanisms 
for this reaction have been proposed. In the generally accepted mechanism phthalimide 
149 acts as an electron acceptor and the carboxylate as the electron donor in a photo-
induced electron transfer (PET). The resultant carboxyl radical (150) decarboxylates to 
form carbon based radical 151 which can engage in further radical processes (Scheme 
75).81  
 
Scheme 75 
The mechanism of phthalimide photochemical decarboxylation proposed by 
Griesbeck et al.81 
 
Translating this work to the maleimide-mediated decarboxylation reaction allows us to put 
forward several mechanisms (Scheme 76). In these proposed mechanisms the electron 
transfer takes place from either the singlet (153) or triplet (154) excited state. Formation of 
decarboxylated product 158 from the excited state could proceed as a single concerted 
radical elimination (route 1), or via intermediate 156 in a two-step process (route 2). It is 
also possible that intermediate 156 could engage in a “back” electron transfer from the 
maleimide to form a carbon centred anion (157), and enecarbamate 158 could 
subsequently form through an anionic elimination (route 3). In each case the maleimide 
would be released as thiolate 159 which could undergo further transformations.   
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Scheme 76 
Possible mechanisms for the photochemical decarboxylation of C-terminal 
cysteine-maleimides. 
 
Without more detailed studies it is impossible to assign a mechanism with complete 
confidence, but given the similarities in photochemistry and structure between phthalimides 
and maleimides it is reasonable to assume parallels between the two. Laser flash 
photolysis studies on phthalimides by Griesbeck et al.. deduced that the electron transfer 
most likely takes place from the triplet state rather than the singlet state.81,288,297 With 
regards to the possible routes for decarboxylation (route 1, 2 or 3) it is reasonable to 
assume the stability of intermediate 156 would play an important role in determining the 
preferred pathway. Work with phthalimides has shown similar carbon centred radicals are 
stable enough to undergo both intra- and intermolecular radical addition reactions, and in 
fact this is often the preferred fate.81,286,288,298 However, the near quantitative yield of 
enecarbamate 134 and high yield of enamide 144 suggest that an intermediate such as 
156 is short lived or that a concerted mechanism is more likely. That being said, work with 
phthalimides has shown elimination from similar carbon centred radicals can occur as a 
preferred route provided the leaving group is sufficient.287 Perhaps the least likely route is 
route 3, which involves the formation of intermediate 157 and subsequent back electron 
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transfer from the maleimide to the carbon centred radical.  Back electron transfers with 
phthalimides are seldom seen and only occur in the presence of strongly electron 
withdrawing groups adjacent to the radical.288   
Based on current evidence and the work with phthalimides it seems most likely the reaction 
proceeds via electron transfer from the triplet state followed by a concerted radical 
decarboxylation-elimination. However, without further work the intricacies of this particular 
decarboxylation remain a mystery. The knowledge gained from the study of this reaction 
was employed towards the generation of more general photocleavable linkers which will be 
discussed in the next chapter.  
2.3.6: Conclusions and future work 
A novel thiomaleimide-mediated decarboxylation of C-terminal cysteine residues was 
discovered and studied using two small molecule cysteine models. The reaction proceeds 
rapidly to produce the corresponding enecarbamates and enamides in good yields 
(Scheme 77).  
 
Scheme 77 
The photochemical decarboxylation of C-terminal thiomaleimides to produce 
enecarbamates or enamides.  
 
These reactions provide the first example of a maleimide-mediated photochemical 
decarboxylation and expand the utility of maleimides into the realm of photocleavable 
linkers.  
The utility of this approach is limited by the necessity of a C-terminal cysteine and an 
inability to isolate the released chemical payload, possibly due to extended polymerisation. 
This second problem precludes the use of this reaction for in vivo therapeutic applications 
due to toxicity concerns. However, the reaction could still find use in a research capacity for 
applications in which the identity of the released compound is unimportant e.g.  
photochemical protein uncaging (Scheme 78). 
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Scheme 78 
Utilising the maleimide-mediated C-terminal cysteine decarboxylation for protein 
uncaging.  
 
2.4: Dithiomaleimide based photocleavable linkers 
2.4.1: Aims and introduction 
Given the significant drawbacks of the C-terminal-cysteine decarboxylation we decided to 
design a new set of photocleavable linkers based around the maleimide scaffold. The 
previous work demonstrated the ability of thiomaleimides to act as electron acceptors in 
photochemical electron transfer reactions and it was envisioned that this could be exploited 
in the design of improved maleimide based photocleavable linkers. Work by Griesbeck et 
al. showed N-phthaloyl-serine/threonine analogues can participate in photochemical 
elimination reactions via a decarboxylation.80,83,287 A competition exists between elimination 
to form 161 and protonation to form 162, with a better leaving group favouring elimination 
and vice versa (Scheme 79) (Section 1.1.3.1, page 23). 
 
Scheme 79 
The photochemical decarboxylation-elimination reaction of acetylated N-phthaloyl-
amino acid 160. 
 
Griesbeck et al. suggested this work could inform development of novel photocleavable 
linkers for protein uncaging. Though the reaction is high yielding, phthalimides are not ideal 
for biomodification as they have no built in point of attachment. A photocleavable linker 
based on a phthalimide structure would require an additional chemical moiety to react 
specifically with the protein. This complicates synthesis and decreases the appeal of this 
method. In addition to this the irradiation times are prohibitively long, requiring at least two 
hours of intense irradiation for efficient photocleavage.287 
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The work outlined in the previous chapter demonstrated the similarities between 
phthalimides and thiomaleimides in regards to decarboxylation reactions. It was 
hypothesised that if we could emulate the acetylated-N-phthaloyl-amino acid 
decarboxylation reaction with thiomaleimides we could develop a cysteine selective 
photocleavable linker (Scheme 80). This approach also holds several advantages over the 
previously described C-terminal-cysteine decarboxylation. The chemical payload is 
released as a more traditional leaving group rather than a thiomaleimide, potentially 
alleviating problems associated with polymerisation, and the reaction is no longer restricted 
to C-terminal cysteine residues. Removal of the latter restriction opens up the possibility of 
using dithiomaleimides, rather than monothiomaleimides, further expanding the utility of the 
reaction. 
 
Scheme 80 
A conceptual scheme demonstrating thiomaleimide based photocleavable linkers. 
 
2.4.2: Synthesis of a simple cysteine-maleimide model 
In order to test the proposed decarboxylation-elimination reaction a suitable model had to 
be synthesised. A dithiomaleimide-serine model was synthesised to closely mimic the 
previous work on phthalimides and allow for an effective comparison. Due to the novel 
nature of this work no previous synthetic routes to this compound exist and a considerable 
amount of strategy development was necessary. Several routes were explored to the 
desired compound which was eventually furnished in a good yield over three steps. 
2.4.2.1: Synthesis of dibromomaleimide-N-L-serine 
The first step in the process was the synthesis of dibromomaleimide-N-L-serine 167 which 
could serve as an intermediate in the synthesis of the final compound and also a useful 
synthetic building block for similar constructs. The first route to this compound was via dual 
tert-Butyl protected serine 164. Protection of both the alcohol and carboxylic acid of the 
serine proceeded almost quantitatively in one step. Reaction of 164 with activated 
carbamate 165 and subsequent tert-Butyl deprotection yielded the desired 
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dibromomaleimide-N-L-serine 167 in an overall yield of 64%. Despite the success of this 
route we wished to eliminate the protection and deprotection steps and find a more direct 
path to dibromomaleimide-N-L-serine 167. Difficulties were encountered due to the 
insolubility of L-serine 163 in the organic solvents typically employed in the reactions of 
amines with carbamate 165. Equally problematic was the solubility and stability of 
carbamate 165 in aqueous solutions. Eventually a system was found which yielded the 
desired compound 167 in a 67% yield in a single step, improving on the overall yield of the 
three step route. This involved using a THF / H2O solvent mixture to solubilise both 
components and allow for attack of the amine on the carbamate. Immediate extraction with 
dichloromethane followed by treatment with para-toluenesulfonic acid promoted ring 
closing and formation of the product. Attempts to synthesise 165 via condensation of L-
serine with dibromomaleic anhydride 168, synthesised using a known protocol,156 produced 
a complex mixture of products which could not be separated. These synthetic routes are 
summarised below (Scheme 81). 
 
Scheme 81 
Synthetic routes to dibromomaleimide-N-L-serine 167. 
 
With a reliable route to dibromomaleimide-N-L-serine 167 several strategies for the 
synthesis of the final dithiomaleimide-serine model 170 were assessed. Displacement of 
the maleimide bromines for Boc-L-cys-OMe formed dithiomaleimide-serine 169, though the 
isolated yield of this reaction was lower than expected due to purification difficulties. 
Unfortunately, acetylation of 169 proved difficult. Reaction with acetyl chloride gave a 
mixture of products, possibly due to Boc deprotection by the released hydrochloric acid. 
Attempts to react the serine alcohol with acetic anhydride produced dehydroalanine like 
product 171 as the major species. Despite this, desired acetylated dithiomaleimide-serine 
model 170 was isolated in a small yield. This indicates the desired product forms but 
subsequent deprotonation of the alpha proton results in elimination of the acetyl group and 
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formation of side product 171. This unwanted reactivity could be minimised by decreasing 
reaction times, but a concurrent decrease in the consumption of starting material 169 
limited the usefulness of this approach (Scheme 82).  
 
Scheme 82 
Synthetic routes towards acetylated dithiomaleimide-serine model 170 via 
dithiomaleimide-serine 169. 
 
Greater success was found by first acetylating dibromomaleimide-N-L-serine 167 before 
introducing Boc-L-cys-OMe. Though acetylation using acetyl chloride was unsuccessful 
using the corresponding acyl bromide produced acetylated dibromomaleimide-serine 172 in 
an excellent yield under base free conditions. Substitution of the maleimide bromines for 
Boc-L-cys-OMe yielded the final product dithiomaleimide-serine model 170 in a good yield 
(Scheme 83).  
 
Scheme 83 
Synthetic routes towards acetylated dithiomaleimide-serine model 170 via 
acetylated dibromomaleimide-serine 172. 
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2.4.2.2: Irradiation of a simple cysteine model 
Irradiation of acetylated dithiomaleimide-serine 170 in a buffer / acetonitrile solvent system 
resulted in the consumption of the starting material within 40 minutes. Purification of the 
resultant mixture yielded the suspected ene-maleimide 173 and also protonated side 
product 174 (Scheme 84).  
 
Scheme 84 
The irradiation of acetylated dithiomaleimide-serine model 170. 
 
This result confirmed the hypothesis that thiomaleimides could undergo photochemical 
decarboxylation-elimination reactions, albeit in a lower yield than the corresponding 
phthalimides (95%287). Irradiation times were significantly reduced; 40 minutes with a 125 
W lamp compared to two hours with an 800W lamp at millimolar concentrations. The two 
products formed were analogous to the product observed during the phthalimide work and 
provide another example of similarities between phthalimide and thiomaleimide 
photochemistry. To confirm the release of acetic acid the reaction was repeated in organic 
solvent with pyridine as a base in a sealed NMR tube (Scheme 85). Analysis after 
irradiation clearly showed the formation of acetic acid by both 1H and 13C NMR in a 1:1 ratio 
with compound 173. Protonated side product 174 was also observed. The presence of 
acetic acid (175) released in equimolar quantities gives confidence that the released 
product is not undergoing further reactions.  
 
Scheme 85 
The irradiation of acetylated dithiomaleimide-serine model 170 in the presence of 
pyridine in DMSO-d6. 
 
2.4.3: A postulated mechanism for thiomaleimide 
decarboxylation-elimination 
As with the C-terminal decarboxylation discussed in the previous chapter a mechanism for 
this thiomaleimide decarboxylation can be inferred from the related decarboxylation 
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reactions of N-phthaloyl-amino acids.287 Whilst no detailed study of this particular 
phthalimide photochemical decarboxylation-elimination has been performed the key 
photochemical steps are likely to be identical to the previously reported phthalimide 
decarboxylation reactions (Scheme 86). Photochemical excitation of the phthalimide (176) 
is followed by an intersystem crossing to the triplet state 177. An electron is then 
transferred from the carboxylate to the triplet phthalimide to produce carboxylate radical 
178. Two pathways for the elimination of the acetate group were proposed; a direct E2 -
elimination (route 1) or a two-step process involving an intermediate carbon anion (179) in 
an E1cB-like elimination (route 2). It is by this second route that protonated impurity 162 is 
formed.  It was proposed that substitution at the beta position of the amino acid can 
influence the route for decarboxylation. The authors state that in both cases acetate is 
released, though do not specify how this occurs in the concerted mechanism. As the 
concerted elimination is radical in nature it stands to reason that the leaving group would 
be pushed out as a carboxy radical rather than the anionic acetate. It is possible that “back” 
electron transfer from the phthalimide to the carboxy radical occurs, regenerating the 
phthalimide and forming the acetate, though this is not explicitly addressed by the authors.  
 
Scheme 86 
The proposed mechanism for the formation of phthalimides 161 and 162 during the 
irradiation of acetylated N-phthaloyl-serine carboxylate 176.  
 
Based on this information a mechanism for the maleimide based decarboxylation can be 
proposed (Scheme 87). Photoexcitation of thiomaleimide-serine carboxylate 180 to the 
excited singlet/triplet state (181) is followed by electron transfer from the carboxylate to the 
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maleimide. Elimination can then occur via either a concerted E2 -elimination or a two step 
E1cB like mechanism. The increased presence of protonated product 174 suggests the two 
step route is more likely in the case of maleimides, as formation of such a product would be 
impossible through a concerted elimination. Of course it is entirely possible that a 
competition could be occurring between both routes.      
 
Scheme 87 
The proposed mechanism for the photochemical thiomaleimide decarboxylation-
elimination reaction. 
 
2.4.4: Photochemical cleavage from a peptide model 
2.4.4.1: Preparing and irradiating a suitable Octreotide model 
Given that the eventual aim of this work was to design photocleavable linkers that are 
compatible with proteins and peptides we decided to test the new photochemical 
decarboxylation on a peptide model. Octreotide 74 was employed for this purpose due to 
its simplicity and familiarity. A modified protocol for the modification of Octreotide 74 was 
devised and implemented. Reducing the disulfide with a slight excess of TCEP and 
subsequently reacting with acetylated dibromomaleimide-serine 172 yielded the desired 
Octreotide conjugate 184 (Scheme 88). The reaction was followed using LCMS and a clear 
change in retention time was observed (Scheme 88) (Figure 44). Analysis of this peak 
using both ES+ and ES- ionisation modes showed the desired mass.  
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Scheme 88 
The modification of Octreotide 74 with acetylated dibromomaleimide-serine 172. 
Figure 44 
A UPLC trace showing the modification of Octreotide 74 with acetylated 
dibromomaleimide-serine 172: (A) Octreotide 74, (B) Octreotide conjugate 184. See 
experimental section for ES spectra (Section 3.2.7.1, page 202, Figure 90). 
 
Subsequent irradiation of Octreotide conjugate 184 resulted in complete consumption 
within five minutes and the formation of three new products (Scheme 89) (Figure 45). The 
peak at 5.87 minutes had an m/z value of 1140, which corresponds to the desired 
Octreotide ene-maleimide 185. The secondary peak at 5.70 minutes had a m/z value of 
1199, which corresponds to protonated Octreotide conjugate 186. Based on the work done 
with small molecule model 170 this was entirely expected. Starting material 184 was not 
detected by the mass analyser in this peak, showing that despite the similar retention times 
between starting material 184 and side product 186 a full conversion had taken place. 
Though baseline separation of the two product peaks could not be achieved, splitting the 
peaks down the middle and integrating gives an approximated yield of 66% for the desired 
product 185 and 19% for the protonated species 186. This is in agreement with the results 
obtained on the small molecule model. All integrations were performed on the UV-Vis trace 
scanning at 280 nm to prevent interference from the maleimide absorbance.  
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Scheme 89 
The irradiation of Ocreotide conjugate 184. Irradiation was performed using a 5W 
395 nm LED torch. 
Figure 45 
A UPLC trace scanning at 280 nm of the crude mixture of products formed from the 
irradiation of Octreotide conjugate 184. m/z values are shown next to the 
corresponding peak and matched the expected values. See experimental section 
for ES spectra (Section 3.2.7.1, page 206 ,Figure 97 & Figure 98). 
 
In addition to the two expected products an additional peptidic species was formed with a 
retention time of 4.90 minutes and an m/z value of 1116. This value matches exactly with 
Octreotide-succinimide 187, a side product previously encountered during the bis-
modification work discussed previously (Section 2.1.2, page 51) (Figure 46). 
 
Figure 46 
Octreotide-succinimide 187 formed as a side product during the irradiation of 
Octreotide conjugate 184. 
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Injection of a pure sample of Octreotide-succinimide 187 showed the same retention time 
as the side-product observed during the irradiation of 184, providing evidence for its 
formation. The unexpected formation of 187 poses the question as to how such a species 
could form under the reaction conditions. No obvious mechanism, given the knowledge 
gained from the small molecule work and the research on phthalimides, presents itself. One 
plausible route is via the protonation at the double bond of the maleimide after 
decarboxylative formation of anion 188. This is best seen via alternate resonance form 189. 
This could form an iminium ion (190) which is subsequently attacked by water, leading to 
cleavage of the N-C bond and formation of succinimide 187 (Scheme 90). 
 
Scheme 90 
A proposed mechanism for the photochemical formation of Octreotide-succinimide 
187. 
 
Though protonation at the double bond seems unlikely when compared to elimination or 
direct protonation at the alpha position this mechanism does provide a route to the 
observed product. Attempts to observe aldehyde 191 by ESI mass spectrometry were 
unsuccessful, though given the reactive nature of aldehydes this was unsurprising.  
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2.4.5: Altering the scaffold of the thiomaleimide photocleavable 
linker 
2.4.5.1: Synthesis of structurally varied dibromomaleimide linkers 
Though the initial work on the simple model system was a success we felt that the reaction 
was not explored to a satisfactory level. A quick look at the basic scaffold of the 
photocleavable linker reveals several targets for modification, namely the alpha & beta 
positions and the leaving group (Figure 47). We were interested in how the photochemical 
decarboxylation-elimination would be affected by changes in these key positions and if 
possible improve the yield of the desired photochemical cleavage.  
 
Figure 47 
A schematic showing the various points on the photocleavable scaffold which can 
be targeted for substitution. 
 
These dibromomaleimides were subsequently inserted into the disulfide bond of Octreotide 
74 and their photochemical reactivity studied using the UPLC-MS method previously 
developed.  This provided a simple and reliable strategy to quickly compare the effects of 
these structural changes.   
Synthesis of acetylated dibromomaleimide-threonine 
Work by Griesbeck et al. demonstrated N-phthaloyl-L-threonine is able to undergo efficient 
photochemical decarboxylation.287 To test the effect of this alteration on the photochemical 
decarboxylation-elimination on thiomaleimides, acetylated dibromomaleimide-threonine 192 
was synthesised. Reaction of L-threonine 192 with carbamate 165 gave dibromomaleimide- 
threonine 193 in a good yield. Subsequent acetylation furnished acetylated 
dibromomaleimide-threonine 194 in an overall yield of 52% (Scheme 91). 
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Scheme 91 
The synthesis of acetylated dibromomaleimide-threonine 194.  
 
Synthesis of acetylated dibromomaleimide--Me-serine 
The work with phthalimides was not extended to testing the ramifications of substitution at 
the alpha position of the amino acid, though given the influence of substitution at the beta 
position it is reasonable to assume some effect would be observed. In fact, any effect could 
be more pronounced as the alpha position is more directly involved in the two step E1cB 
mechanism of elimination. Acetylated dibromomaleimide--Me-serine 197 was synthesised 
in two steps using a modified version of the previously employed synthetic route. L--Me-
serine 195 was reacted with dibromomaleic anhydride 168 to produce dibromomaleimide-
-Me-serine 196. Attempts to produce 196 via reaction of L--Me-serine 195 with 
carbamate 163 were unsuccessful, with extended reaction times leading only to 
degradation of the carbamate starting material. TLC analysis of the reaction mixture 
indicated that the secondary amine was simply unable to react with the carbamate, the 
added steric bulk of the methyl group perhaps preventing nucleophilic attack. 
 
Scheme 92 
The synthesis of acetylated dibromomaleimide--Me-serine 197. 
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Interestingly reaction of L--Me-serine 195 with dibromomaleic anhydride 168 proceeded 
well despite the same reaction producing a complex mixture when attempted with simple L-
serine 163. The addition of the methyl group appears to stabilise this serine analogue 
towards the reaction conditions. This suggests the side products seen in the reaction of L-
serine 163 with dibromomaleic anhydride 168 (Scheme 81) are likely a result of enolisation.  
Synthesis of phenylacetyl-dibromomaleimide-serine 
The effect of the leaving group on the efficiency of the decarboxylation-elimination was not 
thoroughly studied on phthalimides;287 only two different groups were tested. We wanted to 
see what effect changing the leaving group from acetic acid to phenylacetic acid would 
have on the overall reactivity of these compounds. Several routes to target compound 199 
were tested (Scheme 93). Attempts to form the ester via a HATU mediated coupling were 
unsuccessful, and a DCC coupling reaction furnished the product in a very poor yield. 
Cross reactivity of DMAP with dibromomaleimides has been previously noted in the lab so 
the low yield in this case was unsurprising. Reaction of dibromomaleimide-serine 167 with 
phenylacetyl chloride in refluxing chloroform furnished a mixture of three inseparable 
compounds of similar structure (198). Analysis of the mixture suggested a bromine-chlorine 
exchange had occurred as a result of the liberation of chlorine during the reaction. 
Fortunately, addition of excess tetra-N-butylammonium bromide to this mixture furnished 
the compound 199 in a good overall yield, presumable through a chlorine-bromine 
exchange.  
 
Scheme 93 
Routes towards the synthesis of phenylacetyl-dibromomaleimide-serine 199. 
 
Using this knowledge a one pot synthesis was devised in which the tetra-N-butylammonium 
bromide was added at the start of the reaction. This reaction proceeds at room temperature 
to furnish the desired compound in a single step and a good yield (Scheme 94). 
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Scheme 94 
Optimised synthesis of functionalised dibromomaleimide 199.  
 
The fact that the reaction between dibromomaleimide-serine 167 and phenylacetyl chloride 
in the presence of tetra-N-butylammonium bromide proceeds at room temperature 
suggests that phenylacetyl bromide acts as an intermediate. Previous attempts to react 167 
with acyl chlorides at room temperature in the absence of base were ineffective, and 
conversion of acyl chlorides to acyl bromides by tetra-N-butylammonium bromide has been 
reported.306,307  
Synthesis of carbamate-dibromomaleimide-serine analogues 
Many fluorophores and cytotoxic compounds contain amine functionality so developing a 
method to release amines would increase the utility of this reaction. Carbamic acids 
spontaneously decarboxylate in aqueous environments to release amines so are ideal 
leaving groups in this respect.308 Carbamates are also far more hydrolytically stable than 
esters and are thus more desirable for in vivo applications.309,310 carbamate-
dibromomaleimides 200 and  201 were easily synthesised in base free conditions by the 
reaction of dibromomaleimide-serine 167 with the appropriate isocyanate in the presence 
of molybdenum(VI) dichloride dioxide (Scheme 95).311  
 
Scheme 95 
The synthesis of carbamate-dibromomaleimide-serine analogues 200 and 201.  
 
Synthesis of thiocarbamate-dibromomaleimide-serine  
To see what effect exchanging oxygen for sulfur would have on the photochemical 
decarboxylation-elimination thiocarbamate-dibromomaleimide-serine 205 was synthesised. 
L-cysteine 202 was selectively N-Boc protected to produce Boc-cysteine 203. Subsequent 
reaction with benzylisocyanate produced thiocarbamate 204. This step was low yielding 
and highlights the limitations of this catalytic approach. One pot Boc deprotection and 
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subsequent reaction with carbamate 165 produced thiocarbamate-dibromomaleimide-
serine 205. 
 
Scheme 96 
The synthesis of thiocarbamate-dibromomaleimide-serine 205. 
 
2.4.5.2: Comparing the effects of structural modifications 
Octreotide 74 was reduced and modified with the newly synthesised library of 
dibromomaleimides according to the optimised protocol. Modification proceeded efficiently 
in each case with only trace amounts of native Octreotide 74 remaining in the cases of 206c 
and 206d (Scheme 97) (Figure 48). 
 
Scheme 97 
The modification of Octreotide 74 with functionalised dibromomaleimide linkers.  
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Figure 48 
LCMS traces showing successful modification of Octreotide 74 with 
dibromomaleimides (B) 194, (C) 197, (D) 199, (E) 200, (F) 201, and (G) 205. All m/z 
values matched the expected. For full LCMS spectra see experimental section 
(section 3.2.7.1, page 202).  
 
Irradiation of Octreotide conjugates 206a-f in buffer resulted in the complete consumption of 
starting material within five minutes (Scheme 98). In each case the desired ene-maleimide 
was observed, in addition to the protonated species and Octreotide succinimide 187. No 
other products were observed (Figure 49), suggesting the reaction is not drastically 
affected by these modifications, though the ratios of the products were different in each 
case. The UPLC traces are shown below for each case and the results summarised in 
Table 2.  
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Scheme 98 
The irradiation of Octreotide conjugates 206a-f. Irradiation was performed using a 
5W 395 nm LED torch. 
 
Table 2 
A summary of the products obtained from the irradiation of Octreotide conjugates 
207a-f. 
 
 R1 R2 R3 Y ene-
maleimide 
185/207a-f / % 
protonated 
product 
186/208a-f / % 
Succinimide 
187 / % 
184 H H Me O 66(a) 19(a) 15 
206a H Me Me O 50(a) 26(a) 24 
206b Me H Me O 80 0 20 
206c H H Bn O 83 17 0 
206d H H NBn O 52 29 19 
206e H H NPh O 65 25 10 
206f H H NBn S 31 40 29 
(a) Yield is approximated due to poor peak resolution. 
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Figure 49 
LCMS traces showing the irradiation of Octreotide conjugates 206a-f. (A) Irradiation 
of 206a, (B) Irradiation of 206b, (C) Irradiation of 206c, (D) Irradiation of 206d, (E) 
Irradiation of 206e, (F) Irradiation of 206f. ES+ m/z values are shown in the colour 
corresponding to the peak label and all matched the expected values. See 
experimental section for ES spectra (section 3.2.7.1). 
 
The effect of methylation at the alpha and beta positions 
Methylation at the beta position has a negative effect on the photocleavage, seeming to 
favour the formation of protonated product 208a and succinimide 187. Griesbeck et al. 
noticed a similar effect with N-phthaloyl-allo-threonine and argued that an unfavourable 
steric clash between the beta-methyl and the phthalimide discouraged concerted 
elimination by forcing the carboxylate and the leaving group away from the ideal 
antiperiplanar configuration (Figure 50). They argue that this forces the decarboxylation to 
proceed via the two step mechanism, consequently enabling protonation of the 
intermediate. It is important to note that the authors assign a higher priority to the clash 
between the carboxylate and the acetate than the clash between the acetate and the 
phthalimide.  
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Figure 50 
Newman projections of the proposed transition states formed during the irradiation 
of N-phthaloyl-L-serine 209 and N-phthaloyl-allo-threonine 210.287 
 
Though this same argument cannot be directly applied to the example of Octreotide 
conjugate 206a it is possible the geometrical conformation forced by the beta-methyl is 
discouraging concerted elimination or encouraging a two step elimination.  
In contrast methylating at the alpha position has a positive effect on the photocleavage 
efficiency. A 14% increase of the desired ene-maleimide is seen when compared to the 
unmethylated structure. Protonated species 208a was not detected, either by LC or MS, 
though succinimide 187 was still observed. One potential reason behind this increase in 
yield takes into account the geometrical considerations. The addition of the methyl group 
on the alpha carbon could encourage an antiperiplanar orientation of the acetyl and 
carboxylate groups and promote concerted elimination, favouring formation of the ene-
maleimide (Figure 51). 
 
Figure 51 
A Newman projection of the hypothesised transition state of the irradiation of 
acetylated dithiomaleimide--Me-serine 211. 
 
As with the phthalimide work this argument is conditional on the carboxylate being deemed 
more sterically repulsive than the maleimide. This gives priority to avoiding a clash between 
the carboxylate and the acetate, rather than between the acetate and the maleimide. 
Another explanation is that the additional bulk, however small, of the methyl group inhibits 
protonation for purely steric reasons. Thus even if the mechanism proceeds via the two 
step E1cB like mechanism protonation would be depressed and the elimination product 
favoured (Scheme 99). The presence of succinimide 187, assuming the mechanism of 
protonation at the double bond proposed in Scheme 90 is correct, lends weight to this 
purely steric argument.  
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Scheme 99 
A possible explanation for the decrease in protonated product 208b observed with 
Octreotide conjugate 206b. 
 
The effect of changing the leaving group 
This work also highlighted the importance of the leaving group on the efficiency of the 
reaction. Exchanging acetate for phenylacetate, benzyl carbamic acid, phenyl carbamic 
acid or benzylthiocarbamic acid as the leaving group (206c-f) produces significant changes 
in the yield of ene-maleimide 207c-f. Since there are no significant geometrical differences 
between the standard scaffolds of Octreotide conjugates 184 and 206d-f the differences in 
reactivity can be attributed mostly to the effect of the leaving group. The general trend is 
that the lower the pKa of the leaving group the higher the decarboxylative yield. The 
exception to this rule is the benzylthiocarbamic acid 206f, which has a very low calculated 
pKa but also the lowest yield of decarboxylation. Chemical intuition suggests better leaving 
groups would favour elimination over protonation, so these results are unsurprising 
(Scheme 100). It is also in agreement with the work done with the phthalimides.287 
 
Scheme 100 
A proposed explanation for the effect of the leaving group on the thiomaleimide 
dedcarboxylation-elimination. pKa values were calculated using the ACD i-Lab 
software. Literature values for phenylacetic acid312 and acetic acid313 were also 
obtained.  
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This work provided a more satisfactory insight into the photochemical thiomaleimide 
decarboxylation-elimination and informs the design of the next generation of maleimide 
based photocleavable linkers.  
2.5.6: Developing a photocleavable antibody-drug-conjugate 
The overall aim of this work was to develop a novel class of photocleavable linkers which 
could be used to create a photocleavable antibody drug conjugate. We envisioned creating 
a photocleavable alkyne “click” handle which upon functionalisation with a suitable 
cytotoxic payload could be utilised for this purpose (Scheme 101).  
 
Scheme 101 
A hypothetical photocleavable protein-drug conjugate based on the thiomaleimide 
photocleavable linkers. 
  
 
Proceeding via the alkyne handle expands the choice of chemical payloads to any azide 
functionalised moiety and increases the versatility of this approach when compared to 
direct attachment of the drug. This approach also simplifies synthesis by minimising the 
amount of time spent handling the toxic Doxorubicin on a synthetic scale.  
2.4.6.1: Synthesis of a photocleavable click handle 
The first step towards the generation of the photocleavable ADC was deciding on the 
appropriate photocleavable linker. The previous work showed that the leaving group can 
have a profound effect on the yield of the photocleavage, with acetate leaving groups 
cleaving in higher yields than the corresponding carbamic acid leaving groups. For these 
reasons it was decided to synthesise alkyne-dibromomaleimide-serine 214 from 3-butynoic 
acid 212. A one pot procedure was developed in which the acid chloride is generated in 
situ using oxalyl chloride. Subsequent addition of dibromomaleimide-serine 167 and tetra-
N-butylammonium bromide furnishes the desired product in a good yield (Scheme 102). 
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Interestingly attempts to generate the acid bromide directly using oxalyl bromide were 
unsuccessful.  
 
Scheme 102 
The synthesis of photocleavable alkyne-dibromomaleimide-serine 214. 
 
2.4.6.2: Synthesis of a doxorubicin-azide analogue 
Doxorubicin, trade name Adriamycin, is a cytotoxic drug originally reported in 1969314 and 
remains one of the most potent anti-tumour agents with FDA approval.  Doxorubicin also 
displays reasonable absorbance and fluorescence which makes it easy to track by 
chromatographic methods. These characteristics, coupled with safety concerns over more 
toxic drugs, made Doxorubicin a logical choice for this work. 2-azidoacetic acid 217 was 
synthesised from bromoacetic acid 216 in a good yield and subsequently coupled to 
Doxorubicin.HCl 215 using HBTU and DIPEA (Scheme 103).  
 
Scheme 103 
The synthesis of Dox-azide 218. 
 
2.4.6.3: Generation of a photocleavable scFv-Doxorubicin ADC 
An Anti-CEA scFv (previously employed in section 2.2.2, page 68) was chosen as the 
antibody fragment of choice for the photocleavable ADC. The primary reason for this was 
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the fact that CEA does not internalise upon binding of the antibody, meaning the ADC 
remains attached to the cell membrane upon binding to the antigen. Any photochemically 
released drug will be released into the extra-cellular environment and subsequently 
internalise, either via a different receptor mediated process or by general endocytosis. A 
non-internalising antibody was chosen due to the high thiol content of the intra-cellular 
environment. As discussed previously thiomaleimides are cleaved from proteins in the 
presence of excess thiol. This would decrease the efficiency of the photochemical cleavage 
and lead to non-specific cleavage of the drug. Though non-internalising ADCs are less 
commonly employed there are several successful examples that demonstrate the validity of 
this approach.159,315,316 The scFv, rather than the full antibody, was chosen primarily for its 
simplicity and availability. Anti-CEA scFv 97 was reduced and modified according to a 
previously optimised protocol. Dox-azide 218 and dibromomaleimide-alkyne 214 were “pre-
clicked” before being added to a reduced sample of scFv 97 to produce Doxorubicin 
modified scFv 220. The “pre-click” reaction was necessitated by the presence of a histidine 
tag on the scFv which binds copper and complicates Cu(ii) click reactions.  LCMS confirmed 
successful modification. (Scheme 104) (Figure 52). 
 
 
Scheme 104 
The modification of scFv with “pre clicked” photocleavable Dox analogue 219. 
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Figure 52 
MS data (A) scFv 97 (B) Doxorubicin-ScFv analogue 220. See experimental section 
for full spectra (Section 3.2.7.2, page 211, Figure 106). 
 
Irradiation of modified scFv 220 resulted in cleavage of Doxorubicin analogue 222 in an 
overall yield of 64% within 5 minutes (Scheme 105). The release of Dox-carboxylate 222 
and decrease of modified scFv 220 was monitored using HPLC scanning at 480 nm (Figure 
53). A standard solution of Dox-carboxylic acid 222, generated from a Cu(ii) click reaction of 
Dox-azide 218 and 3-butynoic acid 212, was injected to confirm the identity of the released 
species. Extended irradiation times did not increase the concentration of Doxorubicin 
analogue 222, suggesting the maximum achievable conversion in this system was reached 
within five minutes. No decrease in the absorbance at 280 nm was observed, showing the 
protein was stable to the irradiation and the decrease at 480 nm was due to release of Dox-
carboxylic acid 222. 
128 
 
 
Scheme 105 
The irradiation of scFv-Dox 220 and the synthesis of Dox-carboxylic acid 222. 
Irradiation was performed using a 5W 395 nm LED torch. 
Figure 53 
(A) A HPLC trace showing the release of Dox-carboxylate 222 and decrease in 
concentration of scFv-Dox 220. (B) A graph showing the release of Dox-
carboxylate 222 and decrease in concentration of scFv-Dox 220. See experimental 
section for a HPLC trace of a standard solution of Dox-carboxylate 222 (section 
3.1.2.4, page 171, Figure 61). 
 
This reaction demonstrates a significant improvement in efficiency over the recently 
published photocleavable ADC based on a cyanine photocage, which reported a 62% yield 
after 33 minutes of irradiation with a much more powerful light source (25 mW·cm−1 
compared to 0.9 mW·cm−1). This suggests the above reaction is more efficient that the 
current state of the art. Though the yield was good it was lower than anticipated based on 
the work done with Octreotide 74. It was hoped the adjacent triazole ring would inductively 
withdraw electrons from the ester and decrease the pKa of the leaving group, leading to a 
high yield of released Doxorubicin-carboxylate 222. Nevertheless, this work represents the 
first maleimide based photocleavable ADC and is a good example of the utility of maleimide 
photochemistry.  
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2.4.6.4: Cell kill assay for the photocleaved Doxorubicin analogue 
Before proceeding to test the cell killing efficacy of photocleavable scFv 220 we wished to 
get a measure of the cytotoxicity of the released compound. An accurate idea of the 
performance of the released drug would help to inform the experimental parameters for the 
work with the antibody fragment. Several dilutions of Doxorubicin-carboxylic acid 222 were 
prepared (10 M to 0.5 nm) and tested against three CEA expressing cell lines; HeLa, 
CaSki and Capan-1. As a control native Doxorubicin.HCl 215 was tested under the same 
conditions. Cell viability after three days was tested and expressed as a function of 
concentration of the Doxorubicin analogue (Figure 54). These experiments were performed 
by collaborators in the UCL Cancer Institute.  
 
 
Figure 54 
Cell viability after three days as a function of concentration of Dox-carboxylic acid 
222 and Doxorubicin 215 for three cell lines: (A) Hela, (B) CaSki and (C) Capan-1. 
Data was analysed and compiled by Dr Enrique Rota of the UCL cancer institute.  
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Disappointingly no significant effect on the cell viability was seen in any of the cell lines 
treated with Dox-carboxylic acid 222. Though a slight decrease in cell viability was seen 
with the Hela cell line, both CaSki and Capan-1 displayed an increase in the cell count after 
three days. Native Doxorubicin 215 behaved as expected in each case, demonstrating the 
validity of the cell lines. Though some decrease in activity was expected complete 
annulment of the cytotoxicity was not anticipated.  These results demonstrate that the 
structural modification to Doxorubicin has a deleterious effect on the cytotoxicity of the 
drug. This observed effect could be caused by the inability of the drug to interact with the 
cellular target, or an inability to pass through the cell membrane.  Though the mechanism 
of action of Doxorubicin is not fully understood it is generally accepted that the cytotoxic 
effects are caused by intercalation of the Doxorubicin pharmacophore with DNA in the 
nucleus of the cell. This intercalation inhibits the progression of topoisomerase II and 
prevents successful replication.317–320 Though the sugar ring aids in the interaction with 
DNA, structure activity relationships of Doxorubicin analogues have shown that alterations 
to the ring, such as in Doxorubicin-carboxylic acid 222, are typically well tolerated.321–324 
That being said it is entirely possible that the addition of the triazole ring and the carboxylic 
acid inhibit the desired interaction and annul the cytotoxicity of the drug. Carboxylic acid 
containing Doxorubicin analogues are not well reported, though an example was found in 
the literature in which cytotoxicity was retained with a Doxorubicin analogue containing a 
pendant carboxylic acid.322 As mentioned previously it is entirely possible that Doxorubicin-
carboxylic acid 222 is simply unable to pass through the cell membrane by passive 
transport. Native Doxorubicin 215 is known to cross the cell membrane via endoytosis, the 
relative hydrophobic aromatic ring system and positively charged amine aiding positive 
interactions with the lipid membrane. Doxorubicin-carboxylic acid 222 exists as a 
carboxylate within the extra-cellular environment thus may be less able to cross the lipid 
membrane than native Doxorubicin 215. Regardless of the reasons it is clear that the 
addition of the pendant carboxylic acid tail has nullified the cytotoxicity of the drug and 
invalidates the use of doxorubicin-scFv 220 as a photocleavable ADC.  
2.4.6.5: Cell kill assay for Doxorubicin-amine 
As it was apparent releasing the Doxorubicin with a pendant carboxylic acid was not ideal a 
different approach was appraised. Though the photochemical thiomaleimide 
decarboxylation-elimination is less efficient with carmabic acid leaving groups the yields are 
still sufficiently high. Carbamic acids spontaneously decarboxylate to release amines, 
rather than carboxylates, which could be advantageous for the release of Doxorubicin 
analogues. By exchanging the ester for a carbamate in Doxorubicin-scFv 220 we hoped 
that the released drug would not suffer from the same potency issues as Dox-carboxylic 
acid 222 (Scheme 106).  
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Scheme 106 
Proposed scFv-drug conjugate 223 utilising a carbamate link between the 
Doxorubicin analogue and the photocleavable scaffold.  
 
Because of time considerations Dox-amine 224 was synthesised and tested in a cell kill 
assay before time was spent developing a protocol to generate the proposed carbamate 
Doxorubicin-scFv 223. Dox-amine 224 was synthesised in a single step via the Cu(ii) click 
reaction of Dox-azide 218 and propargyl amine (Scheme 107). 
 
Scheme 107 
The synthesis of Dox-amine 224. 
 
As with the previous cell kill assay several dilutions of Dox-amine 224 were prepared (10 
M to 0.5 nm) and tested against three CEA expressing cell lines; Hela, CaSki and Capan-
1. Cell viability after three days of incubation with Dox-amine 224 and Doxorubicin HCl 215 
at 37 °C was tested and expressed as a function of the concentration of the Doxorubicin 
analogues (Figure 55). Once again this work was performed by collaborators at the UCL 
Cancer Institute.  
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Figure 55 
Cell viability after three days as a function of concentration of Dox-amine 224 and 
Doxorubicin 215 for three cell lines: (A) Hela, (B) CaSki and (C) Capan-1. 
 
Disappointingly the results once again suggested the Dox-amine analogue 224 had only a 
minimal impact on the viability of the cells. The Hela cell line represents the best case 
scenario with a 20% decrease in viability at a concentration of 10 M, though this is too 
high for any practical application. It is unlikely that Dox-amine 224 would have any trouble 
entering the cell, as in this case the structural modification should not drastically alter the 
interaction of the compound with the cell membrane. The ineffectiveness of this 
Doxorubicin analogue suggests that the triazole ring may be having a negative effect on 
the ability of the drug to interact with DNA.  
2.4.7: Conclusions 
A novel photochemical decarboxylation-elimination reaction based on the thiomaleimide 
scaffold was explored (Scheme 108). The tolerance of the reaction towards a variety of 
structural modifications was tested and mechanistic insights drawn from the data obtained. 
This photochemical reaction represents an incredibly efficient photochemical 
decarboxylation, with irradiation times of less than five minutes compared to 6 - 24 hours 
for the comparable phthalimides.287  
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Scheme 108 
The novel thiomaleimide decarboxylation-elimination applied to several Octreotide 
conjugates.  
 
The reaction was also employed to cleave a Doxorubicin analogue from an Anti-CEA scFv 
antibody fragment, demonstrating 64% cleavage within five minutes of irradiation 
(Scheme 109). The lower reaction times with a considerably less powerful photon source 
represent a significant advantage when compared to currently employed methods.245  
 
Scheme 109 
The photocleavable scFv-Dox conjugate based around novel thiomaleimide based 
photocleavable linkers.  
 
  
The ease of synthesis, cysteine selectivity, low irradiation times, high cleavage yields and 
high wavelength of activation of these photocleavable linkers offer several significant 
benefits over the current state of the art and are certainly worthy of further investigation.  
Though work towards realising the final application is still underway current results suggest 
that these reagents could play an important role in the emerging field of photochemically 
activated antibody based therapeutics.  
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2.4.8: Future Work 
2.4.8.1: Perfecting the photochemical-scFv-Doxorubicin conjugate 
Though the “click” approach to generating a photocleavable ADC would be desirable it has 
become apparent that the changes to the Doxorubicin structure required to allow this 
approach have a considerable detrimental effect on the cytotoxicity of the drug. To remedy 
this situation a more direct approach will be taken by attaching the Doxorubicin directly to 
the photocleavable scaffold via a carbamate. Upon irradiation pure Doxorubicin 215 will be 
released, ensuring the desirable cytotoxic effect (Scheme 110).  
 
Scheme 110 
A proposed method for utilising the thiomaleimide photocleavable linkers to 
release native Doxorubicin 215. 
 
Two synthetic strategies towards the target dibromomaleimide have been designed 
(Scheme 111). The first route involves preparation of tert-Butyl protected 
dibromomaleimide-serine 225, followed by conversion of the alcohol to a chloroformate and 
in situ reaction of the chloroformate with an amine to generate Doxorubicin functionalised 
dibromomaleimide carbamate 227. Subsequent tert-Butyl deprotection would then reveal 
the necessary carboxylic acid to furnish target compound 228. The second route starts 
from Boc-tert-Butyl protected serine 229. Formation of the carbamate via the chloroformate 
is followed by deprotection of both the Boc and tert-Butyl groups in a single step to produce 
Dox-serine 231. This species could then be reacted with activated dibromomaleimide 163 
to produce the target compound 228. In addition to proceeding via the chloroformate other 
coupling reagents such as carbonyldiimidazole and para-nitrophenolchloroformate could be 
explored for the formation of the carbamate.  
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Scheme 111 
Proposed routes to the target doxorubicin releasing photocleavable linker 228. 
 
2.4.8.2: Determining the quantum yield 
Though the low reaction times of the photochemical thiomaleimide decarboxylation-
elimination suggest a very efficient reaction it is necessary to obtain a quantum yield of 
photocleavage to get a true measure of the efficiency. Actinometry will be employed for this 
purpose and a direct comparison with a state of the art O-nitrobenzyl photocleavable linker 
will be made. Benzylcarbamate-dithiomaleimide-serine 232 has been synthesised for this 
purpose (Scheme 112).  
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Scheme 112 
The synthesis of benzylcarbamate-dithiomaleimide-serine 232. 
 
By monitoring the release of benzylamine as a function of absorbed photons a quantum 
yield of photocleavage will be obtained for these novel photocleavable linkers. A 
collaboration with Dr Michael Terzidis and Professor Richard Curry at the University of 
Surrey has already been established to complete this work.  
2.4.8.3: Long term outlook 
Given the advantages listed above the potential of this reaction is tremendous, though a 
significant body of work is still required to truly understand its intricacies and fully explore 
any possibilities. It would be interesting to alter the substitution on the maleimide alkene to 
test the affect that this would have on the efficiency of the reaction (Figure 56). It is known 
that the UV/Vis absorbance characteristics of maleimides are greatly affected by 
substitution at the alkene so it is reasonable to assume some effect on the efficiency of the 
reaction would be observed.  
 
Figure 56 
Proposed modifications to the maleimide alkene of the photocleavable linkers. max 
values for thiomaleimides63, dithiomaleimides63 and aminomaleimides325 were 
obtained from the literature.  
 
If substitution at the maleimide alkene was found to have no detrimental effect on the 
efficiency of the reaction a whole range of tuneable photocleavable linkers could be 
synthesised. This could lead to the development of an orthogonal system in which two 
different maleimide based photocleavable linkers are utilised to release two separate 
chemical payloads (Scheme 113). 
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Scheme 113 
A conceptual application of orthogonal maleimide based photocleavablelinkers. 
 
The two payloads could target separate therapeutic targets or even work synergistically to 
add a further layer of defence against off-target side effects i.e. payload A could be 
released in a pro-drug form and be subsequently converted to the active form by release of 
payload B. A “theranostics” approach could also be taken in which one payload is a 
therapeutic and the second is a diagnostic tool to monitor the effectiveness of the 
therapeutic.  
Looking beyond the realm of photocleavable antibody drug conjugates this reaction could 
be employed for any application in which the incredibly efficient spatio-temporal release of 
a target compound is desired.  Thus this reaction could be used in any application which 
currently employs photocleavable linkers i.e. protein puricication,326 solid phase 
synthesis,327  photopolymerisation,21,92 photorelease of fluorescent probes,328 amongst 
many others.89  
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3: Experimental 
3.1: Synthetic organic chemistry 
3.1.1: General experimental 
All reagents and starting materials were obtained from chemical suppliers, unless 
specifically stated otherwise, and were used as received. Reactions were monitored by thin 
layer chromatography using pre-coated SIL G/UV 254 plates purchased from VWR. Flash 
chromatography was carried out manually using Kiesegel 60 M 0.04/0.063 mm silica gel or 
automatically using a BioTage Isolera with KP-Snap or KP-Sil columns. Reverse phase 
chromatography was carried out using a BioTage Isolera 1 with 10g C-18 prepacked 
colums provided by BioTage. Petrol refers to petroleum ether (40 - 60 °C). NMR spectra 
were recorded using a Bruker AC300, AC500 or AC600 spectrometer (300 MHz, 500 MHz 
and 600 MHz respectively).  Chemical shifts (δ) are given in ppm units relative to the 
solvent reference and coupling constants (J) are measured in Hertz.  Proton (1H) NMR 
multiplicities are shown as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd 
(double doublet), dt (double triplet), etc. Protons adjacent to diastereomeric carbons are 
labled ` and ``. HMBC, HSQC and DEPT were employed to aid with accurate assignments. 
Infrared spectra were recorded on a Perkin Elmer Spectrum 100 FTIR spectrometer (ATR 
mode). Melting points were determined using a Gallenkamp apparatus. High and low 
resolution mass spectrometry of organic molecules was performed using a VG70 SE (EI or 
CI) or an LCT Premier mass spectrometer (ES). Mass spectrometry data for compounds 
141, 217, 218 and 224 were obtained from the EPSRC Mass Spectrometry facility at 
Swansea using an LTQ Orbitrap XL. UV/Vis spectra were obtained using a 
ThermoScientific NanoDrop 2000C running in cuvette mode, using a quartz cuvette with a 
path length of 1 cm3. Extinction coefficients for all compounds were calculated by taking 
measurements at 0.3, 0.2 and 0.1 mM and averaging the results. Optical rotation values 
were obtained using a Perkins Elmer model 343 polarimeter operating at 21 °C (Currently 
non-operational). 
Irradiation at 365 nm was performed using a commercial 5W LED torch purchased from 
Advanced NDT Ltd with an irradiance measurement of approximately 20 mW·cm−3 at 14 
cm. For large scale reactions the UV torch was placed adjacent to the round bottomed flask 
inside a reflective chamber at a distance of 14 cm and the beam directed through the 
solution. For small scale HPLC reactions the UV torch was placed adjacent to a 7 ml 
sample vile inside a reflective chamber at a distance of 14 cm and the beam directed 
through the solution. When a mercury lamp is specified a 125 W lamp from Photochemical 
Reactors Ltd was used in combination with a water cooled Pyrex immersion well. 
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3.1.2: Synthesis 
3.1.2.1: Synthesis of monobromomaleimide reagents 
2,3-dibromosuccinimide267 
 
Maleimide (2.00 g, 20.0 mmol) was dissolved in CHCl3 (15 ml), and bromine (1.16 ml, 20.0 
mmol in 15 ml of CHCl3) was added dropwise over 10 minutes. The reaction mixture was 
refluxed for three hours, and then allowed to cool to room temperature. The yellow 
precipitate was filtered and washed with cold CHCl3 (4 x 20 ml) to give the title compound 
as pale yellow crystals (4.20 g, 16.3 mmol) in an 81% yield.  
 m.p. 125.3 - 126.1 °C; 1H NMR (500 MHz, CDCl3-d1)  = 8.41 (1H, s, H-1), 4.73 (2H, s, H-
3, 4); 13C NMR (125 MHz, CDCl3-d1) 169.8 (C-2,5), 42.8 (C-3,4); IR (solid, cm−1) 3284, 
2988, 2947, 1790, 1730; MS (EI) m/z [M, relative intensity] 254.8 [79Br79BrM, 4.9], 256.8 
[81Br79BrM, 10], 258.8 [81Br81BrM, 5]. Data matched the literature.267 
monobromomaleimide 93267 
 
2,3-dibromosuccinimide (1.00 g, 3.89 mmol) and sodium acetate trihydrate (1.59 g, 11.7 
mmol) were dissolved in acetic acid (24 ml). The reaction mixture was refluxed for 90 
minutes then cooled to room temperature. The solvent was evaporated, the crude solid 
dissolved in ethyl acetate (20 ml) and washed with sat. aqueous NaHCO3 (3 x 20 ml). The 
organic phase was separated, dried over MgSO4 and the solvent removed in vacuo. The 
impure solid was purified by flash chromatography (60% ethyl acetate in petrol) to afford 
the title compound 93 as a white powder (555 mg, 3.19 mmol) in an 82% yield.  
m.p. 157.3 - 157.9 °C; 1H NMR (500 MHz, CDCl3-d1)  = 7.48 (1H, s, H-1), 6.89 (1H, s, 
H-4); 13C (125 MHz, CDCl3-d1)  = 168.0 (C-5), 164.9 (C-2), 132.9 (C-3), 132.3 (C-4); IR 
(solid, cm−1) 3231, 3104, 2681, 1780, 1763, 1708, 1578; MS (EI+) m/z [M, relative intensity] 
174.9 [M79BrM+H, 100], 176.9 [M81BrM+H, 98]; Exact mass calcd for [C4H3NO279Br] 
175.93417, found 175.93420. Data matched the literature.267 
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2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethan-1-aminium 2,2,2-
trifluoroacetate 108151 
 
Tert-Butyl (2-aminoethyl)carbamate (200 mg, 1.26 mmol) was dissolved in CH2Cl2 (53 ml), 
and a solution of dansyl chloride (366 mg, 1.37 mmol) and triethylamine (455 l, 3.25 
mmol) in CH2Cl2 (53 ml) was added at room temperature. After stirring for four hours at 
room temperature the solvent was removed in vacuo and the residue was purified by flash 
chromatography (40% ethyl acetate in petrol) to afford a viscous oil. Trifluoroacetic acid (14 
ml) was added and the cloudy grey solution was stirred for two hours at room temperature 
before all solvent was removed in vacuo. Dissolution in CH2Cl2 and subsequent cooling to 0 
°C resulted in precipitation of a solid which was collected and washed with Et2O (4 x 5 ml) 
to afford title compound 108 as a white solid (364 g, 0.895 mmol) in a 71% yield.  
m.p. 159.4 – 161.4 °C (lit. m.p.160 - 162 °C151); 1H NMR (600 MHz, MeCN-d3)  = 8.56 (1H, 
d, J = 8.7, H-4), 8.26 (1H, d, J = 8.7, H-2), 8.18 (1H, dd, J = 7.3, J = 1.1, H-9), 7.51 - 7.63 
(2H, m, H-8, 3), 7.27 (1H, d, J = 7.3, H-7), 3.08 (2H, t, J = 6.0, H-15), 3.01 (2H, t, J = 6.0, 
H-16), 2.87 (6H, s, H-12, 13); 13C NMR (150 MHz, MeCN-d3)  = 161.7 (q, JC-F = 27.3, C-
18), 153.0 (C-6), 135.7 (C-1), 131.3 (C-4), 130.7 (C-10), 130.2 (C-5), 130.2 (C-9), 129.3 (C-
8), 124.3 (C-3), 119.8 (C-2), 117.1 (C-19), 116.3 (C-7), 45.7 (C-12, 13), 41.0 (C-15), 41.0 
(C-16);19F NMR (280 MHz, MeCN-d3)  = -70.5 (F-20 - 22); IR (solid, cm−1) 3090, 1659, 
1624, 1530; MS (ES+) m/z [M, relative intensity] 362.2 [C14H15F3N2O4S, 100], 294.1 [M+H-
TFA, 22]; Exact mass calcd for [C14H20N3O2S]  294.1276, found 294.1280. Data matched 
the literature151 
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N–(2-(3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-5-
(dimethylamino)naphthalene-1-sulfonamide 110151 
 
 
Bromomaleic anhydride (21 l ,0.223 mmol) was added in a single portion to a solution of 
compound 108 (100 mg, 0.246 mmol) in AcOH (2.3 ml) and stirred at room temperature for 
90 minutes before being raised to reflux for a further two hours. All solvent was removed in 
vacuo and the resulting crude material purified by flash chromatography (0 - 50% ethyl 
acetate in petrol) to afford a brown oil which was triturated with ethyl acetate to produce 
compound 110 as a brown solid (66 mg, 0.0.146 mmol) in an 65% yield. 
m.p. decomposition above 70 °C (lit. m.p. 70 - 71 °C151); 1H NMR (600 MHz, MeCN-d3)  = 
8.53 (1H, d, J = 8.7, H-4), 8.12 (2H, dd, J = 10.9, J = 8.3, H-2, 9), 7.39 - 7.73 (2H, m, H-3, 
8), 7.26 (1H, d, J = 7.5, H-7), 6.67 (1H, s, H-20), 5.99 (1H, t, J = 6.2, H-14), 3.45 (1H, t, J = 
6.2, H-16), 3.09 (2H, q, J = 6.2, H-15), 2.88 (6H, s, H-12, 13); 13C NMR (150 MHz, MeCN-
d3)  = 169.3 (C-21), 166.3 (C-18), 152.9 (C-6), 135.9 (C-1), 132.9 (C-20), 131.3 (C-4), 
131.1 (C-10), 130.6 (C-5), 130.3 (C-19), 130.1 (C-9), 129.3 (C-8), 124.4 (C-3), 119.9 (C-2), 
116.4 (C-7), 45.7 (C-12, 13), 41.4 (C-15), 39.2 (C-16); IR (solid, cm−1) 3326, 3093, 2950, 
2838, 1717, 1585; MS (EI) m/z [M, relative intensity] 450.9 [79BrM, 97], 452.9 [81BrM, 100]; 
Exact mass calcd for [C18H1879BrN3O4S] 451.02014, found 451.02069. Data matched the 
literature.151  
methyl 3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrole-1-carboxylate 112145 
 
Monobromomaleimide 93 (100 mg, 0.572 mmol) and N-methylmorpholine (62.5 µl, 0.572 
mmol) were dissolved in tetrahydrofuran (5 ml). Methyl chloroformate (44 µL, 0.527 mmol) 
was added dropwise and the reaction stirred at room temperature for 30 minutes. CH2Cl2 
(10 ml) was added and the organic phase washed with saturated aqueous Na2CO3 (3 x 3 
ml). The organic layer was dried over MgSO4 and all solvent was removed in vacuo to yield 
title compound 112 as a pale pink solid (130 mg, 0.555 mmol) in a 97% yield. 
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m.p. 121.3 - 122.7 °C (lit. m.p 120 - 122 °C145); 1H NMR (600 MHz, CDCl3-d1)  = 7.02 (1H, 
s, H-4) 4.02 (3H, s, H-7); 13C (125 MHz, CDCl3-d1)  = 163.32 (C-5), 160.90 (C-2), 147.57 
(C-6), 133.32 (C-4), 133.14 (C-3), 54.74 (C-7); IR (solid, cm−1) 2966, 1814, 1769, 1729; 
1606; MS (CI+) m/z [M, relative intensity] 234.0 [79BrM+H, 8], 236.0 [89BrM+H, 9]; Exact 
mass calcd for [C6H5NO479Br] 233.93965, found 233.93922. Data matched the literature.145  
3-bromo-1-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-1H-pyrrole-2,5-dione 114 
 
Compound 112 (120 mg, 0.513 mmol) was dissolved in CH2Cl2 (20 ml), 2-(2-(2-
methoxyethoxy)ethoxy)ethanamine (84.0 mg, 0.513 mmol) was added and the reaction 
stirred at room temperature for two hours. The solvent was removed in vacuo and the 
crude product was purified by flash chromatography (2 - 10% MeOH in CH2Cl2) to produce 
title compound 114 as a yellow oil (130 mg, 0.404 mmol) in a 79% yield. 
1H NMR (600 MHz, CDCl3-d1) = 6.70 (1H, s, H-4), 3.77 (2H, t, J = 6.0, H-6), 3.65 (2H, t, 
J = 6.0, H-7) 3.58 - 3.63 (6H, m, H-8, 9, 10), 3.53 (2H, t, J = 4.8, H-11), 3.37 (3H, s, H-12); 
13C (150 MHz, CDCl3-d1)  = 168.56 (C-5), 165.37 (C-2), 132.01 (C-3), 131.48 (C-4), 
72.0, 70.7 (x 2), 70.2 (C-8, 9, 10, 11), 67.78 (C-7), 59.20 (C-12), 38.31 (C-6); IR (film, cm−1) 
2970, 2875, 1720, 1588; MS (EI) m/z [M, relative intensity] 201.9 [M79Br-C5H11O3, 80], 
203.9 [M81Br-C5H11O3, 82]; Exact mass calcd for [C11H16BrNO5] 321.02119, found 
321.02157. Data matched the literature.267  
tert-Butyl (3-aminopropyl)carbamate 115329 
 
Di-tert-Butyl dicarbonate (200 mg, 0.917 mmol) was dissolved in CHCl3 (16 ml) and added 
dropwise over three hours to a solution of 1,3-diaminopropane (765 µL, 9.17 mmol) in  
CHCl3 (50 ml) at 0 °C. After this time the solution was returned to room temperature and 
allowed to stir for 15 hours. The solution was then diluted with CHCl3 (100 ml) and washed 
with K2CO3 (2 x 50 ml) followed by H2O (2 x 50 ml). The organic layer was separated, dried 
over MgSO4, and then concentrated in vacuo to produce 115 as an orange oil (155 mg, 
0.890) in a 97% yield. Product was taken on without further purification: 1H NMR (600 MHz, 
CDCl3-d1)  = 5.10 (1H, br. s., H-5), 3.10 (2H, q, J = 6.6, H-4), 2.68 (2H, t, J = 6.6, H-2), 
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1.54 (2H, q, J = 6.6, H-3), 1.45 (2H, br. s., H-1), 1.36 (9H, s, H-8 , 9, 10); 13C (125 MHz, 
CDCl3-d1)  = 156.3 (C-6), 79.5 (C-7), 39.7 (C-2) 38.4 (C-4), 33.4 (C-3) 28.5 (C-8, 9, 10); IR 
(solid, cm−1) 3356, 2971, 2940, 2871, 1737, 1680, 1583; MS (EI) m/z [M, relative intensity] 
175.2 [M+H, 100]. Spectra matched the literature.329 
tert-Butyl (3-(5-((4S)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)propyl)carbamate 116 
 
D-Biotin (295 mg, 1.21 mmol), HBTU (398 mg, 1.05 mmol) and DIPEA (221 µL, 1.27 mmol) 
were dissolved in DMF (5 ml) and stirred for 20 minutes at room temperature. This mixture 
was then added dropwise over 20 minutes to a solution of tert-Butyl (3-
aminopropyl)carbamate 115 (140 mg, 0.804 mmol) in DMF (3 ml) and stirred for two hours 
at room temperature. After this time toluene (70 ml) was added and all solvent was 
removed in vacuo. The crude residue was purified by column chromatography (2% - 10% 
MeOH/CH2Cl2 followed by subsequent purification in 70% ethyl acetate in petrol) to yield 
title compound 116 as a yellow oil (225 mg, 0.512 mmol) in a 70% yield.  
1H NMR (600 MHz, CDCl3-d1)  = 6.91 (1H, s, H-16), 6.73 (1H, s, H-20), 5.80 (1H, s, H-4), 
5.14 (1H, s, H-6)  4.40 - 4.55 (1H, m, H-3) 4.25 - 4.32 (1H, m, H-7), 3.10-3.15  (3H, m, H-8 
+ H-19), 2.89 (1H, dd, J = 12.6, J = 8.5, H-2`), 2.72 (1H, dd, J = 12.6, J = 8.5, H-2``), 2.32 
(2H, t, J = 7.5, H-17), 2.19 (2H, t, J = 7.8, H-13), 1.74 - 1.59 (6H, m, H-10, 12, 18), 
δ1.37-1.47 (11H, m, H-11, H-24-26); 13C (125 MHz, CDCl3-d1) = 173.92 (C-14) 
164.31(C-5), 156.72 (C-21), 79.36 (C-23) 62.01 (C-3), 60.32 (C-7), 55.88 (C-8), 40.68 
(C-2), 37.35 (C 19) 36.64 (C-17), 36.06 (C-13) 30.04, 29.80, 25.94, 24.89 (C-10, 11, 12, 
18), 28.54 (C 24-26); IR (solid, cm−1) 3450, 2960, 1744, 1608, 1550; MS (CI) m/z [M, 
relative intensity] 401.2 [M+H, 6] 301.2 [C13H25N4O2S, 100]; Exact mass calcd for 
[C18H33N4O4S] 401.22170, found 401.22256. 
N-(3-(3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propyl)-5-((4S)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide 117 
 
Compound 116 (100 mg, 0.250 mmol) was dissolved in trifluoroacetic acid (5 ml) and 
stirred for 15 hours. After this time toluene (50 ml) was added and the solvent removed in 
vacuo. The crude material was dissolved in acetic acid (10 ml) and bromomaleic anhydride 
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(45.0 mg, 0.250 mmol) was added. The reaction was heated under reflux for three hours, 
then allowed to return to room temperature. All solvents were removed in vacuo and the 
crude residue purified by flash chromatography (2% to 10% MeOH in CH2Cl2) to afford title 
compound 117 as a white powder (75.0 mg, 0.164 mmol) in a 66% yield. 
1H NMR (400 MHz, MeOD-d4) = 7.96 (1H, br. s., H-16), 7.13 (1H, s, H-23), 4.48 - 4.53 
(1H, m, H-3), 4.34 (1H, dd, J = 7.5, J = 4.4, H-7), 3.59 (2H, t, J = 7.2, H-19), 3.23 - 3.27 
(1H, m, H-8), 3.20 (2H, q, J = 9.2, H-17), 2.95 (1H, dd, J = 12.8, J = 5.0, H-2`), 2.72 (1H, d, 
J = 12.8, H-2``), 2.22 (2H, t, J = 11.6, H-13), 1.57 - 1.85 (6H, m, H-10, 12, 18), 1.44 - 1.52 
(2H, m, H-11); 13C NMR (150 MHz, DMSO-d6)  = 172.0 (C-14), 169.0 (C-21), 165.6 (C-
24), 162.7 (C-5), 132.6 (C-23), 130.4 (C-22), 61.0 (C-3), 59.2 (C-7), 55.4 (C-8), 41.4 (C-2), 
36.3 (C-19), 36.1 (C-17), 35.2 (C-13), 28.2, 28.1, 28.1 (C-10, C-12, C-18), 25.3 (C-11); IR 
(solid, cm−1) 3287, 2932, 2861, 1779, 1700, 1645, 1590, 1548; MS (ES+) m/z [M, relative 
intensity] 481.1 [M79BrM+Na, 98], 483.1 [M81BrM+Na, 100]; Exact mass calcd for 
[C17H2379BrN4O4SNa] 481.0521, found 481.0533. 
3.1.2.2: Synthesis of C-terminal cysteine models 
(((9H-fluoren-9-yl)methoxy)carbonyl)-L-cysteine 132 
 
Fmoc-Cys-(Trt)-OH (1.00 g, 1.71 mmol) was suspended in CH2Cl2 (68 ml) and stirred 
under argon at room temperature. To this suspension triisopropylsilane (2 ml, 9.76 mmol) 
was added, followed by trifluoroacetic acid (8 ml, 104 mmol). The solution was stirred for 10 
minutes at room temperature, before all solvent was removed in vacuo. Excess 
trifluoroacetic acid was azeotropically removed by co-evaporation with CH2Cl2. The 
resulting white solid was placed onto filter paper and washed with hexane (8 x 30 ml), 
before being dried under vacuum to produce title compound 132 as a white solid (563 mg, 
1.64 mmol) in a 96% yield. 
m.p. 115.5 - 117.0 °C; 1H NMR (600 MHz, DMSO-d6)  = 7.90 (2H, d, J = 7.4, H-13, 9), 
7.74 (2H, d, J = 7.4, H-10, 6), 7.70 (1H, d, J = 8.0, H-18), 7.42 (2H, t, J = 7.4, H-12, 8), 7.33 
(2H, t, J = 7.4, H-7, 11), 4.31 (2H, d, J = 6.5, H-14), 4.24 (1H, t, J = 6.5, H-1), 4.12 (1H, dt, 
J = 8.0, J = 4.3, H-19), 2.85 - 2.93 (1H, m, H-20`), 2.70 - 2.77 (1H, m, H-20``), 1.23 (1H, 
broad s, H-21); 13C NMR (150 MHz, DMSO-d6)  = 171.9 (C-22), 156.1 (C-16), 143.8 (C-2, 
5), 140.8 (C-3, 4), 127.7 (C-7, 11), 127.1 (C-8, 12), 125.3 (C-6, 10), 120.2 (C-9, 13), 65.7 
(C-14), 56.6 (C-19), 46.6 (C-1), 25.5 (C-20); IR (solid, cm−1) 3312, 1696, 1531, 1447, 1426; 
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MS (ES+) m/z [M, relative intensity] 366.1 [M+Na] 100], 179.1 [C14H11, 7]; Exact mass calcd 
for [C18H17NO4SNa] 366.0776, found 366.0748. 
N-(((9H-fluoren-9-yl)methoxy)carbonyl)-S-(2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-
L-cysteine 133 
 
Fmoc-cysteine 132 (177 mg, 0.515 mmol) and sodium acetate (93.0 mg, 1.133 mmol) were 
dissolved in MeOH (10 ml) and stirred for five minutes under argon. Monobromomaleimide 
93 (100 mg, 0.567 mmol) was subsequently added and the solution stirred for 20 minutes 
at room temperature. All solvent was removed in vacuo, the crude material suspended in 
ethyl acetate (25 ml) and washed with 10% aqueous citric acid (12 ml). The organic layer 
was collected, dried over MgSO4 and all solvent removed in vacuo. Purification by flash 
chromatography (2% - 8% MeOH in CH2Cl2 with 1% AcOH) afforded title compound 133 as 
a light orange powder (200 mg, 0.457 mmol) in a 90% yield.  
m.p. decomposition above 120 °C; 1H NMR (600 MHz, DMSO-d6)  = 11.03 (1H, s, H-29), 
7.91(1H, br. s, H-10), 7.89 (2H, d, J = 7.5, H-22, 26), 7.70 (2H, dd, J = 7.5, J = 3.1, H-19, 
23), 7.42 (2H, t, J = 7.5, H-21, 25), 7.32 (2H, t, J = 7.5, H-20, 24), 6.49 (1H, s, H-3), 4.25 - 
4.35 (3H, m, H-13, 9), 4.23 (1H, t, J = 7.2, H-14), 3.43 (1H, dd, J = 13.5, J = 4.3, H-8`), 3.25 
(1H, dd, J = 13.5, J = 9.3, H-8``); 13C NMR (150 MHz, DMSO-d6)  = 171.4 (C-28), 170.9 
(C-2), 169.3 (C-5), 156.0 (C-11), 150.0 (C-4), 143.8 (C-15, 18), 140.7 (C-17, 16), 127.7 (C-
20, 24), 127.1 (C-21, 25), 125.2 (C-19, 23), 120.2 (C-22, 26), 119.5 (C-3), 65.9 (C-13), 52.5 
(C-9), 46.6 (C-14), 32.7 (C-8); IR (solid, cm−1)  3316, 1735, 1705, 1685,  1529, 1448; MS 
(ES+) m/z [M, relative intensity] 461.1 [M+Na, 100], 366.1 [M-C4H2O2N+Na, 5], 
179.1[C14H11,1]; Exact mass calcd for [C22H18N2O6SNa] 461.0783, found 461.0760; 344 
(MeOH) = 3523 M−1·cm−1.   
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(9H-fluoren-9-yl)methyl vinylcarbamate 134 
 
Method 1 
Compound 133 (40.0 mg, 0.0912 mmol) and sodium acetate (8.22 mg, 0.100 mmol) were 
dissolved in MeOH (240 ml) and the entire solution degassed with argon for 30 minutes. 
The solution was irradiated using a medium pressure mercury lamp for one hour. All 
solvent was removed in vacuo at room temperature and the resulting crude material was 
washed with Et2O (3 x 20 ml). The organic washings were collected and the organic solvent 
evaporated in vacuo to yield enamide 134 as a white solid (22 mg, 0.0867 mmol) in a 95% 
yield. 5 mg (0.0188 mmol) of the product was dissolved in MeOD-d4 containing sodium 
acetate (5 mg, 0.0610 mmol) for stabilisation.*Under non-basic conditions degradation to 
amide 136 was observed*  
m.p. decomposes above 130 °C; 1H NMR (600 MHz, MeOD-d4)  = 7.80 (2H, d, J = 7.5, H-
9, 13), 7.66 (2H, d, J = 7.5, H-9, 6, 10), 7.39 (2H, t, J = 7.5, H-8, 12), 7.32 (2H, t, J = 7.5, H-
7, 11), 6.63 (1H, dd, J = 15.8, J = 9.0, H-17), 4.55 (1H, d, J = 15.8, H-18a), 4.41 (2H, d, 
J = 6.8, H-14), 4.23 (2H, m, H-18b + H-1); 13C NMR (150 MHz, MeOD-d4)  = 156.2 (C-15), 
145.1 (2, 5), 142.6 (3, 4), 131.4 (C-17), 128.8 (C-7,11), 128.2 (C-8, 12), 126.1 (C-6, 10) 
121.0 (C-9, 13) 93.8 (C-18) 68.0 (C-14), 48.3 (C-1); IR (solid, cm−1) 3313, 2922, 2852, 
1699, 1649; MS (EI) m/z [M, relative intensity] 265.1 [M+H, 3], 178.1 [Fmoc-CH3,100]; 
Exact mass calcd for [C17H15NO2Na] 288.1000, found 288.0989. 
(9H-fluoren-9-yl)methyl carbamate 136 
 
Enecarbamate 134 (20.0 mg, 0.0750 mmol) was dissolved in CH3Cl (1 ml) and 0.5 ml of 
dilute HCl (0.1 M) was added. The solution was stirred vigorously at room temperature for 
30 minutes before all solvent was removed in vacuo to yield title compound 136 as a white 
solid (18.0 mg, 0.0750 mmol) in a quantitative yield. 
m.p. 198.5 - 201.5 °C; (lit. m.p. 192 - 195 °C330); 1H NMR (600 MHz, CDCl3-d1)  = 7.78 
(2H, d, J = 7.5, H-9, 13), 7.61 (2H, d, J = 7.5, H-6, 10), 7.42 (2H, t, J = 7.5, H-8, 12), 7.33 
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(2H, t, J = 7.5, H-11, 7), 4.60 (2H, broad s, H-16), 4.42 (2H, d, J = 7.0, H-14), 4.25 (1H, t, J 
= 7.0, H-1); 13C NMR (150 MHz, CDCl3-d1)  = 156.7 (C-15), 143.9 (C 2, 5), 141.4 (C-3, 4), 
127.9 (C-7, 11), 127.2 (C-8, 12), 125.1 (C-6, 10), 120.1 (C-9, 13), 67.0 (C-14), 47.2 (C-1); 
IR (solid, cm−1); MS (ES+) m/z [M, relative intensity] 262.1 [M+Na, 70], 179.1 [C14H11, 5]; 
Exact mass calcd for [C15H13NO2Na] 262.0844, found 262.0824. 
2,5-dioxopyrrolidin-1-yl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-phenylalaninate 
138 
 
Fmoc-L-Phe (3.00 g, 7.74 mmol) and N-Hydroxysuccinimide (897 mg, 7.74 mmol) were 
suspended in CH2Cl2 (90 ml) and stirred under argon at room temperature. 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide was added and the resulting solution stirred for four 
hours.  All solvent was removed in vacuo and the resulting white solid dissolved in CH2Cl2 
(50.0 ml). The organic layer was washed with 10% aqueous citric acid (10 ml), followed by 
saturated Na2CO3 (30 ml) and finally brine (2 x 30 ml). The organic layer was dried over 
MgSO4 and all solvent removed in vacuo to produce title compound 138 as a white powder 
(3.50 g, 7.22 mmol) in a 97% yield. 
m.p. 68 - 71 °C; 1H NMR (600 MHz, CDCl3-d1)  = 7.77 (2H, d, J = 7.5, H-9, 13), 7.54 (2H, 
dd, J = 7.5, J = 3.4, H-6, 10), 7.41 (2H, t, J = 7.5, H-8, 12), 7.26 - 7.34 (7H, m, H-7, 11, 
22 - 26), 5.27 (1H, d, J = 8.6, H-18), 5.06 (1H, dt, J = 8.6, J = 6.0, H-19), 4.45 (1H, dd, J 
= 10.6, J = 7.2, H-14`), 4.35 (1H, dd, J = 10.6, J = 7.2, H-14``), 4.19 (1H, t, J = 7.2, H-1), 
3.33 (1H, dd, J = 14.2, J = 6.0, H-20`), 3.23 (1H, dd, J = 14.2, J = 6.0, H-20``), 2.82 (4H, s 
H-29 + 30); 13C NMR (150 MHz, CDCl3-d1)  = 168.8 (C-28, 31), 167.6 (C-27), 155.4 (C-
16), 143.9 (C-2, 5), 141.4 (C-3, 4), 134.5 (C-21), 129.8 (C-26, 22), 128.9 (C-25, 23), 127.9 
(C-7, 11), 127.7 (C-24), 127.2 (C-8, 12), 125.3 (C-6, 10), 120.1 (C-9, 13), 67.3 (C-14), 53.1 
(C-19), 47.2 (C-1), 38.1 (C-20), 25.7 (C-29 + 30); IR (solid, cm−1) 3329, 1737, 1702; MS 
(EI) m/z [M, relative intensity] 484.1 [M+H, 1], 178.1 [C14H11, 100], 165.1 [C13H9, 17); Exact 
mass calcd for [C28H24N2O6] 484.16344, found 484.163121. 
 
 
 
 
 
 
 
 
148 
 
S-Trityl-L-cysteine 140 
 
  
Fmoc-Cys-Trt-OH (600 mg, 1.02 mmol) was dissolved in piperidine (10.0 ml, 30% in DMF) 
and stirred at room temperature for one hour. All solvent and excess piperidine was 
removed by co-evaporation with toluene to leave a crude white solid. This solid was 
transferred to filter paper and washed with hexane (12 x 10 ml) to produce title compound 
140 as a white powder (366 mg, 1.01 mmol) in a quantitative yield.  
m.p. decomposition above 190 °C; 1H NMR (600 MHz, DMSO-d6)  = 7.30 - 7.28 (15H, m, 
Phe), 2.91 (1H, dd, J = 9.2, J = 4.3 Hz, H-2), 2.57 (1H, dd, J = 12.6, J = 4.3, H-3`), 2.40 
(1H, dd, J = 12.6, J = 9.2, H-3``); 13C NMR (150 MHz, DMSO-d6)  = 167.9 (C-4), 144.3 
(C-6, 12, 18), 129.2 (C-7, 11, 13, 17, 19, 23), 128.1 (C-8, 10, 14, 16, 20, 22), 126.8 (C-9, 
15, 21), 66.0 (C-5), 53.4 (C-2), 33.5 (C-3); IR (solid, cm−1) 3051, 1650; MS (ES+) m/z [M, 
relative intensity] 243.1 [C(C6H5)3, 100]; Exact mass calcd for [C22H21NO2SNa] 386.1191, 
found 386.1198. 
N-((((9H-fluoren-9-yl)methoxy)carbonyl)-L-phenylalanyl)-S-trityl-L-cysteine 141 
 
N,N-Diisopropylethylamine (0.570 ml, 3.3 mmol) was added to a suspension of compounds 
138 (800 mg, 1.65 mmol) and 140 (602 mg, 1.65 mmol) in DMF (35 ml) and stirred at room 
temperature for one hour. Toluene (100 ml) was added and all solvent removed in vacuo to 
produce a crude gum. Purification by flash chromatography (1 - 6% MeOH in CH2Cl2  with 
1% AcOH) produced dipeptide 141 as a white powder (640 mg, 0.87 mmol) in a 53% yield. 
m.p. 109.5 - 111.0 °C; 1H NMR (600 MHz, DMSO-d6)  = 8.44 (1H, d, J = 7.3, H-18), 7.88 
(2H, d, J = 7.6, H-9, 13), 7.65 (1H, d, J = 8.7, H-29), 7.62 (2H, d, J = 7.6, H-6, 10), 7.40 
(2H, t, J = 7.6, H-8, 12), 7.12 - 7.35 (22H, m, H-7, 11, 22-26, 35-39, 43-47, 49-53), 4.31 
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(1H, td, J = 8.7, J = 3.4, H-30), 4.18 (1H, td, J = 7.3, J = 5.2, H-19), 4.03 - 4.14 (3H, m, H-1, 
14``, 14`), 3.00 (1H, dd, J = 13.7, J = 3.4, H-31`), 2.75 (1H, dd, J = 13.7, J = 3.4, H-31``), 
2.52 (1H, dd, J = 12.1, J = 5.2, H-20`), 2.42 (1H, dd, J = 12.1, J = 5.2, H-20``); 13C NMR 
(150 MHz, DMSO-d6)  = 171.7 (C-40), 171.6 (C-27), 155.8 (C-16), 144.2 (C-48, 42, 34), 
143.8 (C-2,5), 140.7 (C-4, 3), 138.1 (C-21), 125.3-129.3 (C-7,11, C-6,10, C-8,12, C-22-26, 
35-39, 43-47, 49-53) 120.1 (C-9, 13), 66.2 (C-33), 65.7 (C-14), 56.0 (C-30), 55.0 (C-19), 
46.5 (C-1), 40.0 (C-31), 37.4 (C-20); IR (solid, cm−1) 3287, 3089, 1712, 1623 1592; MS 
(ES+) m/z [M, relative intensity]  731.3 [M+H, 100]; Exact mass calcd for [C46H40N2O5S] 
731.2585, found 731.2578. 
(((9H-fluoren-9-yl)methoxy)carbonyl)-L-phenylalanyl-L-cysteine 142 
 
Triisopropylsilane (480 µl, 2.33 mmol) and trifluoroacetic acid (2.4 ml) were added to a 
solution of 141 (300 mg, 0.408 mmol) in CH2Cl2 (20 ml) and stirred at room temperature for 
15 minutes. All solvent was removed in vacuo, and excess trifluoroacetic acid was co-
evaporated with Et2O (4 x 20 ml). The resulting white solid was transferred to filter paper 
and washed with hexane (5 x 30 ml) to give title compound 142 (190 mg, 0.387 mmol) as a 
white solid in a 95% yield.  
m.p. decomposition above 130 °C; 1H NMR (600 MHz, DMSO-d6)  = 8.36 (1H, d, J = 7.7, 
H-16), 7.88 (2H, d, J = 7.5, H-9, 13), 7.68 (1H, d, J = 8.9, H-26), 7.63 (2H, t, J = 7.5, H-6, 
10), 7.41 (2H, dt, J = 7.5, J = 5.1, H-8, 12), 7.32 (2H, t, J = 7.5, H-11, 7), 7.23 - 7.31 (4H, m, 
H-20, 21, 23, 24), 7.18 (1H, t, J = 7.5, H-22), 4.45 (1H, td, J = 7.7, J = 4.7, H-17), 4.34 (1H, 
td, J = 8.9, J = 3.7, H-27), 4.11 - 4.21 (3H, m, H-1, 14), 3.03 (1H, dd, J = 13.6, J = 3.7, 
H-28`), 2.90 (1H, ddd, J = 13.5, J = 8.5, J = 4.6, H-28``), 2.75 - 2.84 (2H, m, H-18), 2.43 
(1H, t, J = 8.5, H-29); 13C NMR (150 MHz, DMSO-d6)  = 171.8 (C-30), 171.5 (C-25), 155.8 
(C-15), 143.8 (C-2,5), 140.7 (C-3,4), 138.1 (C-19), 129.3 (C-20, 24), 128.1 (C-21, 23), 
127.7 (C-7, 11), 127.1 (C-8, 12), 126.3 (C-22), 125.4 (C-6, 10), 120.1 (C-9, 13), 65.7 
(C-14), 56.0 (C-17), 54.4 (C-27), 46.6 (C-1), 37.4 (C-18), 25.6 (C-28); IR (solid, cm−1) 3302, 
3062, 2901, 1700, 1688, 1656; MS (ES+) m/z [M, relative intensity] 513.1 [M+Na], 75], 
206.1 [C11H13NOS2]; Exact mass calcd for [C27H26N2O5S]+Na 513.1460, found 513.1456. 
 
 
 
 
150 
 
N-((((9H-fluoren-9-yl)methoxy)carbonyl)-L-phenylalanyl)-S-(2,5-dioxo-2,5-dihydro-
1H-pyrrol-3-yl)-L-cysteine 143 
 
Compound 142 (50 mg, 0.102 mmol) and sodium acetate (18.4 mg, 0.224 mmol) were 
dissolved in MeOH (2 ml) and stirred for five minutes under argon. Monobromomaleimide 
93 (20 mg, 0.112 mmol) was subsequently added and the solution stirred for 30 minutes at 
room temperature. All solvent was removed in vacuo, the crude material suspended in ethyl 
acetate (5 ml) and washed with 10% aqueous citric acid (2 ml). The organic layer was 
collected, dried over MgSO4 and all solvent removed in vacuo. Purification by flash 
chromatography (2% - 8% MeOH in CH2Cl2 with 1% AcOH) afforded cysteine-maleimide 
143 as an off white wax (47 mg, 0.080 mmol) in a 79% yield.  
1H NMR (600 MHz, DMSO-d6)  = 7.87 (2H, d, J = 7.5, H-9, 13), 7.73 (2H, d, J = 7.9, H-16), 
7.62 (2H, t, J = 6.6, H-6, 10), 7.40 (2H, td, J = 7.5, J = 4.5, H-8, 12), 7.22 - 7.34 (7H, m, H- 
7, 11, 20, 21, 23, 24, 26), 7.17 (1H, t, J = 7.1, H-22), 6.49 (1H, s, H-34), 4.41 - 4.55 (1H, m, 
H-17), 4.27 (1H, t, J = 7.4, H-27), 4.08 - 4.15 (3H, m, H-1, 14), 3.44 (2H, dd, J = 13.4, J = 
5.1, H-28``), 3.30 (3H, dd, J = 13.4, J = 7.4, H-28``), 3.03 (1H, dd, J = 13.7, J = 3.2, H-18`), 
2.76 (1H, dd, J = 13.7, J = 11.3, H-18``);13C NMR (150 MHz, DMSO-d6)  = 171.7 (C-35), 
171.4 (C-25), 169.3 (C-33), 167.6 (C-31), 155.5 (C-15), 151.1 (C-30), 143.8 (C-2,5), 140.6 
(C-3,4), 138.0 (C-19), 129.3 (C-20, 24), 128.2 (C-21, 23), 127.7 (C-7, 11), 127.1 (C-8, 12), 
126.2 (C-22), 125.1 (C-6, 10), 119.8 (C-9, 13), 119.2 (C-34),  65.6 (C-14), 56.3 (C-17), 55.1 
(C-27), 46.5 (C-1), 37.3 (C-18), 33.1 (C-28); IR (solid, cm−1) 3300, 3123, 2932, 1710, 1651, 
1535; MS (ES+) m/z [M, relative intensity] 608.2 [M+Na, 50], 586.2 [M+H, 35], 
179.1[C14H11,1]; Exact mass calcd for [C31H27N3O7S] 586.1648, found 586.1668; 344 
(MeOH) = 3321 M−1·cm−1.   
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(9H-fluoren-9-yl)methyl (S)-(1-oxo-3-phenyl-1-(vinylamino)propan-2-yl)carbamate 
144 
  
Dipeptide 143 (30.0 mg, 0.0512 mmol) and sodium acetate (4.62 mg, 0.0563 mmol) were 
dissolved in MeOH (135 ml) and the entire solution degassed with argon for 30 minutes. 
The solution was irradiated using the UVG-2 torch for 60 minutes. All solvent was removed 
in vacuo at room temperature and the resulting crude material washed with Et2O (3 x 15 
ml). Collection of the organic washings and subsequent evaporation gave enamide 144 as 
a white solid (17 mg, 0.0414 mmol) in an 81% yield.  
m.p. 152.0 - 152.8 °C; 1H NMR (600 MHz, CDCl3-d1)  = 7.77 (2H, d, J = 7.5, H-13, 9), 7.53 
(2H, t, J = 7.5, H-6, 10), 7.41 (2H, t, J = 7.5, H-8, 12), 7.15 - 7.34 (7H, m, H-24, 25, 23, 26, 
22, 11, 7), 6.87 (1H, dt, J = 15.4, J = 9.8, H-30), 4.50 (1H, d, J = 15.8, H-31a), 4.47 (1H, dd, 
J = 8.5, 5.5, H-19), 4.43 (1H, d, J = 8.7, H-31b), 4.39 (2H, overlapping multiplet, H-14), 4.19 
(1H, t, J = 6.8, H-1), 3.16 (1H, dd, J = 13.0, 8.5, H-20`), 3.06 (1H, dd, J = 13.0, 5.5, H-20``); 
13C NMR (150 MHz, CDCl3-d1)  = 168.3 (C-27), 154.4 (C-16), 143.7 (C-2, 5), 141.4 (C-3, 
4), 129.4 (C-30), 129.0 (C-7,11), 127.9 -120.2 (C-6, 8, 9, 10, 12, 13, 21-26), 97.1 (C-31),  
67.3 (C-14), 56.4 (C-19), 47.2 (C-1), 38.3 (C-20); IR (solid, cm−1) 3289, 2953, 1685, 1665, 
1643; MS (ES+) m/z [M, relative intensity] 435.2 [M+Na, 100], 175.1 [C11H13NO, 15]; Exact 
mass calcd for [C26H24N2O3Na] 435.1685, found 435.1673. 
N-(((9H-fluoren-9-yl)methoxy)carbonyl)-S-(1-methyl-2,5-dioxo-2,5-dihydro-1H-
pyrrol-3-yl)-L-cysteine 146 
 
Fmoc-cysteine 132 (200 mg, 0.582 mmol) and sodium acetate (105 mg, 1.28 mmol) were 
dissolved in MeOH (11.3 ml) and stirred for five minutes under argon. N-
Methylmonobromomaleimide (121 mg, 0.640 mmol) was subsequently added and the 
solution stirred for 20 minutes at room temperature. All solvent was removed in vacuo, the 
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crude material suspended in ethyl acetate (35 ml) and washed with 10% aqueous citric 
acid (15 ml). The organic layer was collected, dried over MgSO4 and all solvent removed in 
vacuo. Purification by flash chromatography (2% - 6% MeOH in CH2Cl2 with 1% AcOH) 
afforded title compound 146 as a light orange powder (242 mg, 0.535 mmol) in a 92% 
yield.  
m.p.105 - 107 °C; 1H NMR (600 MHz, DMSO-d6)  = 7.98 (1H, d, J = 8.3, H-9), 7.89 (2H, d, 
J = 7.5, H-17, 20), 7.70 (2H, d, J = 7.5, H-14, 23), 7.42 (2H, t, J = 7.5, H-16, 21), 7.32 (2H, 
t, J = 7.5, H-15, 22), 6.59 (1H, s, H-3), 4.26 - 4.35 (3H, m, H-11, 8), 4.17 - 4.26 (1H, m, 
H-12), 3.46 (1H, dd, J = 13.7, J = 4.7, H-7`), 3.27 (1H, dd, J = 13.7, J = 9.4, H-7``), 2.85 
(3H, s, H-6); 13C NMR (150 MHz, DMSO-d6)  = 171.3 (C-25), 169.5 (C-2), 167.9 (C-5), 
156.0 (C-10), 149.5 (C-4), 143.8 (C-13, 24), 140.8 (C-18, 19), 127.7 (C-15, 22), 127.1 
(C-16, 21), 125.2 (C-14, 23), 120.2 (C-17, 20), 118.7 (C-3), 65.9 (C-11), 52.4 (C-8), 46.6 
(C-12), 32.4 (C-7); IR (solid, cm−1) 3311, 1702, 1675, 1535; MS (ES+) m/z [M, relative 
intensity] 475.1 [M+Na, 100]; Exact mass calcd for [C23H20N2O6SNa] 475.0940, found 
475.0952; MeOH) = 3813 M−1·cm−1.    
N-(((9H-fluoren-9-yl)methoxy)carbonyl)-S-(1-(2-((5-(dimethylamino)naphthalene)-
1-sulfonamido)ethyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-L-cysteine 148 
 
Fmoc-L-Cysteine 132 (16.0 mg, 0.0465 mmol) and sodium acetate (8.4 mg, 0.102 mmol) 
were dissolved in MeOH (1.5 ml) and stirred under argon for five minutes. Compound 110 
(21.0 mg, 0.0465 mmol) was added resulting in an cloudy suspension. MeOH was added 
dropwise until complete dissolution (20 ml) and the mixture stirred at room temperature for 
one hour. All solvent was removed in vacuo, the crude material suspended in CH2Cl2 (15 
ml) and washed with 10% aqueous citric acid. The organic layer was collected, dried over 
MgSO4 and all solvent removed in vacuo. The crude material was purified by flash 
chromatography (2 - 5% MeOH in CH2Cl2 with 1% AcOH) to produce compound 148 as an 
orange solid (11.0 mg, 0.0154 mmol) in a 33% yield. 
1H NMR (600 MHz, MeOD-d4)  = 8.48 (2H, d, J = 8.3, H-12), 8.19 (1H, d, J = 8.7, H-17), 
8.10 (2H, d, J = 7.1, H-10), 7.77 (2H, d, J = 7.7, H-35, 39), 7.65 (2H, t, J = 7.7, H-32, 36), 
7.43 - 7.55 (2H, H-11, 16), 7.36 (2H, td, J = 7.7, J = 3.0, H-34, 38), 7.29 (2H, q, J = 7.7, 
H-33, 37), 7.22 (2H, d, J = 7.5, H-15), 5.92 (1H, s, H-4), 4.40 (2H, m, H-22, 26`), 4.34 (1H, 
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dd, J = 10.5, J = 7.0, H-26``), 4.21 (1H, t, J = 7.0, H-27), 3.41 (3H, m, H-21`, 6), 3.16 - 3.25 
(1H, m, H-21``), 3.10 (2H, t, J = 5.8, H-7), 2.84 (6H, s, H-19, 20); 13C NMR (150 MHz, 
MeOD-d4)  = 170.5 (C-23), 170.5 (C-5), 169.0 (C-2), 153.0 (C-25), 151.1 (C-14), 145.2 
(C-28, 31), 145.2 (C-3), 142.6 (C-29, 30), 136.6 (C-9), 131.4 (C-12), 131.0 (C-18), 130.7 
(C-13), 130.4 (C-17), 129.3 (C-16), 128.8 (C-33, 37), 128.2 (C-34, 38), 126.2 (C-32, 36), 
124.3 (C-11), 120.9 (C-10), 120.6 (C-35, 39),119.0 (C-4), 116.2 (C-15), 68.1 (C-26), 47.9 
(C-27), 45.8 (C-19, 20), 41.5 (C-7), 38.7 (C-6), 34.6 (C-21); MS (ES+) m/z [M, relative 
intensity] 715.2 [M+H, 20]; Exact mass calcd for [C36H35N4O8S2] 715.1896, found 715. 
1918; MeOH) = 4672 M−1·cm−1.    
3.1.2.3: HPLC analysis of the Irradiation of C-terminal cysteine models 
General method for the irradiation of C-terminal cysteine models 
 
Sodium acetate (1.1 equiv.) was added to a solution of C-terminal cysteine model (133, 
146 or 148) in MeOH (0.1 ml, 380 M solution). The mixture was irradiated using the 365 
nm UVG-2 torch for 50 minutes, with samples taken every 10 minutes for analysis by 
LCMS. LCMS was performed on a Waters Acquity uPLC connected to Waters Acquity 
Single Quad Detector and a photodiode array. Flow rate was set at 0.600 ml/min. A 
Hypsersil Gold (100 x 2.1 mm) column at 50 C was employed. Solvent A is H2O (0.1% 
formic acid), solvent B is MeCN (0.1% formic acid Mobile phase: 95:5 A:B; gradient over 15 
min to 5:95 A:B. MS mode ES+ ; scan range: m/z ¼ 100–1000; scan time: 0.25 s. A 
capillary voltage of 3.5 kV and a cone voltage of 50 V was employed.  
UV/Vis traces for injected standards. 
 
Figure 57 
UV/Vis trace for enecarbamate 134. 
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Figure 58 
UV/Vis trace for carbamate 136. 
 
 
Figure 59 
UV/Vis trace for Fmoc-L-cys-N-methylmaleimide 146. 
 
 
Figure 60 
UV/Vis trace for Fmoc-L-cys-N-dansylmaleimide 148 
 
3.1.2.4: Synthesis of photocleavable linkers 
Tert-Butyl O-(tert-butyl)-L-serinate 164 
 
L-Serine (1.00 g, 9.43 mmol) was suspended in tert-Butylacetate (30 ml) and stirred under 
argon. Perchloric acid (0.900 ml, 70% in water, 10.4 mmol) was added and the mixture 
stirred for five hours. After this time saturated NaHCO3 (100 ml) was added and the 
solution stirred for 30 minutes. The mixture was extracted with CH2Cl2 (2 x 150 ml), the 
organic layers combined and washed with brine (100 ml), and then dried over MgSO4. All 
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solvent was removed in vacuo to afford title compound 164 as a clear oil (1.76 g, 8.11 
mmol) in an 86% yield. 
1H NMR (600 MHz, CDCl3-d1)  = 3.61 (1H, dd, J = 8.5, 4.6, H-3’), 3.55 (1H, dd, J = 8.5, , 
H-3’’), 3.48 (1H, t, J = 4.2, H-2), 2.15 (2H, s, H-1), 1.47 (9H, s, H-10, 11, 12), 1.17 (9H, s, 
H-5, 6, 7); 13C NMR (150 MHz, CDCl3-d1)  = 173.2 (C-8), 81.3 (C-9), 73.0 (C-4), 63.8 (C-
3), 55.6 (C-2), 28.2 (C-10, 11, 12), 27.5 (C-5, 6, 7); IR (solid, cm−1) 3379.04 (br), 2974.21 
(m), 2850.51 (m), 1731.98 (s); MS (ES+) m/z [M, relative intensity] 218.2 ([M+H], 100); 
Exact mass calcd for [C11H24NO3] 218.1756, found 218.1750. 
methyl 3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrole-1-carboxylate 165 
 
N-Methylmorpholine (18.8 mmol, 2.10 ml) and methyl chloroformate (18.8 mmol, 1.45 ml) 
were added sequentially to a solution of 2,3,-dibromomaleimide (18.8 mmol, 4.80 g) in 
tetrahydrofuran (80 ml). The solution was stirred at room temperature for 30 minutes, 
before all solvent was removed in vacuo. The crude material was dissolved in CH2Cl2 (300 
ml) and washed with brine (100 ml). The organic layer was dried over MgSO4 and all 
solvent removed to produce title compound 165 as a pale purple powder (5.70 g, 18.2 
mmol) in a 97% yield.  
m.p. 115 - 117 °C (lit. m.p. 115 - 118 °C145); 1H NMR (500 MHz, CDCl3-d1)  = 4.00 (3H, s, 
H-7); 13C NMR (125 MHz, CDCl3-d1)  = 159.3 (C-6), 147.0 (C-2, 5), 131.5 (C-3, 4), 54.9 
(C-7); IR (solid, cm−1) 2961, 1808, 1765, 1724, 1600;  MS (ES+) m/z [M, relative intensity] 
310.7 [79Br79Br+H, 49], 312.7 [81Br79Br+H, 100], 314.7 [81Br81Br+H, 51]; Exact mass calcd 
for [C6H479Br2NO4] 310.8423, found 310.8421. Data matched the literature.145  
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tert-Butyl (S)-3-(tert-butoxy)-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-
1-yl)propanoate 166 
 
Compound 164 (0.902 g, 4.15 mmol in 5 ml CH2Cl2) was added to a stirring solution of 
carbamate 165 (1.3 g, 4.15 mmol) in CH2Cl2 (60 ml). The solution was left to stir at room 
temperature for 60 minutes. After this time all solvent was removed in vacuo and the crude 
material purified by flash chromatography (10 - 20% ethyl acetate in petrol) to yield 166 as 
a dark yellow oil (1.40 g, 3.08 mmol) in a 74% yield.  
1H NMR (600 MHz, MeOD-d4)  = 4.83 (1H, dd, J = 9.6, 6.2, H-6), 3.89 - 3.91 (2H, m, H-7`, 
7``), 1.45 (9H, s, H14, 15, 16), 1.12 (9H, s, H-9, 10, 11); 13C NMR (150 MHz, MeOD-d4)  = 
167.5 (C-12), 164.8 (C-2, 5), 130.6 (C-3, 4), 84.5 (C-13), 75.0 (C-8), 59.6 (C-6), 56.2 (C-7), 
28.1 (C-14, 15, 16), 27.7 (C-9, 10, 11); IR (solid, cm−1) 3052, 2964, 1742, 1602; MS (ES+) 
m/z [M, relative intensity] 452.0 [79Br79BrM+H, 49], 454.0 [81Br79BrM+H, 100], 456.0 
[81Br81BrM+H, 51]; Exact mass calcd for [C15H279Br2NO5] 451.9786, found 451.9708.  
(S)-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-hydroxypropanoic acid 
167 
 
Method 1 
L-Serine (0.554 g, 5.27 mmol) and sodium carbonate (0.558 g, 5.27 mmol) were dissolved 
in a tetrahydrofuran:water mixture (50:50, 56 ml) and stirred under argon at room 
temperature for five minutes. Carbamate 165 (1.65 g, 5.27 mmol) was added in a single 
portion and the resulting solution stirred for 90 seconds before being acidified to pH = 2-3 
through addition of solid citric acid. The solution was extracted with CH2Cl2 (4 x 112 ml) 
and dried over a generous amount of MgSO4. All solvent was removed in vacuo and the 
crude material dissolved in CH2Cl2 (56 ml). A spatula tip of para-toluenesulfonic acid (~100 
mg) was added and the solution stirred at room temperature for one hour.  All solvent was 
removed in vacuo and the crude material purified by flash chromatography (0 - 4% MeOH 
in CH2Cl2 with 1% AcOH) to produce title compound 167 as white crystals (1.20 g, 3.52 
mmol) in a 67% yield. Standing at room temperature resulted in transformation of the solid 
to a clear gum.  
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Method 2 
Trifluoroacetic acid (20 ml) was added slowly to a solution of compound 166 (0.5 g, 1.1 
mmol) in CH2Cl2 (40 ml) at 0 °C. The solution was returned to room temperature and 
allowed to stir for four hours. All solvent was removed in vacuo to produce title compound 
167 as a white solid (346 mg, 1.01 mmol) in a quantitative yield. Standing at room 
temperature resulted in transformation of the solid to a clear gum.  
1H NMR (600 MHz, MeOD-d4) = 4.89 (1H, dd, J = 8.7, J = 6.4, H-6), 4.10 - 4.13 (2H, m, 
H-7`, 7``); 13C NMR (150 MHz, MeOD-d4)  = 170.0 (C-8), 165.0 (C-2, 5), 130.6 (C-3, 4), 
59.7 (C-7), 57.1 (C-6); IR (solid, cm−1) 3489, 2970, 2901, 1719, 1593; MS (ES+) m/z [M, 
relative intensity] 363.9 [79Br79BrM+Na, 49], 365.9 [81Br79BrM+Na, 100], 367.9 
[81Br81BrM+Na, 51]; Exact mass calcd for [C7H579Br2NO5Na] [M+Na] 363.8432, found 
363.8637. 
(S)-2-(3,4-bis(((R)-2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)thio)-
2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-hydroxypropanoic acid 169 
 
Compound 167 (350 mg, 1.02 mmol) and sodium acetate (258 mg, 3.15 mmol) were 
dissolved in MeOH (23 ml). Boc-L-Cys-OMe (504 mg, 2.14 mmol) was added and the 
reaction stirred under argon at room temperature for 40 minutes. All solvent was removed 
in vacuo, the crude material dissolved in ethyl acetate (30 ml) and washed with 10% 
aqueous citric acid (10 ml). The organic layer was collected, dried over MgSO4 and all 
solvent removed in vacuo. The crude material was purified by flash chromatography (ethyl 
acetate with 0.5% AcOH) to produce title compound 169 (614 mg, 0.942 mmol) in a 92% 
yield. Further purification was performed (0 - 4% MeOH in CH2Cl2 with 1% AcOH) to 
produce a pure sample (420 mg, 0.644) in a 63% yield. 
m.p. 115.0 - 117.0 °C; 1H NMR (600 MHz, DMSO-d6)  = 7.47 (2H, d, J = 8.3, H-23, 13), 
4.65 (1H, t, J = 7.5, H-6), 4.26 (2H, ddd, J = 10.0, J = 8.3, J = 4.3, H-10, 20), 3.89 (2H, d, J 
= 7.5, H-7), 3.77 (2H, dd, J = 13.4, J = 4.3, H-9`, 19`), 3.64 (3H, s, H-12, 22), 3.40 (2H, dd, 
J = 13.4, J = 10.0, H-9``, 19``), 1.38 (18H, s, H-16, 17, 18, 26, 27, 28); 13C NMR (150 MHz, 
DMSO-d6)  = 170.8 (C-11, 21), 168.7 (C-8), 165.4 (C-2, 5), 155.3 (C-14, 24), 134.9 (C-3, 
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4), 78.7 (C-15, 25), 57.9 (C-7), 54.9 (C-6), 53.8 (C-10, 20), 52.3 (C-12, 22), 32.2 (C-9,19), 
28.1 (C-16, 17, 18, 26, 27, 28); IR (solid, cm−1) 3370, 2978, 1705, 1512; MS (ES+) m/z [M, 
relative intensity] 674.2 [M+Na, 95], 652.2 [M+H, 40]; Exact mass calcd for 
[C25H37N3O13S2Na] 652.1846, found 652.1849. 
(S)-3-acetoxy-2-(3,4-bis(((R)-2-((tert-butoxycarbonyl)amino)-3-methoxy-3-
oxopropyl)thio)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoic acid 170 
 
Method 1 
Compound 172 (320 mg, 0.491 mmol) and N,N-Diisopropylethylamine (214 l, 1.73 mmol) 
were dissolved in CH2Cl2 (7 ml). Acetic anhydride (139 l, 1.47 mmol) was added and the 
reaction stirred under argon at room temperature for 16 hours. All organic solvent was 
removed in vacuo, the crude material dissolved in ethyl acetate (20 ml) and washed with 
10% aqueous citric acid (7 ml). The organic layer was collected, all solvent removed in 
vacuo and dried over MgSO4. Purification by flash chromatography (40% ethyl acetate in 
CH2Cl2 with 1% AcOH) yielded 170 (65 mg, 0.094 mmol) in a 19% yield. Compound 171 
(150 mg, 0.237 mmol) was also obtained in a yield of 48%. 
Method 2 
Compound 172 (683 mg, 1.77 mmol) and sodium acetate (450 mg, 5.49 mmol) were 
dissolved in MeOH (39 ml). Boc-L-Cys-OMe (875 mg, 3.72 mmol) was added and the 
solution stirred under argon at room temperature for 30 minutes, resulting in a bright yellow 
solution. All solvent was removed in vacuo, the crude material dissolved in ethyl acetate 
(60 ml) and washed with 10% aqueous citric acid (20 ml). The organic layer was collected, 
dried over MgSO4 and all solvent removed in vacuo. The crude material was purified by 
flash chromatography (0 - 5% MeOH in CH2Cl2 in 1% AcOH) to yield title compound 170 as 
a yellow powder (856 mg, 1.23 mmol) in a 70% yield.  
m.p. 78.6 - 79.9 °C; 1H NMR (600 MHz, MeOD-d4) = 4.96 (1H, dd, J = 9.8, J = 3.9, H-6), 
4.73 (1H, dd, J = 11.5, J = 3.9, H-7`), 4.50 (1H, dd, J = 11.5, J = 9.8, H-7``), 4.41 (2H, dd, J 
= 8.3, J = 4.5, H-12, 22), 3.86 (2H, dd, J = 13.7, J = 4.5, H-11`, 21`), 3.73 (6H, s, H-14, 24), 
3.50 (2H, dd, J = 13.7, J = 8.3, H-11``, 21``), 2.01 (3H, s, H-9), 1.44 (18H, s, H-18, 19, 20, 
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28, 29, 30); 13C NMR (150 MHz, MeOD-d4)  = 172.4 (C-8), 172.4 (C-13, 23), 169.7 (C-10), 
166.8 (C-2, 5), 157.7 (C-16, 26), 137.3 (C-3, 4), 80.9 (C-17, 27), 62.3 (C-7), 55.3 (C-6), 
53.1 (C-14, 24), 52.8 (C-12, 22), 34.0 (C-11, 21), 28.7 (C-18, 19, 20, 28, 29, 30), 20.7 (C-
9); IR (solid, cm−1) 3370, 2977, 1743, 1708, 1508; MS (ES+) m/z [M, relative intensity] 
711.2 [M+H2O, 100], 716.2 [M+Na, 75], 694.2 [M+H, 45]; Exact mass calcd for 
[C27H40N3O14S2] 694.1952, found 694.1918. 
2-(3,4-bis(((R)-2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)thio)-2,5-
dioxo-2,5-dihydro-1H-pyrrol-1-yl)acrylic acid 171 
 
See experimental procedure for compound 170. 
m.p. 74.6 - 76.9 °C; 1H NMR (600 MHz, MeOD-d4)  = 6.58 (3H, s, H-7a), 5.96 (1H, s, H-
7b), 4.46 (2H, dd, J = 8.4, J = 4.4, H-10, 20), 3.87 (2H, dd, J = 13.9, J = 4.4, H-9`, 19``), 
3.74 (6H, s, H-12, 22), 3.52 (2H, dd, J = 13.9, J = 8.4, H-9``, 19``), 1.43 (18H, s, H-16, 17, 
18, 26, 27, 28);13C NMR (150 MHz, MeOD-d4)  = 172.3 (C-11, 21), 165.8 (C-2, 5), 165.2 
(C-8), 157.7 (C-14, 24), 137.7 (C-3, 4), 131.2 (C-6), 128.7 (C-7), 81.0 (C-15, 25), 55.3 (C-
10, 20), 52.9 (C-12, 22), 33.3 (C-9, 19), 28.6 (C-16, 17, 18, 26, 27, 28); IR (solid, cm−1) 
3367, 2977, 1712, 1640, 1510; MS (ES+) m/z [M, relative intensity] 656.2 [M+Na, 100], 
634.2 [M+H, 30]; Exact mass calcd for [C25H36N3O12S2Na] 656.1740, found 656.1750. 
 (S)-3-acetoxy-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoic 
acid 172 
 
Acetyl bromide (0.432 ml, 5.84 mmol) in CH2Cl2 (7.5 ml) was added dropwise to a solution 
of compound 167 (500 mg, 1.46 mmol) in CH2Cl2 (7.5 ml). The solution was stirred under 
argon at room temperature for four hours. After this time a 10% aqueous citric acid solution 
(5 ml) was slowly added and the solution stirred for five minutes. The organic layer was 
separated, dried over MgSO4 and all solvent removed in vacuo. The crude material was 
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purified by flash chromatography (0 - 5% MeOH in CH2Cl2 with 1% AcOH) to yield title 
compound 172 as a white solid (520 mg, 1.35 mmol) in a 93% yield.  
m.p. 63.2 - 65.2 °C; 1H NMR (600 MHz, MeOD-d4)  = 5.09 (1H, dd, J = 9.9, J = 4.3, H-6), 
4.72 (1H, dd, J = 11.7, J = 4.3, H-7`), 4.53 (1H, dd, J = 11.7, J = 9.9, H-7``), 1.97 - 2.05 
(3H, m, H-9); 13C NMR (150 MHz, MeOD-d4)  = 177.8 (C-8), 170.6 (C-10), 164.5 (C-2, 5), 
130.2 (C-3, 4), 66.6 (C-6), 60.2 (C-7), 20.1 (C-9); IR (solid, cm−1) 3452, 3124, 2945, 1717, 
1594; MS (ES+) m/z [M, relative intensity] 380.9 [79Br79BrM+H, 49], 382.9 [79Br81BrM+H, 
100], 384.9 [81Br81BrM+H, 49]; Exact mass calcd for [C9H879Br2NO6] 380.8484, found 
380.8486. 
dimethyl 3,3`-((2,5-dioxo-1-vinyl-2,5-dihydro-1H-pyrrole-3,4-
diyl)bis(sulfanediyl)(2R,2`R)-bis(2-((tert-butoxycarbonyl)amino)propanoate) 173 
 
Compound 170 (100 mg, 0.144 mmol) was dissolved in MeCN:phosphate buffer pH = 7.4 
(80:20, 96 ml), degassed with argon for 30 minutes and irradiated at room temperature with 
a medium pressure mercury lamp for 40 minutes. The solution was subsequently acidified 
to pH = 2-3 through addition of solid citric acid and extracted with CH2Cl2 (2 x 125 ml). The 
organic layers were combined, dried over MgSO4 and all solvent removed in vacuo. The 
crude mixture was purified by flash chromatography (0 - 20% ethyl acetate in petrol) to 
produce compound 173 as an orange solid (60 mg, 0.102 mmol) in a 71% yield and 
compound 174 as a yellow solid (15 mg, 0.0230 mmol) in a 16% yield.  
m.p. 78.0 – 80.6 °C; 1H NMR (400 MHz, MeOD-d4)  = 6.68 (1H, dd, J = 16.3, J = 9.9, H-6), 
5.82 (1H, d, J = 16.3, 7a), 4.92 (1H, d, J = 9.9, 7b), 4.50 (2H, dd, J = 8.0, J = 4.3, H-9, 19), 
3.92 (2H, dd, J = 13.8, J = 4.3, H-8`, 18`), 3.77 (6H, s, H-11, 21), 3.53 (2H, dd, J = 13.8, J = 
8.0, H-8``, 18``), 1.45 (18H, s, H-15, 16, 17, 25, 26, 27);13C NMR (150 MHz, DMSO-d6)   = 
170.8 (C-10, 20), 164.2 (C-2, 5), 155.3 (C-13, 23), 136.5 (C-3, 4), 123.7 (C-6), 102.5 (C-7), 
78.7 (C-14, 24), 53.9 (C-9, 19), 52.3 (C-11, 21), 32.2 (C-8, 18), 28.1 (C-15, 16, 17, 25, 26, 
27); IR (solid, cm−1) 2978, 2496, 1751, 1703, 1675, 1637, 1517; MS (ES+) m/z [M, relative 
intensity] 590.2 [M+H, 100]; Exact mass calcd for [C24H36N3O10S2] 590.1842, found 
590.1865. 
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dimethyl 3,3`-((1-(2-acetoxyethyl)-2,5-dioxo-2,5-dihydro-1H-pyrrole-3,4-
diyl)bis(sulfanediyl)(2R,2`R)-bis(2-((tert-butoxycarbonyl)amino)propanoate) 174 
 
See experimental procedure for compound 173. 
1H NMR (600 MHz, MeOD-d4)  = 4.44 (3H, dd, J = 8.5, J = 4.7, H-11, 21), 4.21 (2H, t, J = 
5.8, H-7), 3.87 (2H, dd, J = 13.9, J = 4.7, H-10`, 20`), 3.77 (2H, t, J = 5.8, H-6), 3.73 (6H, s, 
H-13, 23), 3.46 (2H, dd, J = 13.9, J = 8.5, H-10``, 20``), 2.00 (3H, s, H-9),1.44 (18H, s, H-
17, 18, 19, 27, 28, 29);13C NMR (150 MHz, MeOD-d4)  = 172.7 (C-8), 172.4 (C-12, 22), 
167.5 (C-2, 5), 157.6 (C-15, 25), 137.3 (C-3, 4), 81.0 (C-16, 26), 62.7 (C-7), 55.5 (C-11, 
21), 53.1 (C-13, 23), 38.7 (C-6), 34.0 (C-10, 20), 28.7 (C-17, 18, 19, 27, 28, 29), 20.8 (C-9); 
IR (solid, cm−1) 2977, 2928, 1741, 1702, 1505; MS (ES+) m/z [M, relative intensity] 672.2 
[M+Na, 100] 650.2 [M+H, 20]; Exact mass calcd for [C26H40N3O12S2] 650.2053, found 
650.2056. 
(2S,3R)-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-hydroxybutanoic acid 
193 
 
L-Threonine (0.762 g, 6.39 mmol) and sodium carbonate (0.677 g, 6.39 mmol) were 
dissolved in a tetrahydrofuran:water mixture (50:50, 68 ml) and stirred under argon at room 
temperature for five minutes.  Carbamate 165 (2 g, 6.39 mmol) was added in a single 
portion and the resulting solution stirred for 90 seconds before being acidified to pH = 2 - 3 
through addition of solid citric acid. The solution was extracted with CH2Cl2 (4 x 112 ml) 
and dried over a generous amount of MgSO4. All solvent was removed in vacuo and the 
crude material dissolved in CH2Cl2 (56 ml). A spatula tip of para-toluenesulfonic acid (~100 
mg) was added and the solution stirred at room temperature for one hour.  All solvent was 
removed in vacuo and the crude material purified by flash chromatography (0 - 4% MeOH 
in CH2Cl2 with 1% AcOH)  to produce title compound 193 as a grey solid (1.24 g, 3.47 
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mmol) in a 54% yield. Standing at room temperature resulted in transformation of the solid 
to a cloudy gum.  
1H NMR (600 MHz, CDCl3-d1)  = 4.86 (1H, d, J = 4.3, H-6), 4.66 (1H, dq, J = 6.4, J = 4.3, 
H-7), 1.25 (3H, d, J = 6.4, H-8); 13C NMR (150 MHz, CDCl3-d1)  = 170.6 (C-9), 164.5 (C-2, 
5), 130.2 (C-3, 4), 66.6 (C-7), 60.2 (C-6), 20.1 (C-8); IR (solid, cm−1) 3429, 2980, 2924, 
1788, 1716, 1594; MS (ES+) m/z [M, relative intensity] 355.9 [79Br79Br+H, 49], 357.9 
[79Br81Br+H, 100], 359.9 [81Br81Br, 51]; Exact mass calcd for [C8H879Br2NO5] 355.8769, 
found 355.8770. 
(2S,3R)-3-acetoxy-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoic 
acid 194 
 
Acetyl bromide (0.200 ml, 2.75 mmol) in CH2Cl2 (3.5 ml) was added dropwise to a solution 
of compound 193 (245 mg, 0.686 mmol) in CH2Cl2 (3.5 ml). The solution was stirred under 
argon at room temperature for four hours. After this time a 10% aqueous citric acid solution 
(3 ml) was slowly added and the solution stirred for five minutes. The organic layer was 
separated, dried over MgSO4 and all solvent removed in vacuo. The crude material was 
purified by flash chromatography (0 - 5% MeOH in CH2Cl2 with 1% AcOH) to yield title 
compound 194 as a white solid (265 mg, 0.666 mmol) in a 97% yield. 
1H NMR (500 MHz, CDCl3-d1)  = 5.64 (1H, dq, J = 6.5, J = 5.4, H-7), 4.84 (1H, d, J = 5.4, 
H-6), 2.01 (3H, s, H-10), 1.35 (3H, d, J = 6.5, H-8); 13C NMR (125, MHz, CDCl3-d1)  = 
170.2 (C-9), 170.0 (C-11), 162.9 (C-2, 5), 129.8 (C-3, 4), 67.5 (C-7), 56.6 (C-6), 21.0 (C-
10), 18.2 (C-8); IR (solid, cm−1) 3452, 3065, 2924, 1724, 1594; MS (ES+) m/z [M, relative 
intensity] 397.9 [79Br79BrM+H, 49], 399.9 [79Br81BrM+H, 100], 401.9 [81Br81BrM+H, 51]; 
Exact mass calcd for [C10H1079Br2NO6] 397.8879, found 397.8882. 
(S)-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-hydroxy-2-
methylpropanoic acid 196 
 
Dibromomaleic anhydride (75 mg, 0.293 mmol) and -methyl-L-serine (23.3 mg, 0.195 
mmol) were dissolved in AcOH (1.3 ml) and raised to reflux over 20 minutes. The solution 
was stirred at reflux for 40 minutes before being returned to room temperature. A solution 
of 10% aqueous citric acid (10 ml) was subsequently added and the aqueous layer 
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extracted with CH2Cl2 (3 x 20 ml). The organic layers were combined, dried over MgSO4 
and all solvent was removed in vacuo. The crude material was purified by flash 
chromatography (1 - 3% MeOH in CH2Cl2 with 1% AcOH) to yield title compound 196 as an 
off-white wax (37 mg, 0.104 mmol) in a 54% yield.  
1H NMR (600 MHz, MeOD-d4)  = 4.15 (1H, d, J = 11.7, H-8`), 3.83 (1H, d, J = 11.7, H-8``), 
1.81 (3H, s, H-7); 13C NMR (150 MHz, MeOD-d4)  = 174.1 (C-9), 165.6 (C-2, 5), 130.4 
(C-3, 4), 67.2 (C-6), 65.0 (C-8), 20.4 (C-7); IR (solid, cm−1) 3483, 3093, 2994, 1724; MS 
(ES-) m/z [M, relative intensity] 352.9 [79Br79BrM-H, 49], 354.9 [81Br79BrM-H, 100], 356.9 
[81Br81BrM-H, 51];  Exact mass calcd for [C8H6NO579Br2] 352.8535, found 352.8525. 
(S)-3-acetoxy-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-2-
methylpropanoic acid 197 
 
Acetyl bromide (20.9 l, 0.282 mmol) in CH2Cl2 (0.4 ml) was added dropwise to a solution 
of compound 196 (25 mg, 0.0704 mmol) in CH2Cl2 (0.4 ml). The solution was stirred under 
argon at room temperature for four hours. After this time a 10% citric acid solution (1 ml) 
was slowly added and the solution stirred for five minutes. CH2Cl2 (2 ml) was added before 
the organic layer was separated, dried over MgSO4 and all solvent removed in vacuo. The 
crude material was purified by flash chromatography (0 - 5% MeOH in CH2Cl2 with 1% 
AcOH) to yield title compound 197 as a clear glass (25 mg, 0.0627 mmol) in an 89% yield. 
1H NMR (600 MHz, CDCl3-d1)  = 4.71 (1H, d, J = 11.7, H-8`), 4.52 (1H, d, J = 11.7, H-8``), 
2.06 (3H, s, H-10), 1.92 (3H, s, H-7); 13C NMR (150 MHz, CDCl3-d1)  = 174.5 (C-11), 
170.8 (C-9), 163.7 (C-2, 5), 129.7 (C-3, 4), 64.9 (C-8), 63.4 (C-6), 20.8 (C-10), 20.2 (C-7); 
IR (film, cm−1) 3501, 2976, 1722, 1604; MS (ES-) m/z [M, relative intensity] 394.9 
[79Br79BrM-H, 49], 396.9 [81Br79BrM-H, 49], 398.9 [81Br81BrM-H, 49]; Exact mass calcd for 
[C10H1079Br2NO6] 397.8875, found 397.8858. 
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2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-(2-
phenylacetoxy)propanoic acid 199 
 
Compound 167 (30.0 mg, 0.0879 mmol) and tetra-n-butylammonium bromide (142 mg, 
0.440 mmol) were dissolved in CH3Cl (1 ml) and stirred under argon in a dried round 
bottomed flask. Phenylacetyl chloride (46.5 l, 0.352 mmol) was added in a single portion 
and the reaction stirred at room temperature for four hours. After this time MeOH (0.5 ml) 
was added and all solvent removed in vacuo. The crude material was dissolved in ethyl 
acetate (5 ml) and washed with 10% aqueous citric acid (2 x 2 ml). The organic layer was 
collected, dried over MgSO4 and all solvent removed in vacuo. The resulting crude material 
was purified by flash chromatography (0 - 25% acetone in CH2Cl2 with 1% AcOH) to yield 
title compound 199 as a clear gum (29 mg, 0.063 mmol) in a 72% yield.  
1H NMR (600 MHz, CDCl3-d1)  = 7.12 - 7.32 (5H, m, H-11-15), 5.09 (1H, dd, J = 10.3, J = 
4.7, H-6), 4.78 (1H, dd, J = 11.8, J = 4.7, H-7`), 4.59 (1H, dd, J = 11.8, J = 10.4, H-7``), 
3.58 (2H, d, J = 2.8, H-9); 13C NMR (150 MHz, CDCl3-d1)  = 171.1 (C-8), 170.3 (C-16), 
162.8 (C-2, 5), 133.3 (C-10), 129.7 (C-3, 4), 129.3 (C-11, 15), 128.8 (C-12, 14), 127.5 (C-
13), 60.4 (C-6), 51.8 (C-7), 41.2 (C-9); IR (solid, cm−1); MS (ES+) m/z [M, relative intensity] 
459.9 [79Br79BrM+H, 39], 461.9 [81Br79BrM+H, 84], 463.9 [81Br81BrM+H, 40]; Exact mass 
calcd for [C15H11Br2NO6] 459.9026, found 459.9025. 
(S)-3-((benzylcarbamoyl)oxy)-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)propanoic acid 200 
 
Compound 167 (200 mg, 0.587 mmol) was dissolved in CH2Cl2 (5.6 ml, 10% diethylether) 
and stirred under argon. Benzyl isocyanate (145 l, 1.174 mmol) was added followed by a 
catalytic ammount of powdered MoO2Cl2 (5 mg), and the solution stirred at room 
temperature for four hours. The solution was subsequently washed with 10% aqueous citric 
acid (2 ml) and the aqueous layer extracted with CH2Cl2 (2 x 5 ml). The organic layers were 
collected, dried over MgSO4 and all solvent removed in vacuo. The crude material was 
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purified by flash chromatography (0 - 3% MeOH in CH2Cl2 with 1% AcOH) to yield title 
compound 200 as a yellow gum (184 mg, 0.387 mmol) in a 66% yield.  
m.p. 63.2 - 65.2 °C; 1H NMR (600 MHz, MeOD-d4)  = 7.18 - 7.33 (6H, m, H-9, 12-16), 5.11 
(1H, dd, J = 10.2, J = 4.5, H-6), 4.70 (1H, dd, J = 11.7, J = 4.5, H-7`), 4.59 (1H, dd, J = 
11.7, J = 10.2, H-7``), 4.22 (2H, s, H-10); 13C NMR (150 MHz, MeOD-d4)  = 169.2 (C-17), 
164.6 (C-2, 5), 158.2 (C-8), 140.3 (C-11), 130.7 (C-3, 4), 129.5 (C-12, 16), 128.2 (C-13, 
15), 128.1 (C-14), 62.0 (C-6), 54.0 (C-7), 45.4 (C-10); IR (solid, cm−1) 3443, 2912, 1743, 
1601, 1513; MS (ES+) m/z [M, relative intensity] 475.0 [79Br79BrM+H, 49], 477.0 
[79Br81BrM+H, 100], 479.0 [81Br81BrM+H, 51]; Exact mass calcd for [C15H13Br2N2O6] 
474.9140, found 474.9133. 
(S)-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3 
((phenylcarbamoyl)oxy) propanoic acid 201 
 
Compound 167 (68 mg, 0.200 mmol) was dissolved in Et2O (2 ml) and stirred under argon 
at room temperature. Phenyl isocyanate (43.5 l, 0.400 mmol) was added, followed by a 
catalytic ammount of powdered MoO2Cl2 (5 mg), and the solution stirred at room 
temperature for three hours. All solvent was removed in vacuo and the product purified by 
flash chromatography (0 - 3% MeOH in CH2Cl2 with 1% AcOH) to yield title compound 201 
as a yellow solid (83 mg, 0.180 mmol) in a 90% yield.  
m.p. 67.2 - 69.5  °C; 1H NMR (600 MHz, CDCl3-d1) = 7.24 - 7.42 (5H, m, H-11-15), 7.09 
(1H, t, J = 6.5, H-9), 5.19 (1H, dd, J = 9.5, J = 4.2, H-6), 4.85 (1H, dd, J = 11.9, J = 4.2, 
H-7`), 4.68 (1H, dd, J = 11.9, J = 9.5, H-7``); 13C NMR (150 MHz, CDCl3-d1)  = 169.5 (C-
16), 165.9 (C-2, 5), 152.7 (C-8), 129.9 (C-3, 4), 137.2 (C-10) 119.0-130 (C-11-15), 61.5 (C-
7), 52.6 (C-6); IR (solid, cm−1) 3293, 2971, 1722, 1595, 1530; MS (EI) m/z [M, relative 
intensity] 459.9 [79Br79BrM, 49], 461.9 [81Br79BrM, 100], 463.9 [81Br81BrM, 51]; Exact mass 
calcd for [C14H1079Br2N2O6] 459.8900, found 459.8901. 
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(tert-Butoxycarbonyl)-L-cysteine 203331 
 
L-Cysteine (2.00 g, 16.5 mmol) and NaHCO3 (3.40 g, 40 mmol) were dissolved in 
water:tetrahydrofuran (1:2.5, 50 ml). Di-tert-Butyl dicarbonate (3.60 g, 16.5 mmol) was 
added in a single portion and the reaction stirred at room temperature for 24 hours. After 
this time the reaction was cooled to 0 °C, ethyl acetate (50 ml) was added and the pH 
adjusted to pH = 2-3 via addition of 2M HCl. The organic layer was separated, and the 
aqueous layer washed with ethyl acetate (2 x 50 ml). The organic layers were combined, 
dried over MgSO4 and all solvent was removed in vacuo to yield title compound 203 as a 
clear viscous oil (3.25 g, 14.7 mmol) in an 89% yield.  
 1H NMR (600 MHz, DMSO-d6) = 7.06 (1H, d, J = 8.3, H-1), 4.05 (1H, m, H-2), 2.83 (1H, 
m, H-3`), 2.69 (1H, m, H-3``), 1.37 (9H, s, H-7, 8, 9); 13C NMR (150 MHz, DMSO-d6)  = 
172.1 (C-4), 155.4 (C-5), 78.3 (C-6), 56.2 (C-2), 48.6 (C-3), 28.2 (C-7, 8, 9); IR (film, cm−1) 
3392, 2978, 1696, 1505; MS (ES+) m/z [M, relative intensity] 239.1 [M+NH4, 52]. Data 
matched the literature.331 
S-(benzylcarbamoyl)-N-(tert-Butoxycarbonyl)-L-cysteine 204 
 
(tert-Butoxycarbonyl)-L-cysteine 203 (550 mg, 2.49 mmol) and benzyl isocyanate (0.614 ml, 
4.98 mmol) were dissolved in THF (24 ml) and stirred under argon. A spatula tip of 
MoO2Cl2 was added and the solution stirred at room temperature for three hours. After 
three hours all solvent was removed in vacuo and the crude material purified by flash 
chromatography (0 - 3% MeOH in CH2Cl2 with 1% AcOH) to produce title compound 204 
as a yellow gum (160 mg, 0.451 mmol) in a 18% yield.  
1H NMR (600 MHz, DMSO-d6)  = 8.74 (2H, t, J = 5.7, H-5), 7.21 - 7.35 (5H, m, H-8-12), 
7.10 (1H, d, J = 9.2, H-1), 4.31 (2H, dd, J = 5.7, J = 3.4, H-6), 3.99 (1H, td, J = 9.2, J = 4.5, 
H-2), 3.33 (1H, dd, J = 13.6, J = 4.5, H-3`), 2.93 (1H, dd, J = 13.6, J = 9.2, H-3``), 1.38 (9H, 
s, H-16, 17, 18); 13C NMR (150 MHz, DMSO-d6)  = 172.4 (C-13), 165.6 (C-4), 155.3 (C-
14), 139.0 (C-7), 128.4 (C-8, 12), 127.2 (C-9, 11), 127.0 (C-10), 78.2 (C-15), 54.1 (C-2), 
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44.0 (C-6), 30.5 (C-3), 28.2 (C-16, 17, 18); IR (solid, cm−1) 3311, 2987, 1728, 1665, 1508; 
MS (ES+) m/z [M, relative intensity] 355.1 [M+H, 100], 255.1 [C11H15N2O3S, 40]; Exact 
mass calcd for [C16H23N2O5S] 355.328, found 355.1330. 
 (R)-3-((benzylcarbamoyl)thio)-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)propanoic acid 205 
 
Compound 204 (60.0 mg, 0.169 mmol) was dissolved in CH2Cl2 (1 ml) before trifluoroacetic 
acid (1 ml) was added and the solution stirred at room temperature for 20 minutes. All 
solvent was removed in vacuo and the crude material dissolved in a THF:H2O mixture 
(50:50, 1.8 ml). The solution was added in a single portion to a round bottomed flask 
containing carbamate 165 (53.0 mg, 0.169 mmol) and sodium carbonate (72 mg, 0.676 
mmol) and the resulting mixture was stirred at room temperature for three minutes. The 
solution was subsequently acidified through addition of solid citric acid to pH = 2-3, the 
aqueous layer extracted with CH2Cl2 (4 x 4 ml) and then the organic layer dried over 
MgSO4. All solvent was removed in vacuo, the crude material dissolved in CH2Cl2 (1.8 ml) 
and a spatula tip (~10 mg) of para-toluenesulfonic acid was added. After stirring at room 
temperature for one hour all solvent was removed in vacuo and the crude material was 
purified by flash chromatography (0 - 7% MeOH in CH2Cl2 with 1% AcOH) to yield title 
compound 205 as a yellow gum (30 mg, 0.0613 mmol) in a 36% yield.  
1H NMR (600 MHz, MeOD-d4)  = 7.06 - 7.40 (5H, m, H-12-16), 4.98 (1H, dd, J = 10.9, 
J = 4.1, H-6), 4.34 (2H, s, H-10), 3.69 (1H, dd, J = 14.7, J = 4.1, H-7`), 3.47 (1H, dd, J = 
14.7, J = 10.9, H-7``); 13C NMR (150 MHz, MeOD-d4)  = 170.3 (C-17), 167.8 (C-8), 164.7 
(C-2, 5), 139.7 (C-11), 130.6 (C-3, 4), 129.6 (C-12, 16), 128.4 (C-13, 15), 128.2 (C-14), 
55.2 (C-6), 45.7 (C-10), 29.7 (C-7); IR (solid, cm−1) 3423, 2912, 1728, 1672; MS (EI) m/z 
[M, relative intensity] 490.0 [79Br79BrM, 49], 492.0 [81Br79BrM, 100], 494.0 [81Br81BrM, 51]; 
Exact mass calcd for [C15H12Br2N2O5S] 489.8828, found 489.8805. 
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(S)-3-(but-3-ynoyloxy)-2-(3,4-dibromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-
yl)propanoic acid 214 
 
3-Butynoic acid (39 mg, 0.468 mmol) was dissolved in CH2Cl2 (1 ml). DMF (catalytic, 4l) 
and oxalyl chloride (42.3 l, 0.491 mmol) were added and the reaction stirred at room 
temperature for one hour. Tetra-n-butylammonium bromide (188 mg, 0.585 mmol) was 
added, followed by compound 167 (40.0 mg, 0.117 mmol), and the reaction stirred at room 
temperature for four hours. After this time MeOH (0.5 ml) was added and all solvent 
removed in vacuo. The resulting crude material was purified by flash chromatography (0 - 
30% acetone in CH2Cl2 with 1% AcOH) to yield title compound 214 as a white wax (29 mg, 
0.063 mmol) in a 51% yield.  
2-azidoacetic acid 217332 
 
Bromoacetic acid (2.00 g, 14.4 mmol) was added over five minutes to a stirring solution of 
sodium azide (1.87 g, 28.8 mmol) in H2O (8.4 ml). The solution was subsequently stirred at 
room temperature for 16 hours before conc. HCl (7 ml) was added dropwise to quench the 
reaction. The aqeous mixture was extracted with Et2O (4 x 10 ml) and all solvent was 
removed in vacuo to produce title compound 217 as a clear liquid (1.33 g, 13.2 mmol) in a 
92% yield. 
1H NMR (600 MHz, CDCl3-d1)  = 3.99 (2H, s, H-2); 13C NMR (150 MHz, CDCl3-d1)  = 
174.5 (C-3), 50.1 (C-2); IR (solid, cm−1) 3243, 2920, 2104, 1716; MS (CI) m/z [M, relative 
intensity] 102.1 [M+H, 46]; Exact mass calcd for [C2H4N3O2] 102.0298, found 102.0299. 
Data matched the literature.332  
Doxorubicin-azide 218 
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Doxorubicin hydrochloride (20.0 mg, 0.0345 mmol) was suspended in CH2Cl2 (3.8 ml) and 
stirred at room temperature. A solution of compound 217 (3.5 mg, 0.0345 mmol) and HBTU 
(39.4 mg, 0.104 mmol) dissolved in CH2Cl2 (7.4 ml) was added dropwise over three 
minutes and the entire solution was stirred at room temperature for 70 minutes. The 
reaction mixture was washed with sat. aqueous NaHCO3 (5 ml), followed by brine (5 ml), 
and dried over MgSO4. All organic solvent was removed in vacuo and the crude material 
purified by column chromatography (0 - 10% MeOH in ethyl acetate) to produce title 
compound 218 as a red solid (20.0 mg, 0.0320 mmol) in a 93% yield.  
1H NMR (600 MHz, MeOD-d4)  = 7.64 - 7.72 (2H, m, H-23, 24), 7.41 (1H, d, J = 8.2, H-22), 
5.37 (1H, d, J = 3.8, H-2), 4.99 (1H, br. s, H-8), 4.74 (2H, d, J = 5.3, H-43), 4.27 (1H, q, J = 
6.5, H-6), 4.12 - 4.19 (1H, m, H-4), 3.94 (3H, s, H-39), 3.85 (2H, s, H-40), 3.62 (1H, br. s, 
H-5), 2.97 (1H, d, J = 18.0, H-11`), 2.78 (1H, d, J = 18.0, H-11``), 2.33 (1H, d, J = 14.4, H-
9`), 2.10 (1H, dd, J = 14.4, J = 4.7, H-9``), 1.98 (1H, td, J = 13.2, J = 3.8, H-3`), 1.76 (1H, 
dd, J = 13.2, J = 4.7, H-3``), 1.27 (3H, d, J = 6.6, H-30); 13C NMR (150 MHz, MeOD-d4)  = 
214.7 (C-42), 187.7 (C-15), 187.4 (C-18), 169.5 (C-27), 162.2 (C-25), 157.2 (C-13), 156.0 
(C-20), 137.1 (C-16), 136.1 (C-23), 135.6 (C-12), 135.0 (C-21), 121.2 (C-17), 120.4 (C-22), 
120.1 (C-24), 112.2 (C-14), 112.0 (C-19), 102.1 (C-2), 77.3 (C-10), 71.2 (C-8), 69.7 (C-5), 
68.4 (C-6), 65.7 (C-43), 57.0 (C-39), 52.8 (C-40), 47.3 (C-4), 37.2 (C-9), 33.9 (C-11), 30.4 
(C-3), 17.3 (C-30); IR (solid, cm−1) 3387, 2932, 2225, 1719, 1672, 1636, 1573; MS (ES-) 
m/z [M, relative intensity] 625.2 [M-H, 100], 647.2 [M+Na, 22]; Exact mass calcd for 
[C29H30N4O12] 652.1787, found 625.1780;  
1H NMR (600 MHz, CDCl3-d1)  = 5.14 (1H, dd, J = 9.9, J = 4.5, H-6), 4.86 (1H, dd, 
J = 11.9, J = 4.5, H-7’), 4.61 (1H, dd, J = 11.9, J = 9.9, H-7’’), 3.27 (2H, d, J = 2.8, H-9), 
2.17 (1H, t, J = 2.8, H-11); 13C NMR (150 MHz, CDCl3-d1)  = 170.4 (C-12), 167.5 (C-8), 
163.0 (C-2, 5), 129.9 (C-3, 4), 74.9 (C-10), 72.4 (C-11), 61.4 (C-6), 51.8 (C-7), 25.7 (C-9); 
IR (solid, cm−1) 3290 (s), 2900, 2832, 1742, 1707, 1587; MS (ES+) m/z [M, relative 
intensity] 407.9 [79Br79BrM+H, 49], 409.9 [79Br81BrM+H, 100], 411.9 [81Br81BrM+H, 49]; 
Exact mass calcd for [C11H979Br2NO6] 407.8713, found 407.8719. 
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Dox-dibromomaleimide 219 
 
Sodium ascorbate and Cu2SO4.H2O (20 l, 47.8 mM suspension of each in degassed 
50:50 H2O and t-BuOH) were added to a stirring solution of alkyne 214 (47.8 mM) and Dox-
azide 218 (239 mM) in a degassed mixture of water and t-BuOH (50:50, 100 l). The 
resulting solution was stirred in the dark at room temperature for 4 hours. After this time 
LCMS showed no trace of starting material 214 and confirmed successful click reaction to 
Dox-dibromomaleimide 219. MS (ES+) m/z [M, relative intensity] 1036.0 [M+H, 100].  
Dox-Carboxylic acid 222 
 
Sodium ascorbate and Cu2SO4.H2O (100 l, 47.8 mM suspension of each in degassed 
50:50 H2O and t-BuOH) were added to a stirring solution of 3-butynoic acid (4.00 mg, 
0.0478 mmol) and Dox-azide 218 (15.0 mg, 0.0239 mmol) in a mixture of degassed H2O 
and t-BuOH (50:50, 0.5 ml). The resulting solution was stirred in the dark at room 
temperature for 16 hours. Acetic acid (50 l) was added, all solvent removed in vacuo and 
the crude product dry loaded onto C18 silica. Purification by reverse phase 
chromatography (0-95% MeCN in H2O) gave a crude red material which was subsequently 
washed with CH2Cl2 (5 x 1 ml) to yield title compound 222 as a red solid (7.0 mg, 0.00986 
mmol) in a 41% yield.  
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1H NMR (600 MHz, DMSO-d6)  = 14.05 (2H, s, H-34), 13.28 (2H, s., H-37), 8.20 (1H, d, J 
= 8.2, H-26), 7.91 (2H, br. s., H-23, 24), 7.84 (1H, s, H-45), 7.65 (1H, s, H-22), 5.46 (1H, br. 
s., H-31), 5.15 - 5.33 (1H, m, H-2), 5.03 (3H, m, H-8, 40), 4.95 (2H, br. s., H-29), 4.86 (1H, 
br. s., H-47), 4.56 (2H, br. s., H-46), 4.17 (1H, q, J = 6.6, H-6), 3.99 (4H, br. s., H-4, 39), 
3.60 (2H, s, H-48), 3.42 (1H, br. s., H-5), 2.96 (2H, dd, J = 18.2, J = 5.6, H-11), 2.19 (1H, d, 
J = 13.6, H-9`), 2.12 (1H, dd, J = 13.2, J = 5.6, H-9``), 1.88 (1H, td, J = 12.7, J = 3.6, H-3`), 
1.49 (1H, dd, J = 12.7, J = 3.6, H-3``), 1.13 (3H, d, J = 6.6, H-30); 13C NMR (150 MHz, 
DMSO-d6)  = 213.9 (C-32), 186.7 (C-15), 186.6 (C-18), 171.6 (C-49), 164.7 (C-27), 160.8 
(C-25), 156.1 (C-13), 154.5 (C-20), 140.2 (C-44), 136.3 (C-16), 135.6 (C-23), 134.8 (C-12), 
134.1 (C-21), 124.8 (C-45), 120.1 (C-17), 119.8 (C-22), 119.0 (C-24), 110.9 (C-14), 110.7 
(C-19), 100.2 (C-2), 75.0 (C-10), 70.1 (C-8), 67.8 (C-5), 66.6 (C-6), 63.7 (C-46), 56.6 (C-
39), 51.5 (C-40), 45.5 (C-4), 36.8 (C-9), 32.1 (C-11), 31.5 (C-48), 29.7 (C-3), 17.0 (C-30); 
IR (solid, cm−1) 3403, 3312, 2893, 1787, 1717, 1611, 1543; MS (ES-) m/z [M, relative 
intensity] 709.2 [M-H, 100], 731.2 [M+Na, 60]; Exact mass calcd for [C33H33N4O14] 
709.1999, found 709.1994;  
 
Figure 61 
A HPLC chromatogram of Dox-carboxylic acid 222 
 
Dox-amine 224 
 
Sodium ascorbate and Cu2SO4.H2O (100 l, 51.0 mM suspension of each in degassed 
50:50 H2O and t-BuOH) were added to a stirring solution of propargylammine (2.81 mg, 
172 
 
0.0510 mmol) and Dox-azide 218 (16 mg, 0.0255 mmol) in a 50:50 mixture of degassed 
H2O and t-BuOH (0.5 ml). The resulting solution was stirred in the dark at room 
temperature for two hours. All solvent was removed in vacuo and the crude product 
dissolved in H2O (5 ml, 0.1% trifluoroacetic acid). The aqueous layer was washed with 
CH2Cl2, the organic layer discarded, and the water removed in vacuo to produce a crude 
red solid which was purified by reverse phase C-18 silica (0-95% MeCN in H2O with 0.1% 
trifluoroacetic acid) to yield title compound 224 as a red wax (9.0 mg, 0.011 mmol) in a 43% 
yield. 1H NMR (600 MHz, DMSO-d6)  = 14.02 (1H, s, H-37), 13.29 (1H, s, H-34), 8.27 (1H, 
d, J = 8.2, H-26), 8.20 (2H, br. s., H-49), 8.03 (1H, s, H-45), 7.89 - 7.93 (2H, m, H-23, 24), 
7.67 (1H, dd, J = 6.5, J = 3.3, H-22), 5.25 (1H, d, J = 2.9, H-2), 5.13 (2H, d, J = 3.3, H-40), 
4.95 (1H, dd, J = 5.7, J = 3.1, H-8), 4.55 (2H, s, H-46), 4.16 (1H, q, J = 6.7, H-6), 4.06 - 
4.13 (2H, m, H-48), 3.94 - 4.03 (4H, m, H-4, 39), 3.41 (1H, br. s., H-5), 2.96 (2H, d, J = 4.7, 
H-11), 2.18 (1H, dd, J = 14.0, J = 3.1, H-9`), 2.14 (1H, dd, J = 14.0, J = 5.7, H-9``), 1.89 
(1H, td, J = 12.6, J = 3.9, H-3`), 1.50 (1H, dd, J = 12.6, J = 4.7, H-3``), 1.14 (3H, d, J = 6.7, 
H-30); 13C NMR (150 MHz, DMSO-d6)  = 213.8 (C-32), 186.6 (C-15), 186.6 (C-18), 164.5 
(C-27), 160.8 (C-25), 158.0 (q, JC-F = 25.5, C-50), 156.1 (C-13), 154.5 (C-20), 139.8 (C-44), 
136.3 (C-16), 135.6 (C-23), 134.8 (C-12), 134.2 (C-21), 125.6 (C-45), 120.0 (C-17), 119.8 
(C-22), 119.1 (C-24), 110.8 (C-14), 110.7 (C-19), 100.3 (C-2), 74.9 (C-10), 70.2 (C-8), 67.9 
(C-5), 66.6 (C-6), 63.6 (C-46), 56.6 (C-39), 51.7 (C-40), 45.5 (C-4), 36.7 (C-9), 33.9 (C-48), 
32.1 (C-11), 29.7 (C-3), 17.0 (C-30); 19F NMR (282MHz, DMSO-d6)  = -73.9 (F-54 - 56); IR 
(solid, cm−1) 3395, 2956, 2893, 1754, 1694, 1643, 1585; (ES+) m/z [M, relative intensity] 
682.2 [M-TFA, 100], 268.1 [C11H18N5O3, 30]; Exact mass calcd for [C32H36N5O12] 682.2350, 
found 682.2352. 
(S)-3-((benzylcarbamoyl)oxy)-2-(3,4-bis(((R)-2-((tert-butoxycarbonyl)amino)-3-
methoxy-3-oxopropyl)thio)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoic acid 
232 
 
Compound 169 (19.2 mg, 0.0295 mmol) was dissolved in CH2Cl2/EtO2 (1.0 ml, 50/50) and 
stirred under argon. Benzyl isocyanate (7.3 l, 0.0589 mmol) was added, followed by a 
spatula tip of powdered MoO2Cl2, and the solution stirred at room temperature for three 
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hours. All solvent was removed in vacuo. The crude material was purified by flash 
chromatography (0 - 10% MeOH in CH2Cl2 with 1% AcOH, multiple columns required) to 
yield title compound 232 as a yellow glass (11 mg, 0.0140 mmol) in a 48% yield.  
1H NMR (600 MHz, MeOD-d4)  = 7.17 - 7.33 (5H, m, 12, 13, 14, 15, 16), 5.00 (1H, dd, J = 
10.2, J = 4.3, H-6), 4.75 (1H, dd, J = 11.1, J = 4.3, H-7`), 4.49 (1H, td, J = 11.1, J = 10.2, H-
7``), 4.41 (2H, dd, J = 8.7, J = 4.8, H-19, 29), 4.25 (2H, d, J = 2.3, H-10), 3.85 (2H, dd, J = 
13.8, J = 4.8, H-18`, 28`), 3.71 (6H, br. s., H-21, 31), 3.49 (2H, dd, J = 13.8, J = 8.7, H-18``, 
28``), 1.39 - 1.46 (18H, m, H-25, 26, 27, 35, 36, 37); 13C NMR (150 MHz, MeOD-d4)  = 
172.4 (C-17), 166.8 (C-2, 5), 158. (C-23, 33), 140.3 (C-11), 137.1 (C-3, 4), 129.5 (C-12, 
16), 128.2 (C-15, 13), 128.1 (C-14), 81.0 (C-24, 34), 62.2 (C-7), 56.0 (C-19, 29), 53.1 (C-
21, 31, 6), 45.4 (C-10), 34.0 (C-18, 28), 30.8, 29.5, 28.7 (C-25, 26, 27, 35, 36, 37); IR 
(solid, cm−1) 3370, 2977, 2929, 1709 (broad, sharp); MS (ES+) m/z [M, relative intensity] 
807.2 [M+Na, 40] 865.2 [M-C5H9O2, 100]; Exact mass calcd for [C33H44O14N4S2Na] 
807.2188, found 807.2184;  = 3705 M−1·cm−1.    
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3.2: Chemical Biology Experimental 
3.2.1: General experimental 
All buffers were passed through a microfilter before use to remove particulates and the pH 
adjusted using 1 M HCl or 1 M NaOH. pH was measured using a Hanna Instruments pH 
210 electronic pH meter. When spin filtration devices are mentioned VivaSpin (GE 
Healthcare) 3000, 5000 or 10000 molecular weight cut off devices were employed. Where 
appropriate PD-10 desalting columns from GE Healthcare were used for protein 
purification. Protein concentrations were determined photometrically using either a Jenway 
2705 spectrophotometer or a ThermoScientific Nanodrop 2000C. For small scale 
centrifugation Eppendorf 5415 R and VWR Galaxy 14D microcentrifuges were employed. 
For large scale Fab fragment preparation an Eppendorf 5810 R centrifuge was used. An 
Eppendorf thermomixer comfort heating block was used for temperature and agitation 
controlled experiments.  
Octreotide was purchased from LKT laboratories. Rituxan 100 and Herceptin 125 were 
purchased from the UCLH pharmacy, Anti-CEA scFv 97 was expressed according to 
literature procedure by Dr Berend Tolner and Dr Maria Livanos of the UCL Cancer Institute. 
Digests of Rituxan and Herceptin were prepared using Pierce Fab fabrication kits according 
to modified versions of the manufacturers protocol.  
Photochemistry on protein and peptide samples 
Irradiation of Octreotide, Rituxan Fab and Herceptin Fab was performed using a 
commercial 5W LED torch purchased from Advanced NDT Ltd with an irradiance 
measurement of approximately 20 mWcm−3 at 14 cm.  Protein and peptide samples were 
placed in a plastic cuvette with the LED positioned 14 cm above, and the whole apparatus 
was encased in reflective foil. When a single LED system is specified a custom built 5W 
LED was provided by collaborators at the University of York. Samples were placed into a 
plastic cuvette with the LED position 1 cm above, and the whole apparatus was encased in 
reflective foil. Irradiation of scFv conjugate 220 was performed using a Tank007 UV torch 
with an irradiance measurement of 6 mW·cm−3 at a distance of 1 cm. 
Buffers 
All buffers were adjusted to the desired pH using 1M HCl or 1M NaOH. When varying 
amounts of EDTA are specified the exact amount is outlined in the protocol.  
Phosphate buffer pH = 6.2: 50:50 MeCN:phosphate buffer (pH = 6.2, 50 mM NaH2PO4). 
Acetate buffer pH = 3.1: 20 mM sodium acetate  
Digest buffer pH = 6.8: 50 mM NaH2PO4, 150 mM NaCl, 1 mM EDTA, 
PBS pH = 7.4: 2.7 mM KCl, 137 mM NaCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, (varying 
amounts of EDTA) 
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PBS pH = 6: 24.6 mM Na2HPO4, 154.4 mM KH2PO4. 
PBS pH = 8: 189.3 mM Na2HPO4, 0.9 mM KH2PO4. 
BBS pH = 8: 5 mM sodium borate, 25 mM NaCl, (varying amounts of EDTA). 
SDS-PAGE methods 
Non-reducing 12% acrylamide gels were made using standard procedures. A 4% stacking 
gel was utilised. Samples (22 µM) were mixed 1:1 with a 1X SDS-loading buffer (1 g SDS, 
3 ml glycerol, 6 ml 0.5 M Tris buffer PH 6.8, 2 mg R-250 dye was diluted 1 in 6 with dd 
H2O), heated for two minutes at 75 °C and loaded onto the gel with a total volume of 4 µL. 
Samples were run at constant current (30 mA) for 40 minutes in 1 x SDS running buffer and 
stained with Coomasie. Gel-Pro analyser version 3.1.00.00 from Media Cybernetics was 
used for densitometry analysis. 
3.2.1.1: HPLC methods 
Octreotide 
A Kinetex 5u XN-C18 100A (260 x 4.60 mm) column at 40 C using a Shimadzu LC-10AD 
liquid chromatography apparatus equipped with a Shimadzu DGU-14A diode array. Flow 
rate was set at 1.00 ml/min. Solvent A is H2O (0.1% formic acid), solvent B is MeCN (0.1% 
formic acid). Mobile phase: 75:25 A:B; gradient to 35:65 A:B over 24.5 minutes: gradient to 
5:95 A:B up to 26 minutes, followed by 75:25 A:B to completion of 30 minutes. For 
analytical work an injection volume of 20 µl at 10 µM was used.  For semi-preparative 
purification of 90 an injection volume of 100 µl at 100 µM was employed. 
Anti-CEA scFv 
A Hypersil Gold C4 (50 x 2.1 mm) column at 50 C was employed on a Agilent 
Technologies 1260 Infinity LC equipped with a Agilent Technologies 1260 Infinity 
photodiode array. Flow rate was set at 0.600 ml/min. Solvent A is H2O (0.1% formic acid), 
solvent B is MeCN (0.1% formic acid). Mobile phase: 95:5 A:B; gradient over 6 minutes to 
5:95 A:B. An Injection volume of 10 µl at 20 µM was used.  
3.2.1.2: MALDI-TOF methods 
MALDI-TOF was performed on a Shimadzu Biotech Axima CFR in reflectron mode, with 
laser power set at 75.  
3.2.1.3: Tandem-MS methods 
Tandem MS was performed on a ThermoScientific Finnigan LTQ fitted with a Hypersil Gold 
C18 column (100 mm x 2.1 mm). Flow rate was set at Solvent A is H2O (0.1% formic acid), 
solvent B is MeOH (0.1% formic acid). Mobile phase: 95:5 A:B; gradient over 10 minutes to 
5:95 A:B. Ionisation was performed in ES+ mode with a collision energy of 35% for the MS2 
spectra. An injection volume of 25 l was employed.  Spray voltage was 4.5 kV, capillary 
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temperature 280 C. MS scans consisted of three averaged “microscans”, each with a 
maximum injection time of 200 ms.   
3.2.1.4: LCMS methods 
LCMS for Octreotide, anti-CEA scFv and Herceptin was performed on a Waters Acquity 
uPLC connected to Waters Acquity Single Quad Detector and a photodiode array. Flow 
rate was set at 0.600 ml/min. LCMS for Rituxan Fab was performed on a ThermoScientific 
MSQ Plus connected to an Accela 1250 pump and Accela UV-Vis detector. Flow rate was 
set at 0.600 ml/min. All deconvoluted mass spectra were produced using the software 
provided by the manufacturer.  
Octreotide [2+2] work 
An Acquity UPLC BEH C18 (50 x 2.1 mm) column at 50 C was employed; Solvent A is 
H2O (0.1% formic acid), solvent B is MeCN (0.1% formic acid). Mobile phase: 95:5 A:B; 
gradient over 4 minutes to 5:95 A:B. MS mode ES+ ; scan range: m/z ¼ 250–2,000; scan 
time: 0.25 s. A capillary voltage of 3.5 kV and a cone voltage of 50 V was employed. 
Injection volumes of 10 µl at 200 µM were used. Injection volumes of 10 µl at 300 µM were 
used.   
Octreotide decarboxylation work 
An Agilent SB-C18 (20 x 2.1 mm) column at 50 C was employed. Solvent A is H2O (0.1% 
formic acid), solvent B is MeCN (0.1% formic acid). Mobile phase: 95:5 A:B up to 2 
minutes: gradient to 30:70 A:B up to 12.5 minutes: gradient to 5:95 A:B up to 15 minutes 
A:B. MS mode ES+/ES- ; scan range: m/z ¼ 250–2,000; scan time: 0.25 s. A capillary 
voltage of 3.5 kV and a cone voltage of 50 V was employed. Injection volumes of 10 µl at 
200 µM were used.   
Rituxan Fab 
A Hypersil Gold C4 (50 x 2.1 mm) column at 50 C was used for separation. Solvent A is 
H2O (0.1% formic acid), solvent B is MeCN (0.1% formic acid). Mobile phase: 95:5 A:B; 
gradient over 4 min to 5:95 A:B. MS mode ES+ ; scan range: m/z ¼ 250–2,000; scan time: 
0.25 s. A capillary voltage of 3.5 kV and a cone voltage of 50 V was employed. Injection 
volumes of 7 µl at 10 µM were used.  
Herceptin Fab 
A Hypersil Gold C4 (50 x 2.1 mm) column at 50 C was used for separation. Solvent A is 
H2O (0.1% formic acid), solvent B is MeCN (0.1% formic acid). Mobile phase: 95:5 A:B; 
gradient over 4 min to 5:95 A:B. MS mode ES+ ; scan range: m/z ¼ 250–2,000; scan time: 
0.25 s. A capillary voltage of 3.5 kV and a cone voltage of 50 V was employed. Injection 
volumes of 10 µl at 10 µM were used.  Deconvolution was performed using the MaxEnt 1 
algorithm pre-installed on MassLynx software.  
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3.2.2: Octreotide photoactivation 
3.2.2.1: Modification of Octreotide 
Preparation of bis-modified Octreotide 90 
 
A solution of reduced Octreotide 92 (300 mM in 50:50 PBS pH = 6.2:MeCN, 1.00 ml) was 
added dropwise to a solution of bromomaleimide 93 (300 mM in 50:50 PBS pH = 
6.2:MeCN, 100 equiv., 100 µl) over five minutes. After 30 minutes at room temperature the 
solution was placed into dialysis cups (2 KDa MWCO) and dialysed with deionised water 
overnight. All solvent was subsequently removed by lyophilisation, the peptide dissolved in 
deionised water and purified by HPLC. HPLC yield of 70%. Analysis by MALDI-TOF 
confirmed successful conjugation to produce conjugate 90. Expected mass 1211, observed 
mass 1211 (relative to pure Octreotide 1018). 
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Figure 62 
LCMS spectra of crude bis-modified Octreotide 90. HPLC trace and MALDI spectra 
for purified Octreotide conjugate 90. 
 
Preparation of bridged Octreotide 91 
 
Purified conjugate 90 (300 µM in 50:50 PBS pH = 6.2:MeCN, 60 µl) was placed in a 1 cm3 
cuvette and irradiated for two minutes using the 365 nm UVG-2 torch. The subsequent 
solution was analysed by HPLC. Extended irradiation times effected no change in the 
HPLC trace, indicating the reaction had gone to completion: Peaks labelled A (16.14 
minutes), B (16.49 minutes), C (17.26 minutes) and D (17.64 minutes) were analysed by 
MALDI-TOF (expected mass 1211, observed mass 1211). Additionally, the eluent was 
collected between 15.0 and 20.0 minutes and analysed by MALDI-TOF (Expected mass 
1211, observed mass 1211).  
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Figure 63 
HPLC trace for the irradiation of Octreotide conjugate 90.  MALDI-TOF spectrum for 
(A) peak A, (B) peak B, (C) peak C, (D) peak D, and (E) the combined eluent from 
15.0 to 20.0 minutes. 
 
(A) 
(B) 
(C) 
(D) 
(E) 
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Preparation of reduced Octreotide 92 
 
Tris(2-carboxyethyl)phosphine (TCEP) (30 mM in 50:50 PBS pH = 6.2:MeCN, 1.5 equiv., 
15 µl) was added to a solution of Octreotide 74 (300 µM in 50:50 PBS pH = 6.2:MeCN, 1 
ml) and left to react at 37 °C for one hour. LCMS analysis of the solution revealed 
successful reduction to reduced Octreotide 92. Expected mass 1021, observed mass 1021.  
 
Figure 64 
LCMS spectrum for reduced Octreotide 92. 
 
3.2.2.2: Thiol reactivity of Octreotide conjugates 
Preparation of EDT bridged Octreotide 95 
 
Ethanedithiol (100 mM in 50:50 PBS pH = 6.2:MeCN, 10 equiv., 0.3 µl) was added to a 
solution of conjugate 90 (100 µM in 50:50 PBS pH = 6.2:MeCN, 30 µl). After 30 minutes 
LCMS confirmed successful reaction: Expected mass 1306, observed mass 1306.  
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Figure 65 
LCMS of Octreotide conjugate 90 + ethanedithiol to generate conjugate 95. 
 
Treatment of bridged conjugate 91 with ethanedithiol 
 
Ethanedithiol (100 mM in 50:50 PBS pH = 6.2:MeCN, 10 equiv., 0.3 µl) was added to a 
solution of bridged Octreotide 91 (100 µM in 50:50 PBS pH = 6.2:MeCN, 30 µl). After 30 
minutes LCMS showed no change, indicating no reaction had taken place.   
 
Figure 66 
LCMS of conjugate 91 + ethanedithiol. 
 
3.2.2.4: Electrophysiology data 
Worked was performed by Dr Muriel Nobles  
Cell culture  
Cell culture methods and the generation of stable cell lines were carried out as previously 
described.333 HEK293 cells (human embryonic kidney cell line) stably expressing Kir3.1 
and Kir3.2A channels were maintained in minimum essential medium supplemented with 
10% foetal calf serum and 727 μg of G418 (Invitrogen), at 37 °C in humidified atmosphere 
(95% O2, 5% CO2). Cells were transiently transfected with SSTR2 DNA (Missouri S&T 
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cDNA Resource Center) along with pEGFP-N1 (Clontech) for visualization of transfected 
cells using epifluorescence. Transfections were performed with 5 μl of Fugene HD (Roche) 
and 800 ng SSTR2 DNA and 40 ng EGFP DNA. 
Electrophysiology  
Whole cell patch-clamp current recordings were performed with an Axopatch 200B 
amplifier (Axon Instruments) using fire polished pipettes with a resistance of 4-5 M pulled 
from filamented borosilicated glass capillaries (Harvard Apparatus, 1.5 mm OD x 1.17 mm 
ID). Data was acquired and analysed via a Digidata 1322A interface (Axon Instruments) 
and pCLAMP software (version 10.2, Axon Instruments). Cells were clamped at -50 mV. 
The extracellular solution was: NaCl (135 mM), KCl (5.4 mM), CaCl2 (2 mM), MgCl2 (1 
mM), NaH2PO4 (0.33 mM), H-HEPES (5 mM), Glucose (10 mM), buffered to pH 7.4 with 
NaOH. The intracellular solution was: potassium D-gluconate (110 mM), KCl (20 mM), 
NaCl (10 mM), MgCl2 (1 mM), MgATP (2 mM), EGTA (2 mM), Na2GTP (0.3 mM), buffered 
to pH 7.2 with KOH. Octreotide 74 and conjugates 90 and 91 were administrated by a 
gravity driven system, at a concentration of 0.01, 0.1 or 1 μM until the current reaches a 
maximum value. All experiments were done at room temperature. All peptides for testing 
were kept at -80 °C avoiding repetitive thawing/freezing. Currents were elicited by holding 
cells at -50 mV and stepping to potentials between -120 and +60 mV in 10 mV increments 
for 360 ms. Current densities were measured at -120 mV and all data are presented as 
means ± S.E.M. Data were analysed for statistical significance using one way ANOVA with 
a post-hoc test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67 
(A) Current activation from native Octreotide 74 (0.01 µM). (B) Current activation from bis-modified 
Octreotide 90 (1 µM) (C) Current activation from bridged Octreotide 91 (0.1 µM). (D) Current without 
agonist. The maximum current values obtained were as follows: native Octreotide 74 (10 nM, -73.7 
± 5.9 pA/pF, n=10), conjugate 90 (1 µM, -2.1 ± 0.9 pA/pF, n=9, p<0.0001 compared to Octreotide 74) 
and conjugate 91 (100 nM, -16.1 ±4.7 pA/pF, n=10, p<0.0001 compared to Octreotide 74). 
(A) (B) (C) 
(D) 
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3.2.3: Anti-CEA scFv fragment  
3.2.3.1: Anti-scFv fragment modification 
Preparation of bis-modified anti-CEA scFv 98 
 
A solution of dithiothreitol (DTT) (70 mM in PBS + 10% MeCN, 20 equiv., 2.4 µl) was added 
to a solution of scFv 97 (70 µM in PBS pH = 7.4 + 10% MeCN, 120 µL) and left to react for 
one hour at room temperature. After this time the solution was purified by spin filtration (5 
kDa MWCO) into PBS pH = 7.4 + 1mM EDTA. After purification the solution of reduced 
scFv was readjusted to 70 µL and added dropwise to a solution of monobromomaleimide 
93 (70 mM in MeCN, 100 equiv., 7.0 µl) and left to react for 15 minutes. The solution was 
once again purified by spin filtration (5 KDa MWCO) into PBS pH = 7.4. Analysis by LCMS  
and SDS-PAGE confirmed conjugate 98. Expected mass 26944, observed mass 26935. 
See main text for SDS-PAGE (section 2.2.2, page 70, Figure 27). 
 
Figure 68 
Deconvoluted mass spectrum for scFv conjugate 98. 
 
Generation of bridged scFv 99 
 
Anti-CEA scFv conjugate 98 (70 μM in PBS pH = 7.4, 100 μl) was added to a cuvette and 
irradiated using the 365 nm single LED at a distance of 1 cm for 60 minutes. Analysis by 
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SDS-PAGE and LCMS confirmed successful photocycloaddition to produce anti-CEA scFv 
conjugate 99. Expected mass 26935, observed mass 26935.  See main text for SDS-PAGE 
(section 2.2.2, page 70, Figure 27). Densitometry gave a bridging yield of 71%.  
 
Figure 69 
Deconvoluted mass spectrum for scFv conjugate 99. 
 
3.2.3.2: Thiol stability of a bridged anti-CEA scFv conjugate 
 
A solution of -mercaptoethanol (70 mM in PBS pH = 7.4, 100 equiv., 10 l) was added to 
bridged scFv conjugate 99 (70 M in PBS pH = 7.4 + 10% MeCN, 100 l) and left to react 
for 2 hours at 37 °C. SDS-PAGE and LCMS data matched the data for bridged scFv 
conjugate 99 indicating no reaction had taken place. Pure scFv conjugate 97 was 
subjected to the same conditions and complete reduction was seen by SDS-PAGE. See 
main text for SDS-PAGE (section 2.2.2, page 71, Figure 28).  
3.2.4: Rituxan 
3.2.4.1: Preparation of Rituxan Fab 
 
DTT (10 mM in PBS, 0.5 ml) was added to a solution of papain (0.6 ml) in a Pierce 
fabrication filter and spun in a centrifuge at 5000 g for one minute. A further 0.5 ml DTT (10 
mM in PBS) was added and the centrifugation repeated. The filter was once again filled 
with DTT (0 mM in PBS, 0.5 ml) and left to shake in the dark at 25 ºC for one hour. The 
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resin was then washed with digest buffer (4 x 0.4 ml) and a solution of Rituxan 100 (7.00 
mg·ml−1, 0.6 ml in PBS) added. The suspension was agitated at 1100 rpm in the dark at 
37 °C for 20 hours. The resin was separated from the digest by centrifugation at room 
temperature, washed with PBS (3 x 0.5 ml) and both the digest and washes combined. The 
combined fractions were then buffer exchanged into PBS pH = 7.4 + 10mM EDTA and the 
total volume was adjusted to 2 ml. The sample was then applied to a NAb protein A column 
and incubated at room temperature under constant agitation for one hour. The Fab fraction 
was eluted according to manufacturer’s protocol by washing the column with PBS (3 x 1 
ml). Analysis of the solution by SDS-PAGE and LCMS confirmed successful production of 
Rituxan Fab 101. Observed mass 47169.  
 
 
 
Figure 70 
SDS-PAGE and deconvoluted mass spectrum for Rituxan Fab 101. 
 
3.2.4.2: Modification of Rituxan Fab 
Preparation of bis-modified Rituxan Fab fragments 
A general method for the modification of Rituxan Fab fragment 101 is shown below.  
Rituxan Fab 101 (20 μM in PBS pH 7.4 + 10 mM EDTA, 200 μl) was reduced with TCEP 
(20 mM in PBS pH = 7.4, 10 equiv., 2 μl) at 37 °C for 90 minutes. The appropriate 
bromomaleimide (20 mM in MeCN, 100 equiv., 19 μl), was added and the reaction was left 
at room temperature for 30 minutes. The solution was purified by spin filtration (5 kDa 
MWCO) into PBS pH = 7.4 and the concentration adjusted to 20 μM (280 = 68590 
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M−1·cm−1). Analysis by SDS-PAGE and LCMS confirmed Rituxan-Fab conjugate 102 or 
119a-d. 
Rituxan Fab conjugate 102 
 
Expected mass of light chain 23126, observed mass 23125. Expected mass of heavy chain 
24237, observed mass 24236.  See main text for SDS-PAGE (section 2.2.3.2, page 73, 
Figure 30) 
 
Figure 71 
Deconvoluted mass spectrum for Rituxan Fab conjugate 102. 
 
Rituxan Fab conjugate 118a 
 
Expected mass of light chain 23402, observed mass 23401. Expected mass of heavy chain 
24513, observed mass 24511. See main text for SDS-PAGE (section 2.2.3.5, page 78, 
Figure 32). 
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Figure 72 
Deconvoluted mass spectrum for Rituxan Fab Conjugate 118a. 
 
Rituxan Fab conjugate 118b 
 
Expected mass of light chain 23273, observed mass 23270. Expected mass of heavy chain 
24384, observed mass 24380. See main text for SDS-PAGE (section 2.2.3.5, page 78, 
Figure 32). 
 
Figure 73 
Deconvoluted mass spectrum for Rituxan Fab Conjugate 118b. 
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Rituxan Fab conjugate 118c 
 
Expected mass of light chain 23410, observed mass 23408. Expected mass of heavy chain 
24520, observed mass 24519. See main text for SDS-PAGE (section 2.2.3.5, page 78, 
Figure 32). 
 
Figure 74 
Deconvoluted mass spectrum for Rituxan Fab Conjugate 118c. 
 
Rituxan Fab conjugate 118d 
 
Expected mass of light chain 23635, observed mass 23635. Expected mass of heavy chain 
24746, observed mass 24745. See main text for SDS-PAGE (section 2.2.3.5, page 78, 
Figure 32). 
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Figure 75 
Deconvoluted mass spectrum for Rituxan Fab Conjugate 118d. 
 
Irradiation of Rituxan Fab conjugates 
A general method for the generation of bridged Rituxan Fab Fragments 103 and 119b,c is 
shown below. 
Bis-modified Rituxan Fab conjugate 102 or 118b,c (20 μM in PBS pH = 7.4, 50 μl) was 
added to a cuvette and irradiated using the 365 nm single LED at a distance of 1 cm for 30 
minutes. For bis-modified Rituxan Fab conjugates 102, 118b and 118c analysis by SDS-
PAGE and LCMS confirmed successful photocycloaddition to produce bridged Rituxan Fab 
conjugates 103 or 119b,c. Decarboxylated Rituxan Fab was also observed (expected mass 
22953). For bis-modified Rituxan Fab conjugate 118a only the decarboxylative side product 
was observed. For bis-modified Rituxan Fab conjugate 118d no reaction was observed by 
LCMS.  
Bridged Rituxan Fab conjugate 103 
 
Expected mass 47363, observed mass 47362. See main text for SDS-PAGE (section 
2.2.3.5, page 78, Figure 32). Densitometry gives a bridging yield of 85%. 
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Figure 76 
Deconvoluted mass spectrum for Rituxan Fab Conjugate 103. 
 
Irradiation of Rituxan Fab conjugate 118a. 
 
Expected mass of light chain 22953, observed mass 22954. Expected mass of heavy chain 
24513, observed mass 24513. The peak at 23400 indicates unreacted starting bis-modified 
Rituxan Fab conjugate 118a (starting material). See main text for SDS-PAGE (section 
2.2.3.5, page 78, Figure 32).  
 
Figure 77 
Deconvoluted mass spectrum after the irradiation of Rituxan Fab 118a. 
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Bridged Rituxan Fab conjugate 119b 
 
Expected mass 47657, observed mass 47648. See main text for SDS-PAGE (section 
2.2.3.5, page 78, Figure 32). Densitometry gives a bridging yield of 80%.  
 
Figure 78 
Deconvoluted mass spectrum for Rituxan Fab Conjugate 119b. 
 
Bridged Rituxan Fab conjugate 119C 
 
Expected mass 47930, observed mass 47931. See main text for SDS-PAGE (section 
2.2.3.5, page 78, Figure 32). Densitometry gives a bridging yield of 80%.   
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Figure 79 
Deconvoluted mass spectrum for Rituxan Fab Conjugate 119c. 
 
Irradiation of Rituxan Fab conjugate 118d. 
 
Expected mass of light chain 22953, observed mass 22954. Expected mass of heavy chain 
24513, observed mass 24513. The peak at 23400 indicates unreacted starting bis-modified 
Rituxan Fab conjugate 118d. No reaction was observed by LCMS. See main text for SDS-
PAGE (section 2.2.3.5, page 78, Figure 32). 
 
Figure 80 
Deconvoluted mass spectrum for after the irradiation of Rituxan Fab 118d. 
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Non-irradiated control reaction with Rituxan Fab conjugate 102 
 
Bis-modified Rituxan Fab conjugate 102 (20 μM, 50 μl in PBS pH = 7.4) was added to a 
cuvette and left for one hour at 37 °C. Analysis by SDS-PAGE (Figure 81) showed no 
change and LCMS data matched that of the starting material 102. 
 
Figure 81 
SDS-PAGE showing no reaction of Rituxan Fab conjugate 102 upon incubation at 
37 °C. Identical results were obtained at room temperature. 
 
3.2.4.3: Thiol stability of bridged Rituxan Fab conjugates 
Thiol stability of bridged Rituxan Fab 103 
 
Rituxan Fab conjugate 103 was separated into 3 x 30 μl aliquots (22 μM in PBS pH = 7.4) 
and each aliquot reacted with a specific thiol (dithiothreitol, glutathione, β-mercaptoethanol 
220 mM in PBS pH = 7.4, 500 equiv., total thiol concentration 11 mM, 1.5 μl). The solutions 
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were incubated at 37 °C for four hours. Analysis by SDS-PAGE demonstrated the stability 
of the bridge. See main text for SDS-PAGE. LCMS also showed no change.   
Thiol stability of bis-modified Rituxan Fab 102 
 
Rituxan Fab conjugate 102 was separated into 3 x 30 μl aliquots (22 μM, PBS pH = 7.4) 
and each aliquot reacted with a specific thiol (dithiothreitol, glutathione, β-mercaptoethanol 
22 mM in PBS pH = 7.4, 100 equiv., 3 μl). The solutions were incubated at 37 °C for 2 
hours. Analysis by LCMS revealed complete cleavage of the maleimides from the antibody 
fragment to yield reduced Rituxan Fab 105.  Expected mass of light chain 23029, observed 
mass 23029. Expected mass of heavy chain 24139, observed mass 24140.  
 
Figure 82 
Deconvoluted mass spectrum for reduced Rituxan Fab 105. 
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3.2.4.4: Modification of Rituxan 
 
Rituxan (20 M in BBS pH = 8 + 10mM EDTA, 60 l) was reduced with TCEP (20 mM in 
BBS pH = 8, 10 equiv., 0.6 l) for 2 hours at 37 °C. After this time monobromomaleimide 93 
(80 mM in MeCN, 800 equiv., 12 l) was added and left to react at room temperature for 30 
minutes. Purification was performed by buffer swapping into PBS pH = 7.4 using 10 KDa 
MWCO filters. Analysis by SDS-PAGE provided evidence for the formation of Rituxan 
conjugate 120. See main text for SDS-PAGE (section 2.2.4, page 80, Figure 34). 
Irradiation of modified Rituxan 
 
Rituxan conjugate 120 (60 M in PBS pH = 7.4, 40 l) was added to a cuvette and 
irradiated using a single 365 nm 5W LED at a distance of 1 cm at room temperature for 30 
minutes. SDS-PAGE analysis revealed a complex mixture (section 2.2.4, page 80, Figure 
34). 
3.2.5: Herceptin 
3.2.5.1: Preparation of Herceptin Fab 
Immobilized pepsin (0.15 ml) was washed with acetate buffer (4 x 0.3 ml, 20 mM sodium 
acetate trihydrate, pH 3.1). Herceptin 125 (6.55 mg·ml−1 in digest buffer, 0.5 ml) was added 
and the mixture incubated for five hours under constant agitation (1100 rpm) at 37 °C. The 
digest solution was separated from the resin beads, which were washed with digest buffer 
(3 x 0.4 ml). The washes were combined with the digest solution and the volume adjusted 
to 0.5 ml using spin filtration.  Immobilised papain (0.5 ml, 0.25 mg·ml−1) was incubated in 
buffer (10 mM DTT in digest buffer) at 37 °C with constant agitation (1100 rpm) for one 
hour. The papain resin was subsequently filtered and washed with digest buffer (4 x 0.4 ml) 
and the pepsin digest solution prepared earlier was added. The mixture was incubated at 
37 °C with constant agitation (1100 rpm) for 16 hours. The resin was separated from the 
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digest via spin filtration and washed with BBS (3 x 0.4 ml, 25 mM sodium borate, 25 mM 
NaCl, 0.5 mM EDTA). The digest and the washes were combined and buffer swapped for 
BBS using spin filtration columns (10000 MWCO), and the volume was adjusted to 0.5 ml. 
Yield of Her-Fab 8 was determined by UV/Vis spectroscopy (280 = 68590 M−1·cm−1, 2.55 
mg·ml−1, 61%). Her-Fab 127 was confirmed using SDS-PAGE and LCMS. Observed mass 
47645. 
 
 
 
Figure 83 
SDS-PAGE and deconvoluted mass spectrum for Herceptin Fab 127. 
 
3.2.5.2: Modification of Herceptin Fab 
Bis-modification of Herceptin Fab 125 
A general method for the modification of Herceptin Fab fragment 125 is shown below.  
Herceptin Fab 125 (22 μM in BBS, 200 μl) was reduced with TCEP (22 mM in BBS, 5 
equiv., 1 μl) at 37 °C for 90 minutes. The appropriate bromomaleimide (93, 114, 117) (22 
mM in DMF, 100 equiv., 19 μl) was added and the reaction was left at room temperature for 
197 
 
30 minutes. The solution was subsequently purified by desalting column (G-25, GE 
Healthcare) and buffer swapped into PBS pH = 6 using spin filtration (5 KDa MWCO). 
Herceptin Fab conjugate 128a 
 
Expected mass of light chain 23545, observed mass 23544. Expected mass of heavy chain 
24307, observed mass 24305. For SDS-PAGE see main text (section 2.2.5.2, page 83, 
Figure 36).  
 
Figure 84 
Deconvoluted mass spectrum for Herceptin Fab Conjugate 128a. 
 
Herceptin Fab conjugate 128b 
 
Expected mass of light chain 23692, observed mass 23690. Expected mass of heavy chain 
24454, observed mass 24452. For SDS-PAGE see main text (section 2.2.5.2, page 83, 
Figure 36). 
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Figure 85 
Deconvoluted mass spectrum for Herceptin Fab Conjugate 128b. 
 
Herceptin Fab conjugate 128c 
 
Expected mass of light chain 23829, observed mass 23828. Expected mass of heavy chain 
24591, observed mass 24592. For SDS-PAGE see main text (section 2.2.5.2, page 83, 
Figure 36). 
 
Figure 86 
Deconvoluted mass spectrum for Herceptin Fab Conjugate 128c. 
 
Irradiation of Herceptin Fab conjugates 
A general method for the generation of bridged Herceptin Fab Fragments 129a-c is shown 
below.  
Bis-modified Herceptin Fab conjugate 128a-c (22 μM in PBS pH = 6, 120 μl) was added to a 
cuvette and irradiated using the UVG-2 365 nm torch for two minutes. Analysis by SDS-
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PAGE and LCMS confirmed successful photocycloaddition to produce bridged Herceptin 
conjugates 129a-c-. In each case decarboxylative side product Herceptin Fab conjugate 130 
was also observed (expected mass 23372). 
For Herceptin Fab conjugate 128a the same procedure was performed at pH = 8. See main 
text for details.  
Bridged Herceptin Fab conjugate 129a 
 
Expected mass 47851, observed mass 47852. For SDS-PAGE see main text (section 
2.2.5.2, page 83, Figure 36). Densitometry gave a bridging yield of 85%. 
 
Figure 87 
Deconvoluted mass spectrum for Herceptin Fab Conjugate 129a. 
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Bridged Herceptin Fab conjugate 129b 
 
Expected mass 48146, observed mass 48155. For SDS-PAGE see main text (section 
2.2.5.2, page 83, Figure 36). Densitometry gave a bridging yield of 80%. 
 
Figure 88 
Deconvoluted mass spectrum for Herceptin Fab Conjugate 129b. 
 
Bridged Herceptin Fab conjugate 129c 
 
Expected mass 48428, observed mass 48441. For SDS-PAGE see main text (section 
2.2.5.2, page 83, Figure 36). Densitometry gave a bridging yield of 80%. 
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Figure 89 
Deconvoluted mass spectrum for Herceptin Fab Conjugate 129c. 
 
3.2.5.3: ELISA data for Herceptin conjugates 
A 96-well plate was coated overnight at 4 °C with HER2 (0.25 μg⋅ml−1 in PBS, 100 μl). As a 
negative control one row was coated with only PBS. The solutions were removed and each 
well washed (2 x PBS). The wells were subsequently coated with a 1% BSA solution in 
PBS for 1 hour at room temperature. After this the wells were emptied and washed (3 x 
PBS). Solutions of Herceptin Fab 125, Herceptin Fab conjugate 129a and Herceptin Fab 
conjugate 129a in PBS pH = 7.4 were prepared in the following dilutions: 22 nM, 7.33 nM, 
2.44 nM, 0.814 nM, 0.272 nM and 0.0905 nM. The dilutions were placed into the wells, 
each dilution repeated 3 times, and incubated for two hours at room temperature. As 
negative controls PBS only and Herceptin Fab 125 at 22 nM in the absence of HER2 were 
also subjected to the same protocol. The solutions were removed and the wells washed (2 
x 0.1% Tween 20 in PBS, 3 x PBS). Detection antibody (100 μl of anti-human IgG, Fab-
specific-HRP solution, 4 μl of a 1:5000 solution diluted further in 20 ml of PBS) was added 
and left for 1 hour at room temperature. The solutions were removed and the wells washed 
(2 x 0.1% Tween 20 in PBS, 3 x PBS). Finally, an OPD solution (0.5 mg⋅ml-1 OPD in 
phosphate-citrate buffer with sodium perborate, 100 μl) was added to each well. After 2 
minutes the reaction was stopped through addition of 4 M HCl (50 μl). Absorbance was 
measured at 490 nm and corrected by subtracting the average of negative controls. See 
main text for data. Protocol was taken from a literature procedure.144 Data was analysed 
using GraphPad PRISM software. Absorbance values were normalised to the highest 
value, and lines were fit using non-linear regression (log[inhibitor] vs. response - variable 
slope, four parameters). IC50 values were reported as obtained.  
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3.2.7: Dithiomaleimide photocleavable linkers 
3.2.7.1: Modification of Octreotide 
A general experimental for the modification of Octreotide 74. 
 
Tris(2-carboxyethyl)phosphine (TCEP) (30 mM in 50:50 PBS pH = 6.2:MeCN, 1.15 equiv., 
1.15 µl) was added to a solution of Octreotide 74 (300 µM in 50:50 PBS pH = 6.2:MeCN, 
100 µl) and left to react at 37 °C for 90 minutes. The appropriate bridging reagent (172, 
194, 197, 199, 200, 201, 205) (30 mM, 1.2 equiv., 1.2 µl in MeCN) was added and the 
mixture left at room temperature for 20 minutes. Analysis by LCMS showed complete 
bridging to Octreotide conjugates 184, 206a-f. See main text for LC traces (section 2.4.4.1 & 
2.4.5.2).  
Octreotide Conjugate 184 
 
Expected mass 1243, observed mass 1243 (ES− mode). 
 
 
Figure 90 
ES negative mode spectrum of Octreotide conjugate 184. 
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Octreotide Conjugate 206a 
 
Expected mass 1257, observed mass 1257 (ES− mode). 
 
Figure 91 
ES negative mode spectrum of Octreotide conjugate 206a. 
 
Octreotide Conjugate 206b 
 
Expected mass 1257, observed mass 1257 (ES− mode). 
 
Figure 92 
ES negative mode spectrum of Octreotide conjugate 206b. 
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Octreotide Conjugate 206c 
 
Expected mass 1319, observed mass 1319 (ES− mode).
 
Figure 93 
ES negative mode spectrum of Octreotide conjugate 206c. 
 
Octreotide Conjugate 206d 
 
Expected mass 1334, observed mass 1334 (ES− mode). 
 
Figure 94 
ES negative mode spectrum of Octreotide conjugate 206d. 
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Octreotide Conjugate 206e 
 
Expected mass 1320, observed mass 1320 (ES− mode). 
 
Figure 95 
ES negative mode spectrum of Octreotide conjugate 206e. 
 
Octreotide Conjugate 206f 
 
Expected mass 1350, observed mass 1350 (ES− mode). 
 
 
Figure 96 
ES negative mode spectrum of Octreotide conjugate 206f. 
206 
 
A general experimental for the Irradiation of Octreotide conjugates 
 
Octreotide conjugate 184 or 206a-f (200 µM in 50:50 PBS pH = 6.2:MeCN, 40 µl) was 
added to a 1.5 ml Eppendorf tube and irradiated using a 395 nm LED held at a distance of 
4 cm for five minutes. After this time the sample was analysed by LCMS which revealed a 
mixture of the products. See main text for LC details and yields.  
Octreotide Conjugate 186 
 
Expected mass 1199, observed mass 1199 (ES− mode). 
 
Figure 97 
ES negative mode spectrum of Octreotide conjugate 186. 
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Octreotide Conjugate 207c 
 
Expected mass 1339, observed mass 1339 (ES− mode). 
 
Figure 98 
ES negative mode spectrum of Octreotide conjugate 207c. 
 
Octreotide Conjugate 207a 
 
Expected mass 1153, observed mass 1153 (ES− mode). 
 
Figure 99 
ES negative mode spectrum of Octreotide conjugate 207a. 
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Octreotide Conjugate 207b 
 
Expected mass 1153, observed mass 1153 (ES− mode). 
 
Figure 100 
ES negative mode spectrum of Octreotide conjugate 207b. 
 
Octreotide Conjugate 208a 
 
Expected mass 1213, observed mass 1213 (ES− mode). 
 
Figure 101 
ES negative mode spectrum of Octreotide conjugate 208a. 
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Octreotide Conjugate 208c 
 
Expected mass 1275, observed mass 1275 (ES− mode). 
 
Figure 102 
ES negative mode spectrum of Octreotide conjugate 208c. 
 
Octreotide Conjugate 208d 
 
Expected mass 1290, observed mass 1290 (ES− mode). 
 
Figure 103 
ES negative mode spectrum of Octreotide conjugate 208d. 
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Octreotide Conjugate 208e 
 
Expected mass 1276, observed mass 1276 (ES− mode). 
 
Figure 104 
ES negative mode spectrum of Octreotide conjugate 208e. 
 
Octreotide Conjugate 208f 
 
Expected mass 1308, observed mass 1308 (ES+ mode). 
 
Figure 105 
ES negative mode spectrum of Octreotide conjugate 208f. 
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3.2.7.2: Anti-CEA scFv-Dox photocleavable ADC. 
Modification of anti-CEA scFv 220 
 
Anti CEA-scFv 97 (37.2 M in PBS pH = 7.4 + 6 mM EDTA, 200 l) was reacted with DTT 
(37.2 mM in PBS pH =7.4, 20 equiv., 4 l) for one hour at room temperature. After this time 
the solution was purified by desalting column (GE healthcare), buffer swapped into PBS pH 
= 7.4, and the volume readjusted to 200 l. Pre-clicked dibromomaleimide-doxorubicin 
compound 219 (3.72 mM, 10 equiv. 20 l in H2O/t-BuOH) was added and the reaction left 
for 30 minutes at room temperature. After this time the solution was once again purified by 
desalting column, buffer swapped into PBS pH = 7.4, and the concentration adjusted to 20 
M (205 l). Analysis by LCMS revealed successful reaction to produce scFv conjugate 
220. Expected mass 27626, observed mass 27624.  
 
Figure 106 
Deconvoluted mass spectrum for scFv-Dox conjugate 220. 
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Irradiation of anti-CEA scFv-Dox 220 
 
6 aliqouts of anti-CEA scFv conjugate 220 (20 M in PBS pH = 7.4, 5 x 20 l) were taken 
and individually irradiated at room temperature for one, two, three, four, five and six 
minutes using a 395 nm LED torch held a distance of 4 cm. The resulting samples were 
then analysed using HPLC monitoring at 280 and 480 nm to track the release of Dox-
carboxylate 222. See main text for details (section 2.4.6.3, page 127, Scheme 105 & 
Figure 52).  
3.2.8: Cell kill assays for Doxorubicin analoguies 
Below is the general protocol employed by Dr Enrique Miranda Rota of the UCL Cancer 
Institute to test the cell toxicity of Doxorubicin. HCl 215 and Doxorubicin analogues 222 and 
224.  
Capa-1, Caski and Hela cell lines expressing CEA (purchased from ATCC Cell Biology) 
were tryptinised and seeded in 96 well plates at a concentration of 1000 cells per well. The 
wells were incubated at 37 °C and 5% CO2 for 24 hours to allow for attachment of the cells. 
The appropriate Doxorubicin analogue (215, 222, and 224) in serial dilutions (100 M, 33.3 
M, 11.1, M, 3.7 M, 1.23 M, 0.41 M, 0.14 M, 0.046 M, 0.015 M, and 0.005 M) 
was added (10 l) and the cells incubated at 37 °C and 5% CO2 for 72 hours. The cells 
were emptied and washed with PBS (1 x 200 l). An 10% MTS reagent (100 l) was added 
and the wells incubated at 37 °C and 5% CO2 for 1 hour. Visualisation and cell viability was 
calculated by recording the absorbance at 490 nm and subtracting negative controls (non-
treated cells). See main text for details (section 2.4.6.4, page 129, Figure 54 & section 
2.4.6.5, page 132, Figure 55).  
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